0001792044-22-000010 | 10-K | XBRL Viewer

Print Document View Excel Document

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net (loss) earnings	$ (1,269.1)	$ (669.9)	$ 16.8
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	4,506.5	2,216.1	2,019.3
Deferred income tax expense (benefit)	675.7	(213.2)	(192.6)
Litigation settlements and other contingencies, net	323.7	101.1	(11.5)
Loss from equity method investments	61.9	48.4	62.1
Share-based compensation expense	111.2	79.2	56.8
Other non-cash items	411.8	366.4	360.6
Changes in operating assets and liabilities:
Accounts receivable	59.3	78.7	(20.0)
Inventories	(427.6)	(741.9)	(512.9)
Trade accounts payable	(70.4)	(82.7)	(96.3)
Income taxes	(699.6)	3.6	57.9
Other operating assets and liabilities, net	(666.5)	46.0	63.5
Net cash provided by operating activities	3,016.9	1,231.8	1,803.7
Cash flows from investing activities:
Cash received (paid) for acquisitions, net of cash acquired	277.0	415.8	(148.7)
Capital expenditures	(457.2)	(243.0)	(213.2)
Payments for product rights and other, net	(52.2)	(438.2)	(192.8)
Proceeds from sale of property, plant and equipment	18.3	2.1	0.0
Proceeds from sale of assets and subsidiaries	96.7	20.0	28.0
Purchase of marketable securities	(30.2)	(104.8)	(25.8)
Proceeds from the sale of marketable securities	29.8	47.0	27.1
Net cash used in investing activities	(117.8)	(301.1)	(525.4)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	1,710.1	983.3	7.4
Payments of long-term debt	(4,201.3)	(2,484.2)	(1,108.5)
Payments of financing fees	(7.0)	(2.0)	(3.0)
Change in short-term borrowings, net	392.1	1,099.6	(1.8)
Proceeds from exercise of stock options	0.0	0.6	8.1
Taxes paid related to net share settlement of equity awards	(17.4)	(7.9)	(8.4)
Contingent consideration payments	(28.6)	(48.5)	(60.3)
Cash dividends paid	(399.0)	0.0	0.0
Non-contingent payments for product rights	(456.0)	(143.3)	0.0
Other items, net	(4.9)	(3.3)	(2.5)
Net cash used in financing activities	(3,012.0)	(605.7)	(1,169.0)
Effect on cash of changes in exchange rates	(30.9)	33.8	(7.5)
Net (decrease) increase in cash, cash equivalents and restricted cash	(143.8)	358.8	101.8
Cash, cash equivalents and restricted cash — beginning of period	850.0	491.1	389.3
Cash, cash equivalents and restricted cash — end of period	706.2	850.0	491.1
Non-cash transactions:
Common stock issued for the Combination	0.0	10,727.5	0.0
Cash paid during the period for:
Income taxes	641.7	324.4	278.6
Interest	$ 684.8	$ 555.4	$ 470.6

Equity Method Investments (Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Other current liabilities	$ 4,619.6	$ 4,960.7
Other Liabilities, Noncurrent	1,933.6	2,483.1
Clean energy investments
Schedule of Equity Method Investments [Line Items]
Other liabilities	10.9	47.5
Other assets \| Clean energy investments
Schedule of Equity Method Investments [Line Items]
Investments in subsidiaries	$ 0.0	$ 47.9

Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 144.6	$ 118.6
Liability derivatives, fair value	61.0	103.6
Not designated as hedging instrument
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	82.6	90.3
Liability derivatives, fair value	56.7	102.8
Not designated as hedging instrument \| Prepaid expenses and other current assets \| Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	82.6	90.3
Not designated as hedging instrument \| Other current liabilities \| Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Liability derivatives, fair value	$ 56.7	$ 102.8

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-In Capital	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Treasury Stock	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Cumulative Effect, Period of Adoption, Adjustment
Balance at Dec. 31, 2018	$ 12,167.1	$ 0.0	$ 6.0	$ 8,591.4	$ 6,010.7	$ 3.6	$ (999.7)	$ (1,441.3)	$ (3.6)
Balance (in shares) at Dec. 31, 2018			539,289,665				23,490,867
Net earnings	16.8				16.8
Other comprehensive loss, net of tax	(352.3)							(352.3)
Share-based compensation expense	56.8			56.8
Issuance of restricted stock and stock options exercised, net	8.2		$ 0.1	8.1
Issuance of restricted stock and stock options exercised, net (in shares)			1,457,206
Taxes related to the net share settlement of equity awards	(12.8)			(12.8)
Cancellation of restricted stock							(1,107,207)
Balance at Dec. 31, 2019	11,883.8		$ 6.1	8,643.5	6,031.1		$ (999.7)	(1,797.2)
Balance (in shares) at Dec. 31, 2019			540,746,871				24,598,074
Net earnings	(669.9)				(669.9)
Other comprehensive loss, net of tax	939.2							939.2
Share-based compensation expense	79.2			79.2
Issuance of restricted stock and stock options exercised, net	0.6			0.6
Issuance of restricted stock and stock options exercised, net (in shares)			872,802
Taxes related to the net share settlement of equity awards	(6.3)			(6.3)
Cancellation of restricted stock			(24,598,074)				(24,598,074)
Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock	0.0		$ (6.1)	6.1
Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock (in shares)			(541,619,673)
Stock Issued During Period, Value, New Issues	0.0		$ 5.2	(5.2)
Issuance of common stock to Mylan N.V. shareholders (in shares)			541,619,673
Issuance of common stock for the Combination	10,727.5		$ 6.9	10,720.6
Issuance of common stock for the Combination (in shares)			689,874,045
Retirement of Mylan N.V. treasury stock, net	0.0			(999.7)			$ 999.7
Balance at Dec. 31, 2020	22,954.1		$ 12.1	18,438.8	5,361.2		$ 0.0
Balance (in shares) at Dec. 31, 2020			1,206,895,644				0
Net earnings	(1,269.1)				(1,269.1)
Other comprehensive loss, net of tax	(886.3)							(886.3)
Share-based compensation expense	111.2			111.2
Issuance of restricted stock and stock options exercised, net (in shares)			2,611,819
Taxes related to the net share settlement of equity awards	(13.9)			(13.9)
Cash dividends declared, $0.33 per common share					(403.3)
Balance at Dec. 31, 2021	$ 20,492.7		$ 12.1	$ 18,536.1	$ 3,688.8		$ 0.0	$ (1,744.3)
Balance (in shares) at Dec. 31, 2021			1,209,507,463				0

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Foreign Exchange Contract \| Cash flow hedging relationships \| Other income
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Excluded from the Assessment of Hedge Effectiveness	$ 0.0	$ 7.1	$ 0.0

Acquisitions and Other Transactions (Tables)

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

During the year ended December 31, 2021, adjustments were made to the preliminary purchase price recorded at December 31, 2020, and are reflected as “Measurement Period and Other Adjustments” in the table below. The allocation of the $10.73 billion purchase price to the assets acquired and liabilities assumed under the Combination is as follows:


(In millions)	Preliminary Purchase Price Allocation as of December 31, 2020 (a)		Measurement Period and Other Adjustments (b)		Purchase Price Allocation as of December 31, 2021 (as adjusted)
Current assets (excluding inventories and net of cash acquired)	$	2,841.9	$	(38.7)	$	2,803.2
Inventories	2,588.9		(34.2)		2,554.7
Property, plant and equipment	1,394.1		(5.0)		1,389.1
Identified intangible assets	18,040.0		—		18,040.0
Goodwill	2,107.5		295.6		2,403.1
Deferred income tax benefit	1,481.9		196.3		1,678.2
Other assets	792.1		(7.4)		784.7
Total assets acquired	$	29,246.4	$	406.6	$	29,653.0
Current liabilities	2,760.2		419.7		3,179.9
Long-term debt, including current portion	13,076.2		—		13,076.2
Deferred tax liabilities	1,656.9		1.0		1,657.9
Other noncurrent liabilities	1,441.5		(14.1)		1,427.4
Net assets acquired (net of $415.8 of cash acquired)	$	10,311.6	$	—	$	10,311.6

____________

(a)As previously reported in Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

(b)The measurement period adjustments are primarily for 1) certain working capital adjustments, an increase in litigation reserves to reflect facts and circumstances that existed as of the date of the Combination, and other adjustments and 2) the tax implications of these and other adjustments. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and accordingly, the Company has not retrospectively adjusted those consolidated financial statements.

Business Acquisition, Pro Forma Information

Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.


	Year Ended December 31,
(Unaudited, in millions, except per share amounts)	2020		2019
Total revenues	$	18,284.8	$	21,582.7
Net earnings	$	1,483.7	$	1,873.5
Earnings per share:
Basic	$	1.23	$	1.55
Diluted	$	1.23	$	1.55
Weighted average shares outstanding:
Basic	1,206.8		1,205.6
Diluted	1,207.7		1,206.4

Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 3,774.4	$ 3,891.3
Other receivables	492.0	952.5
Accounts receivable, net	4,266.4	4,843.8
Proceeds from Sale and Collection of Receivables	29.6	153.0
Allowance for doubtful accounts
Accounts, Notes, Loans and Financing Receivable [Line Items]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount	$ 154.5	$ 159.9	$ 72.8	$ 98.2
Credit Concentration Risk \| Accounts Receivable \| Three Customers
Accounts, Notes, Loans and Financing Receivable [Line Items]
Concentration risk, percentage	18.00%	12.00%
Variable Consideration [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 1,688.6	$ 1,802.9
Other receivables	1,362.1	1,211.8
Accounts receivable, net	$ 3,050.7	$ 3,014.7

Equity Method Investments (Income Statement) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Total revenues	$ 17,886.3	$ 11,946.0	$ 11,500.5
Gross loss	5,575.5	3,796.7	3,897.6
Operating and non-operating expense	(664.4)	(721.2)	154.4
Net loss	(1,269.1)	(669.9)	16.8
Consolidated Entity
Schedule of Equity Method Investments [Line Items]
Total revenues	326.7	374.5	385.0
Gross loss	(4.6)	(4.6)	(4.4)
Operating and non-operating expense	16.8	19.0	20.0
Net loss	$ (21.4)	$ (23.6)	$ (24.4)

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Employee benefits	$ 271.3	$ 273.0
Litigation reserves	94.4	43.5
Accounts receivable allowances	425.9	393.7
Inventory	187.8	1,187.9
Tax credit and loss carry-forwards	1,256.0	1,080.4
Operating lease assets	63.6	66.5
Interest expense	111.6	67.9
Intangible assets	151.1	156.3
Other	327.8	396.0
Total deferred tax assets, gross	2,889.5	3,665.2
Less: Valuation allowance	(780.4)	(443.6)
Total deferred tax assets	2,109.1	3,221.6
Deferred tax liabilities:
Plant and equipment	19.6	50.2
Operating lease liabilities	63.6	66.5
Intangible assets and goodwill	3,468.3	4,058.6
Other	39.9	22.1
Total deferred tax liabilities	3,591.4	4,197.4
Deferred tax liabilities, net	$ (1,482.3)	$ (975.8)

Debt (Upjohn Senior Notes) (Details) € in Millions, $ in Millions	Oct. 29, 2021	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 EUR (€)
Debt Instrument [Line Items]
Debt Instrument, Conversion Of Unregistered Notes To Registered Notes, As A Percentage	99.90%
Upjohn Inc.
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 11,847.8
Upjohn Inc. \| Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 7,450.0
Upjohn Inc. \| Senior Notes \| 2022 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			1,000.0
Upjohn Inc. \| Senior Notes \| 2025 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			750.0
Upjohn Inc. \| Senior Notes \| 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			750.0
Upjohn Inc. \| Senior Notes \| 2030 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			1,450.0
Upjohn Inc. \| Senior Notes \| 2040 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			1,500.0
Upjohn Inc. \| Senior Notes \| 2050 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			2,000.0
Upjohn Inc. \| Senior Notes \| 2022 Euro Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			916.2
Upjohn Inc. \| Senior Notes \| 2027 Euro Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			1,038.4
Upjohn Inc. \| Senior Notes \| 2.250% Euro Senior Notes due 2024
Debt Instrument [Line Items]
Debt Instrument, Face Amount			916.2
Upjohn Inc. \| Senior Notes \| 2032 Euro Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			1,527.0
Upjohn Inc. \| Senior Notes \| Upjohn Euro Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount \| €				€ 3,600
Upjohn Inc. \| Senior Notes \| Unregistered Upjohn U.S. Dollar Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 7,450.0

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Financial Instruments in Net Investment Hedging Relationships:	$ 479.0	$ (325.8)	$ 76.3
Foreign currency borrowings and forward contracts \| Cash Flow Hedging [Mem
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :	45.8	20.6	16.6
Interest rate swaps \| Cash Flow Hedging [Mem
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :	(3.4)	0.0	3.0
Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Foreign currency borrowings and forward contracts \| Net Investment Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ 436.6	$ (346.4)	$ 56.7

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Lease, Cost

Other information related to leases was as follows:


	As of December 31, 2021
Remaining lease terms	1 year to 23 years
Weighted-average remaining lease term	6 years
Weighted-average discount rate	2.6	%

Lessee, Operating Lease, Liability, Maturity

As of December 31, 2021, maturities of lease liabilities were as follows:


(In millions)
Year ending December 31,
2022	$	82.0
2023	65.0
2024	42.9
2025	28.8
2026	23.9
Thereafter	68.2
Total lease payments	$	310.8
Less imputed interest	23.2
Total lease liability	$	287.6

Nature of Operations (Narrative) (Details)	Dec. 31, 2021 molecule site
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number Of Molecules \| molecule	1,400
Number Of Manufacturing Sites \| site	40

Equity Method Investments (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Schedule of Equity Method Investments [Line Items]
Equity Method Investments Net Gain (Loss) From Impairment and Reduction In Obligations	$ 5.7	$ 21.4	$ 7.0
Loss from equity method investments	$ 61.9	$ 48.4	$ 62.1
Clean energy investments
Schedule of Equity Method Investments [Line Items]
Number of equity method investments	3

Financial Instruments and Risk Management (Narrative) (Details) € in Millions, ¥ in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 JPY (¥)	Dec. 31, 2020 EUR (€)	Dec. 31, 2020 JPY (¥)
Derivative [Line Items]
Notional amount of derivative		$ 750.0
Gain (Loss) on Fair Value Hedges Recognized in Earnings	$ 39.3	(10.1)	$ (17.3)
Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months	21.0
Purchase consideration, contingent consideration	199.7	223.6	250.7
Reclassifications	0.0	0.0
Accretion	9.0	11.6
Contingent consideration payments	(83.2)	(111.8)
Minimum
Derivative [Line Items]
Accretion	6.0
Maximum
Derivative [Line Items]
Accretion	8.0
Respiratory delivery platform [Member]
Derivative [Line Items]
Purchase consideration, contingent consideration	$ 177.8
2020 Euro Senior Notes
Derivative [Line Items]
Debt instrument, interest rate, stated percentage	0.816%			0.816%	0.816%
2022 Euro Senior Notes
Derivative [Line Items]
Long-term debt	$ 0.0	928.8
Debt instrument, interest rate, stated percentage	0.816%			0.816%	0.816%
2.125% Euro Senior Notes due 2025
Derivative [Line Items]
Debt instrument, interest rate, stated percentage	1.023%			1.023%	1.023%
2027 Euro Senior Notes
Derivative [Line Items]
Debt instrument, interest rate, stated percentage	1.362%			1.362%	1.362%
YEN Term Loan
Derivative [Line Items]
Long-term debt	$ 347.6
Senior Notes \| 2.250% Euro Senior Notes due 2024
Derivative [Line Items]
Long-term debt	$ 1,135.8	1,219.9
Debt instrument, interest rate, stated percentage	2.25%			2.25%	2.25%
Senior Notes \| 2.125% Euro Senior Notes due 2025
Derivative [Line Items]
Long-term debt	$ 871.6	944.6
Senior Notes \| 2025 Euro Senior Notes
Derivative [Line Items]
Long-term debt	$ 567.8	609.9
Debt instrument, interest rate, stated percentage	2.125%			2.125%	2.125%
Senior Notes \| 2028 Senior Notes
Derivative [Line Items]
Long-term debt	$ 748.7	748.6
Debt instrument, interest rate, stated percentage	4.55%			4.55%	4.55%
Senior Notes \| 2027 Euro Senior Notes
Derivative [Line Items]
Long-term debt	$ 1,013.0	1,097.4
Senior Notes \| 2032 Euro Senior Notes
Derivative [Line Items]
Long-term debt	$ 1,546.6	1,672.6
Debt instrument, interest rate, stated percentage	1.908%			1.908%	1.908%
Senior Notes \| 2028 Euro Senior Notes
Derivative [Line Items]
Long-term debt	$ 847.4	909.7
Debt instrument, interest rate, stated percentage	3.125%			3.125%	3.125%
Senior Notes \| Senior Notes 2023 3.125%
Derivative [Line Items]
Long-term debt	$ 766.1	781.6
Debt instrument, interest rate, stated percentage	3.125%			3.125%	3.125%
Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative				€ 5,850.0	¥ 40,000	€ 5,955.6	¥ 0
Long-term debt				5,955.6	40,000
Net Investment Hedging \| 2022 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				750.0		750.0
Long-term debt \| €				750.0
Net Investment Hedging \| 2.250% Euro Senior Notes due 2024
Derivative [Line Items]
Notional amount of derivative \| €				1,000.0		1,000.0
Long-term debt \| €				1,000.0
Net Investment Hedging \| 2.125% Euro Senior Notes due 2025
Derivative [Line Items]
Notional amount of derivative \| €				750.0		750.0
Long-term debt \| €				750.0
Net Investment Hedging \| 2025 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				500.0		500.0
Long-term debt \| €				500.0
Net Investment Hedging \| 2028 Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				750.0		750.0
Long-term debt \| €				750.0
Net Investment Hedging \| 2027 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				850.0		850.0
Long-term debt \| €				850.0
Net Investment Hedging \| 2032 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				1,250.0		1,250.0
Long-term debt \| €				1,250.0
Net Investment Hedging \| 2020 Floating Rate Euro Notes
Derivative [Line Items]
Notional amount of derivative \| €				0.0		€ 105.6
Long-term debt \| €				€ 105.6
Net Investment Hedging \| YEN Term Loan
Derivative [Line Items]
Notional amount of derivative \| ¥					40,000		¥ 0
Long-term debt \| ¥					¥ 40,000
Other Noncurrent Liabilities
Derivative [Line Items]
Purchase consideration, contingent consideration	$ 133.0	123.1	130.3
Reclassifications	(49.4)	(58.1)
Accretion	9.0	11.6
Contingent consideration payments	0.0	0.0
Other current liabilities
Derivative [Line Items]
Purchase consideration, contingent consideration	66.7	100.5	$ 120.4
Reclassifications	49.4	58.1
Accretion	0.0	0.0
Contingent consideration payments	$ (83.2)	$ (111.8)
Measurement Input, Discount Rate [Member] \| Minimum
Derivative [Line Items]
Derivative Asset (Liability) Net, Measurement Input		0.021				0.021	0.021
Measurement Input, Discount Rate [Member] \| Maximum
Derivative [Line Items]
Derivative Asset (Liability) Net, Measurement Input		0.105				0.105	0.105
Measurement Input, Discount Rate [Member] \| Contingent consideration \| Minimum
Derivative [Line Items]
Rate used to discount net cash inflows to present values	0.080			0.080	0.080
Measurement Input, Discount Rate [Member] \| Contingent consideration \| Maximum
Derivative [Line Items]
Rate used to discount net cash inflows to present values	0.105			0.105	0.105

Debt (Revolving Facilities and Term Facilities) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Line of Credit Facility [Line Items]
Debt, Current	$ 1,860.3	$ 2,256.3

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Principles of Consolidation Policy

Principles of Consolidation. The consolidated financial statements include the accounts of Viatris and those of its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Investments in equity method affiliates are recorded at cost and adjusted for the Company’s share of the affiliates’ cumulative results of operations, capital contributions and distributions.

Use of Estimates in the Preparation of Financial Statements Policy

Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates.

Foreign Currencies Policy

Foreign Currencies. The consolidated financial statements are presented in U.S. Dollars, the reporting currency of Viatris. Statements of Operations and Cash Flows of all of the Company’s subsidiaries that have functional currencies other than U.S. Dollars are translated at a weighted average exchange rate for the period for inclusion in the consolidated statements of operations and cash flows, whereas assets and liabilities are translated at the end of the period exchange rates for inclusion in the consolidated balance sheets. Translation differences are recorded directly in shareholders’ equity as foreign currency translation adjustments. Gains or losses on transactions denominated in a currency other than the subsidiaries’ functional currency, which arise as a result of changes in foreign currency exchange rates, are recorded in the consolidated statements of operations.

Cash and Cash Equivalents Policy

Cash and Cash Equivalents. Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.

Marketable Securities Policy

Debt and Equity Securities. Debt securities classified as available-for-sale on the date of purchase are recorded at fair value, with net unrealized gains and losses, net of income taxes, reflected in accumulated other comprehensive loss as a component of shareholders’ equity. Net realized gains and losses on sales of available-for-sale debt securities are computed on a specific security basis and are included in other expense, net, in the consolidated statements of operations. Debt securities classified as trading securities are valued using the quoted market price from broker or dealer quotations or transparent pricing sources at the reporting date, with gains and losses included in other expense, net, in the consolidated statements of operations. Fair value is determined based on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit risk or underlying security and overall capital market liquidity. Debt securities are reviewed for impairment by assessing if the decline in market value of the investment below the carrying value is other than temporary.Investments in equity securities with readily determinable fair values are recorded at fair value with changes in fair value recorded in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Investments in entities are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The share of net income or losses of equity method investments are included in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values and investments in equity accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors.

Concentrations of Credit Risk Policy

Concentrations of Credit Risk. Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable.

Viatris invests its excess cash in high-quality, liquid money market instruments, principally overnight deposits and highly rated money market funds. The Company maintains deposit balances at certain financial institutions in excess of federally insured amounts. Periodically, the Company reviews the creditworthiness of its counterparties to derivative transactions, and it does not expect to incur a loss from failure of any counterparties to perform under agreements it has with such counterparties.

Inventories Policy

Inventories. Inventories are stated at the lower of cost and net realizable value, with cost principally determined by the weighted average cost method. Provisions for potentially obsolete or slow-moving inventory, including pre-launch inventory, are made based on our analysis of product dating, inventory levels, historical obsolescence and future sales forecasts. Included as a component of cost of sales is expense related to the net realizable value of inventories.

Property, Plant and Equipment Policy

Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed and recorded on a straight-line basis over the assets’ estimated service lives (3 to 18 years for machinery and equipment and other fixed assets and 15 to 39 years for buildings and improvements). Capitalized software is included in property, plant and equipment and is amortized over estimated useful lives ranging from 3 to 7 years.

Intangible Assets and Goodwill Policy

Intangible Assets and Goodwill. Intangible assets are stated at cost less accumulated amortization. Amortization is generally recorded on a straight-line basis over estimated useful lives ranging from 3 to 20 years. The Company periodically reviews the estimated useful lives of intangible assets and makes adjustments when events indicate that a shorter life is appropriate.

The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of ASC 805, Business Combinations, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective estimated fair values. The cost to acquire businesses is allocated to the underlying net assets of the acquired business based on estimates of their respective fair values. Amounts allocated to acquired IPR&D are capitalized at the date of acquisition and, at that time, such IPR&D assets have indefinite lives. As products in development are approved for sale, amounts are allocated to product rights and licenses and will be amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

Purchases of developed products and licenses that are accounted for as asset acquisitions are capitalized as intangible assets and amortized over an estimated useful life. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses.

The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management's assessment of the fair value of the Company's reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we choose to use qualitative factors and determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test would be required. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations.

Indefinite-lived intangibles, principally IPR&D, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value of IPR&D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested.

Contingent Consideration Policy

Contingent Consideration. Viatris records contingent consideration resulting from business acquisitions at its estimated fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as adjustments to litigation settlements and other contingencies, net within the consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, sales targets and profitability. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.

Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations.

Impairment of Long-Lived Assets Policy

Impairment of Long-Lived Assets. The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.

Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations.

Research and Development Policy

Research and Development. R&D expenses are charged to operations as incurred.

Short-Term Borrowings

Short-Term Borrowings. The Company’s subsidiaries in India have working capital facilities with several banks which are secured by its current assets. The Company also has the CP Notes, Receivables Facility, which will expire in April 2022 and the Note Securitization Facility, which will expire in August 2022. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. As the accounts receivable do not transfer to the banks, any amounts outstanding under the facilities are recorded as borrowings and the underlying receivables continue to be included in accounts receivable, net, in the consolidated balance sheets.

Revenue Recognition Policy

Revenue Recognition. The Company recognizes revenues in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Amounts recorded for revenue deductions can result from a complex series of judgements about future events and uncertainties and can rely heavily on estimates and assumptions. The following section briefly describes the nature of our provisions for variable consideration and how such provisions are estimated:

•Chargebacks: the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Viatris will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels.

•Rebates, promotional programs and other sales allowances: this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products.

•Returns: consistent with industry practice, Viatris maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. Generally, returned products are destroyed and customers are refunded the sales price in the form of a credit.

•Governmental rebate programs: government reimbursement programs in the U.S. include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap” based on historical experience of prescriptions and utilization expected to result in the discount of the “coverage gap”.

Outside the U.S., the majority of our pharmaceutical sales are contractually or legislatively governed. In certain European countries, certain rebates are calculated on the governments total pharmaceutical spending or on specific product sale thresholds. We utilize historical data and obtain third party information to determine the adequacy of these accruals. Also, this provision includes price reductions that are mandated by law outside of the U.S.

Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods.

Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenues in the consolidated statements of operations.

Income Taxes Policy

Income Taxes. Income taxes have been provided for using an asset and liability approach in which deferred income taxes reflect the tax consequences on future years of events that the Company has already recognized in the financial statements or tax returns. Changes in enacted tax rates or laws may result in adjustments to the recorded tax assets or liabilities in the period that the new tax law is enacted.

Earnings Per Common Share Policy

Earnings per Share. Basic earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.

Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:


	Year Ended December 31,
(In millions, except per share amounts)	2021		2020		2019
Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders	$	(1,269.1)	$	(669.9)	$	16.8
Shares (denominator):
Weighted average shares outstanding	1,208.8		601.2		515.7
Basic (loss) earnings per share attributable to Viatris Inc. shareholders	$	(1.05)	$	(1.11)	$	0.03

Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders	$	(1,269.1)	$	(669.9)	$	16.8
Shares (denominator):
Weighted average shares outstanding	1,208.8		601.2		515.7
Share-based awards	—		—		0.8
Total dilutive shares outstanding	1,208.8		601.2		516.5
Diluted (loss) earnings per share attributable to Viatris Inc. shareholders	$	(1.05)	$	(1.11)	$	0.03

The weighted average shares outstanding used in the computation of earnings per share for the year ended December 31, 2020 includes the effect of the 689.9 million shares issued for the closing of the Combination.

Additional stock awards and restricted ordinary shares were outstanding during the years ended December 31, 2021, 2020 and 2019 but were not included in the computation of diluted earnings per share for each respective period because the effect would be anti-dilutive. Excluded shares also include certain share-based compensation awards and restricted shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 12.7 million, 10.3 million and 9.1 million shares for the years ended December 31, 2021, 2020 and 2019, respectively

Stock-Based Compensation Policy

Share-Based Compensation. The fair value of share-based compensation is recognized as expense in the consolidated statements of operations over the vesting period.

Derivatives Policy

Derivatives. From time to time the Company may enter into derivative financial instruments (mainly foreign currency exchange forward contracts, interest rate swaps and purchased equity call options) designed to: 1) hedge the cash flows resulting from existing assets and liabilities and transactions expected to be entered into over the next 24 months in currencies other than the functional currency, 2) hedge the variability in interest expense on floating rate debt, 3) hedge the fair value of fixed-rate notes, 4) hedge against changes in interest rates that could impact future debt issuances, 5) hedge cash or share payments required on conversion of issued convertible notes, 6) hedge a net investment in a foreign operation, or 7) economically hedge the foreign currency exposure associated with the purchase price of non-U.S. acquisitions. Derivatives are recognized as assets or liabilities in the consolidated balance sheets at their fair value. When the derivative instrument qualifies as a cash flow hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged items, are generally included in interest expense. When such instruments do not qualify for hedge accounting the changes in fair value are recorded in the consolidated statements of operations within other expense, net

Financial Instruments Policy

Financial Instruments. The Company’s financial instruments consist primarily of short-term and long-term debt, interest rate swaps, forward contracts and option contracts. The Company’s financial instruments also include cash and cash equivalents as well as accounts and other receivables and accounts payable, the fair values of which approximate their carrying values. As a policy, the Company does not engage in speculative or leveraged transactions.

The Company carries derivative instruments in the consolidated balance sheets at fair value, determined by reference to market data such as forward rates for currencies, implied volatilities, and interest rate swap yield curves. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. In addition, the Company has designated certain long-term debt instruments as net investment hedges.

Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value

Recent Accounting Pronouncements

Recent Accounting Pronouncements.

Adoption of New Accounting Standards

In January 2020, the FASB issued Accounting Standards Update 2020-01, Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 (“ASU 2020-01”), which clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. In addition, ASU 2020-01 states that for the purpose of applying paragraph 815-10-15-141(a) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The Company applied the provisions of ASU 2020-01 as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.

In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (Topic 740) which is intended to simplify the accounting for income taxes by eliminating certain exceptions and simplifying certain requirements under Topic 740. The Company applied the provisions of ASU 2019-12 on a prospective basis as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.

Accounting Standards Issued Not Yet Adopted

In March 2020, the FASB issued Accounting Standards Update 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Entities can apply the provisions of ASU 2020-04 immediately, as applicable, and generally the provisions of the guidance are available through December 31, 2022 as entities transition away from reference rates that are expected to be discontinued. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.

In October 2021, the FASB issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires entities (acquirers) to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. ASU 2021-08 will be effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2022 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.

In November 2021, the FASB issued Accounting Standards Update 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”), which requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 will be effective for fiscal years beginning after December 15, 2021 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its disclosures.

Segment Information (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Reconciliation of Segment Information to Total Consolidated Information

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.


	Net Sales						Segment Profitability
	Years Ended December 31,						Years Ended December 31,
(in millions)	2021		2020		2019		2021		2020		2019
Reportable Segments:
Developed Markets	$	10,428.7	$	8,510.9	$	8,240.0	$	5,143.1	$	4,243.9	$	4,137.3
Greater China	2,212.8		259.9		214.6		1,397.1		52.7		89.9
JANZ	2,027.4		1,195.3		1,192.5		762.4		364.6		323.2
Emerging Markets	3,144.7		1,853.8		1,723.2		1,402.4		610.4		561.9
Total reportable segments	$	17,813.6	$	11,819.9	$	11,370.3	$	8,705.0	$	5,271.6	$	5,112.3

Reconciling items:
Intangible asset amortization expense							(2,702.2)		(1,605.8)		(1,582.7)
Intangible asset impairment charges							(102.8)		(82.4)		(180.6)
Globally managed research and development costs							(751.1)		(555.1)		(639.9)
Litigation settlements & other contingencies							(329.2)		(107.8)		21.4
Transaction related and other special items							(2,832.2)		(1,739.7)		(682.2)
Corporate and other unallocated							(2,021.5)		(1,391.6)		(1,332.8)
(Loss) earnings from operations							$	(34.0)	$	(210.8)	$	715.5

Schedule of Revenue by Major Customers by Reporting Segments

The following table represents the percentage of consolidated net sales to Viatris’ major customers during the years ended December 31, 2021, 2020, and 2019:


	Percentage of Consolidated Net Sales
	2021		2020		2019
McKesson Corporation	9	%	13	%	15	%
AmerisourceBergen Corporation	9	%	10	%	9	%
Cardinal Health, Inc.	5	%	8	%	8	%

Net Third Party Sales Classified Based on Geographic Location of Subsidiaries

Net sales by country are presented on the basis of geographic location of our subsidiaries:


	Year Ended December 31,
(In millions)	2021		2020		2019
United States	$	4,176.4	$	3,746.1	$	3,965.9
China	1,981.5		216.1		171.1

____________

No other country’s net sales represents more than 10% of consolidated net sales.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Provision

The income tax provision (benefit) consisted of the following components:


	Year Ended December 31,
(In millions)	2021		2020		2019
U.S. Federal:
Current	$	12.6	$	(6.4)	$	118.1
Deferred	(182.7)		(277.0)		(165.5)
	(170.1)		(283.4)		(47.4)
U.S. State:
Current	7.7		(0.1)		21.1
Deferred	(10.8)		7.7		(13.6)
	(3.1)		7.6		7.5
Non-U.S.:
Current	(91.3)		168.7		191.0
Deferred	869.2		55.8		(13.5)
	777.9		224.5		177.5
Income tax provision (benefit)	$	604.7	$	(51.3)	$	137.6
Earnings before income taxes:

United States	(1,982.5)		(945.5)		(1,031.4)
Foreign - Other	1,318.1		224.3		1,185.8
Total (loss) earnings before income taxes	$	(664.4)	$	(721.2)	$	154.4

Schedule of Deferred Tax Assets and Liabilities

Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows:


(In millions)	December 31, 2021		December 31, 2020
Deferred tax assets:
Employee benefits	$	271.3	$	273.0
Litigation reserves	94.4		43.5
Accounts receivable allowances	425.9		393.7
Inventory	187.8		1,187.9
Tax credit and loss carry-forwards	1,256.0		1,080.4
Operating lease assets	63.6		66.5
Interest expense	111.6		67.9
Intangible assets	151.1		156.3
Other	327.8		396.0
	2,889.5		3,665.2
Less: Valuation allowance	(780.4)		(443.6)
Total deferred tax assets	2,109.1		3,221.6
Deferred tax liabilities:
Plant and equipment	19.6		50.2
Operating lease liabilities	63.6		66.5
Intangible assets and goodwill	3,468.3		4,058.6
Other	39.9		22.1
Total deferred tax liabilities	3,591.4		4,197.4
Deferred tax liabilities, net	$	(1,482.3)	$	(975.8)

Statutory Tax Rate to Effective Tax Rate Reconciliation

Prior to the Combination, the applicable income tax rate to Mylan was the U.K. rate of 19%, and following the Combination, the statutory income tax rate applicable to Viatris Inc. is the U.S. rate of 21% for the years ended December 31, 2021 and 2020. A reconciliation of the statutory tax rate to the effective tax rate is as follows:


	Year Ended December 31,
	2021		2020		2019
Statutory tax rate	21.0	%	21.0	%	19.0	%

United States Operations
Clean energy and research credits	9.8	%	12.8	%	(43.4)	%
U.S. rate differentials	—	%	—	%	(3.1)	%
Impact of changes in legislation	—	%	(9.2)	%	—	%
State income taxes and credits	(0.6)	%	(1.6)	%	(4.1)	%
Valuation allowance	(0.1)	%	8.6	%	(118.5)	%
Tax settlements and resolution of certain tax positions	0.1	%	0.1	%	199.6	%
Incremental US Tax on Foreign Earnings	(36.9)	%	(3.6)	%	(8.6)	%
Waived deductions under IRC § 59A	—	%	(3.3)	%	64.5	%
Impact of the Combination and Divestitures	(2.8)	%	5.8	%	7.7	%
Other U.S. items	(6.1)	%	1.5	%	6.9	%
Other Foreign Operations
Luxembourg	(6.7)	%	(5.0)	%	(14.8)	%
Gibraltar	9.4	%	8.0	%	(38.8)	%
Ireland	5.8	%	8.2	%	(13.7)	%
France	(1.1)	%	(2.8)	%	15.2	%
Puerto Rico	4.4	%	(2.5)	%	—	%
Switzerland	1.0	%	2.0	%	—	%
Singapore	28.8	%	1.0	%	—	%
Other	(10.2)	%	(0.4)	%	12.8	%
Deferred tax impact of tax law changes	7.0	%	(0.1)	%	36.7	%
Valuation allowance	(8.3)	%	16.1	%	(9.9)	%
Impact of the Combination and divestitures	(106.9)	%	(42.2)	%	—	%
Withholding taxes	(1.3)	%	(1.6)	%	7.1	%
Tax settlements and resolution of certain tax positions	0.8	%	(3.9)	%	(27.6)	%
Other foreign items	1.9	%	(1.8)	%	2.1	%
Effective tax rate	(91.0)	%	7.1	%	89.1	%

Schedule of Unrecognized Tax Benefits

A reconciliation of the unrecognized tax benefits is as follows:


	Year Ended December 31,
(In millions)	2021		2020		2019
Unrecognized tax benefit — beginning of year	$	391.1	$	92.1	$	96.3
Additions for current year tax positions	—		13.4		—
Additions for prior year tax positions	—		35.7		154.9
Reductions for prior year tax positions	(9.1)		(5.2)		(11.7)
Settlements	(47.3)		(8.9)		(112.5)
Reductions due to expirations of statute of limitations	(7.0)		—		(34.9)
(Reduction) addition due to acquisition	(4.8)		264.0		—
Unrecognized tax benefit — end of year	$	322.9	$	391.1	$	92.1

Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Total equity	$ 20,492.7	$ 22,954.1	$ 11,883.8	$ 12,167.1
Net unrealized gain on marketable securities, net of tax	0.0	1.2
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	(32.2)	26.1
Foreign currency translation adjustment	(1,802.4)	(461.5)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(1,744.3)	(858.0)
Net unrealized gain on marketable securities, net of tax	0.0	1.2
Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax	32.2	(26.1)
Foreign currency translation adjustment	(1,802.4)	(461.5)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(1,744.3)	(858.0)
Cumulative Effect, Period of Adoption, Adjustment
Total equity				0.0
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax			0.2
Accumulated Other Comprehensive Income (Loss), Net of Tax			(3.6)
Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax			(0.2)
Accumulated Other Comprehensive Income (Loss), Net of Tax			(3.6)
AOCI Attributable to Parent [Member]
Total equity	(1,744.3)		(1,797.2)	(1,441.3)
Accumulated Other Comprehensive Income (Loss), Net of Tax			(1,797.2)	(1,441.3)
Accumulated Other Comprehensive Income (Loss), Net of Tax			(1,797.2)	(1,441.3)
AOCI Attributable to Parent [Member] \| Cumulative Effect, Period of Adoption, Adjustment
Total equity				(3.6)
Foreign Currency Translation Adjustment
Foreign currency translation adjustment			(1,674.5)	(1,259.0)
Foreign currency translation adjustment	(1,340.9)	1,213.0	(415.5)
Foreign currency translation adjustment			(1,674.5)	(1,259.0)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	9.2	(18.0)
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	9.2	(18.0)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Cumulative Effect, Period of Adoption, Adjustment
Other Comprehensive Income, Other, Net of Tax			(3.4)
Net Investment Hedging
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	16.7	(353.6)	(74.3)	(130.9)
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	$ 16.7	$ (353.6)	$ (74.3)	$ (130.9)

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Fair Value Hedges Recognized in Earnings	$ 39.3	$ (10.1)	$ (17.3)
Other income \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Financial Instruments Not Designated as Hedging Instruments:	39.3	(10.1)	(17.3)
Fair value hedging relationships \| Interest Expense [Member] \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0.0	22.1	18.7
Fair value hedging relationships \| Interest Expense [Member] \| Senior Notes 2023 3.125%
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Fair Value Hedges Recognized in Earnings	$ 0.0	$ (22.1)	$ (18.7)

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

Summary of Significant Accounting Policies

Cash and Cash Equivalents. Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.

Investments in equity securities with readily determinable fair values are recorded at fair value with changes in fair value recorded in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Investments in entities are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The share of net income or losses of equity method investments are included in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values and investments in equity accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors.

Concentrations of Credit Risk. Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable.

Research and Development. R&D expenses are charged to operations as incurred.

Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:


	Year Ended December 31,
(In millions, except per share amounts)	2021		2020		2019
Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders	$	(1,269.1)	$	(669.9)	$	16.8
Shares (denominator):
Weighted average shares outstanding	1,208.8		601.2		515.7
Basic (loss) earnings per share attributable to Viatris Inc. shareholders	$	(1.05)	$	(1.11)	$	0.03

Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders	$	(1,269.1)	$	(669.9)	$	16.8
Shares (denominator):
Weighted average shares outstanding	1,208.8		601.2		515.7
Share-based awards	—		—		0.8
Total dilutive shares outstanding	1,208.8		601.2		516.5
Diluted (loss) earnings per share attributable to Viatris Inc. shareholders	$	(1.05)	$	(1.11)	$	0.03

The Company paid quarterly cash dividends of $0.11 per share on the Company’s issued and outstanding common stock on June 16, 2021, September 16, 2021, and December 16, 2021. On January 4, 2022, the Company’s Board of Directors declared a quarterly cash dividend of $0.12 per share on the Company’s issued and outstanding common stock, which will be payable on March 16, 2022 to shareholders of record as of the close of business on February 24, 2022. The declaration and payment of future dividends to holders of the Company’s common stock will be at the discretion of the Board of Directors, and will depend upon factors, including but not limited to, the Company’s financial condition, earnings, capital requirements of its businesses, legal requirements, regulatory constraints, industry practice, and other factors that the Board of Directors deems relevant.

On February 28, 2022, the Company announced that its Board of Directors had authorized a share repurchase program for the repurchase of up to $1.0 billion of the Company’s shares of common stock. The Company has not yet repurchased any shares of common stock under the share repurchase program and the share repurchase program does not obligate the Company to acquire any particular amount of common stock.

Share-Based Compensation. The fair value of share-based compensation is recognized as expense in the consolidated statements of operations over the vesting period.

Recent Accounting Pronouncements.

Adoption of New Accounting Standards

Accounting Standards Issued Not Yet Adopted

Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 38.1	$ 37.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0.1	1.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0.0	0.0
Fair Value	38.2	39.1
Debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	38.1	37.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0.1	1.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0.0	0.0
Fair Value	$ 38.2	$ 39.1

Debt (Fair Value) (Narrative) (Details) - USD ($) $ in Millions	Nov. 13, 2020	Dec. 31, 2021	Dec. 31, 2020
Upjohn Inc.
Debt Instrument [Line Items]
Cash paid to acquire asset	$ 12,000
Senior Notes
Debt Instrument [Line Items]
Fair value of long-term debt		$ 22,010	$ 25,900

Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 17,813.6	$ 11,819.9	$ 11,370.3
Lipitor ®
Disaggregation of Revenue [Line Items]
Net sales	1,663.2
Norvasc ®
Disaggregation of Revenue [Line Items]
Net sales	824.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	728.5
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	533.8
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	391.7
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	344.4
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	316.8
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	309.8
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	284.3
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	226.0
Influvac ®
Disaggregation of Revenue [Line Items]
Net sales	299.3
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	201.5
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	185.9
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	168.0
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	$ 161.9

Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	$ 223.6	$ 250.7
Payments	83.2	111.8
Accretion	9.0	11.6
Reclassifications	0.0	0.0
Fair value loss (gain)	50.3	73.1
Balance at end of period	199.7	223.6
Other current liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	100.5	120.4
Payments	83.2	111.8
Accretion	0.0	0.0
Reclassifications	49.4	58.1
Fair value loss (gain)	0.0	33.8
Balance at end of period	66.7	100.5
Other Noncurrent Liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	123.1	130.3
Payments	0.0	0.0
Accretion	9.0	11.6
Reclassifications	(49.4)	(58.1)
Fair value loss (gain)	50.3	39.3
Balance at end of period	$ 133.0	$ 123.1

Employee Benefit Plans (Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2017	Dec. 31, 2020
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	2.30%			1.90%
Expected return on plan assets	5.10%			4.30%
Rate of compensation increase	3.10%			2.90%
Discount rate	1.90%	1.60%	2.30%
Expected return on plan assets	5.10%	4.30%	4.30%
Rate of compensation increase	2.90%	2.70%	2.90%
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	2.50%			1.90%
Expected return on plan assets	0.00%			0.00%
Rate of compensation increase	0.00%			0.00%
Discount rate	1.90%	3.30%	4.30%
Expected return on plan assets	0.00%	0.00%	0.00%
Rate of compensation increase	0.00%	0.00%	0.00%

Consolidated Statements of Comprehensive Earnings - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net loss	$ (1,269.1)	$ (669.9)	$ 16.8
Other comprehensive (loss) earnings, before tax:
Foreign currency translation adjustment	(1,340.9)	1,213.0	(415.5)
Change in unrecognized loss and prior service cost related to defined benefit plans	73.9	(14.0)	(24.8)
Net unrealized (loss) gain on marketable securities	(1.1)	0.6	0.5
Other comprehensive (loss) earnings, before tax	(775.2)	912.6	(343.1)
Income tax provision (benefit)	111.1	(26.6)	9.2
Other comprehensive (loss) earnings, net of tax	(886.3)	939.2	(352.3)
Comprehensive earnings	(2,155.4)	269.3	(335.5)
Cash flow hedging relationships
Other comprehensive (loss) earnings, before tax:
Net unrecognized gain (loss) on derivatives in hedging relationships	36.1	18.2	37.1
Net Investment Hedging
Other comprehensive (loss) earnings, before tax:
Net unrecognized gain (loss) on derivatives in hedging relationships	$ 456.8	$ (305.2)	$ 59.6

Comprehensive Earnings (Tables)

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss, as reflected in the consolidated balance sheets, is comprised of the following:


(In millions)	December 31, 2021		December 31, 2020
Accumulated other comprehensive loss:
Net unrealized gain on marketable securities, net of tax	$	—	$	1.2
Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax	32.2		(26.1)
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax	9.2		(18.0)
Net unrecognized loss on derivatives in net investment hedging relationships, net of tax	16.7		(353.6)
Foreign currency translation adjustment	(1,802.4)		(461.5)
	$	(1,744.3)	$	(858.0)

Components of Other Comprehensive Loss

Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following:


	Year Ended December 31, 2021
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax			62.7		456.8		(1.1)		67.0		(1,340.9)		(755.5)
Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(30.9)		(30.9)										(30.9)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.3	4.3										4.3
Amortization of prior service costs included in SG&A									(0.5)				(0.5)
Amortization of actuarial loss included in SG&A									7.4				7.4
Net other comprehensive earnings (loss), before tax			36.1		456.8		(1.1)		73.9		(1,340.9)		(775.2)
Income tax provision			8.9		86.5		0.1		15.6		—		111.1

Balance at December 31, 2021, net of tax			$	9.2	$	16.7	$	—	$	32.2	$	(1,802.4)	$	(1,744.3)


	Year Ended December 31, 2020
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2019, net of tax			$	(31.6)	$	(74.3)	$	0.6	$	(17.4)	$	(1,674.5)	$	(1,797.2)
Other comprehensive (loss) earnings before reclassifications, before tax			18.5		(305.2)		0.6		(12.1)		1,213.0		914.8
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(4.8)		(4.8)										(4.8)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.5	4.5										4.5
Amortization of prior service costs included in SG&A									—				—
Amortization of actuarial loss included in SG&A									(1.9)				(1.9)
Net other comprehensive (loss) earnings, before tax			18.2		(305.2)		0.6		(14.0)		1,213.0		912.6
Income tax provision (benefit)			4.6		(25.9)		—		(5.3)		—		(26.6)

Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)


	Year Ended December 31, 2019
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2018, net of tax			$	(53.1)	$	(130.9)	$	—	$	1.7	$	(1,259.0)	$	(1,441.3)
Other comprehensive earnings (loss) before reclassifications, before tax			29.3		59.6		0.5		(21.0)		(415.5)		(347.1)
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales	0.7		0.7										0.7
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		7.1	7.1										7.1
Amortization of prior service costs included in SG&A									(0.9)				(0.9)
Amortization of actuarial loss included in SG&A									(2.9)				(2.9)
Net other comprehensive earnings (loss), before tax			37.1		59.6		0.5		(24.8)		(415.5)		(343.1)
Income tax provision (benefit)			12.2		3.0		(0.1)		(5.9)		—		9.2
Cumulative effect of the adoption of new accounting standards			(3.4)		—		—		(0.2)		—		(3.6)
Balance at December 31, 2019, net of tax			$	(31.6)	$	(74.3)	$	0.6	$	(17.4)	$	(1,674.5)	$	(1,797.2)

Balance Sheet Components (Inventories) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory, Net [Abstract]
Raw materials	$ 922.4	$ 958.4
Work in process	993.3	1,438.1
Finished goods	2,062.0	3,075.4
Inventories	3,977.7	5,471.9
Inventory reserves	519.0	353.6
Net realizable value of inventory recognized as expense	$ 474.9	$ 206.1	$ 399.2

Collaboration and Licensing Agreements (Narrative) (Details) $ in Millions					3 Months Ended	12 Months Ended
	Feb. 27, 2019 USD ($)	Sep. 20, 2018 USD ($)	Jan. 30, 2015 USD ($)	Feb. 12, 2013 Product	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jan. 08, 2016 drugs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration liability							$ 199.7	$ 223.6	$ 250.7
Research and development							751.1	555.1	639.9
Proceeds from sale of assets and subsidiaries							96.7	20.0	$ 28.0
Momenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of drugs \| drugs										6
Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments							18.5
FKB
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments		$ 10.0
Upfront payments	$ 33.0	$ 25.0
Research and development	$ 23.3
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development							40.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Scenario, Forecast \| Biosimilars Business
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from sale of assets and subsidiaries					$ 2,000.0
Divestiture of Business, Deferred Cash Consideration.						$ 335.0
Divestiture Of Business, Percentage Ownership In Combined Company After Transaction					12.90%
Divestiture Of Business, Transition Services Agreement, Term						2 years
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Scenario, Forecast \| Biosimilars Business \| Convertible Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Equity consideration					$ 1,000.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Revance [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development								$ 30.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development							50.0
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments							351.0
Maximum \| Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments			$ 293.0
Fiscal Year 2017 \| Maximum \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments							18.0
Generic Biologic Compounds Collaboration [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Insulin Analog Products \| Product				3
Respiratory delivery platform [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration liability							177.8
Product rights and licenses \| Other companies
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Acquisition purchase price							10.0
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned							$ 25.0

Revenue Recognition and Accounts Receivable (Tables)

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:


(In millions)	2021 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	5,759.2		2,207.8		1,197.1		1,677.2		10,841.3
Complex Gx and Biosimilars	1,241.6		0.2		46.5		53.8		1,342.1
Generics	3,427.9		4.8		783.8		1,413.7		5,630.2
Total Viatris	$	10,428.7	$	2,212.8	$	2,027.4	$	3,144.7	$	17,813.6


(In millions)	2020 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	3,920.7		253.9		617.0		443.3		5,234.9
Complex Gx and Biosimilars	1,202.6		0.7		42.8		49.4		1,295.5
Generics	3,387.6		5.3		535.5		1,361.1		5,289.5
Total Viatris	$	8,510.9	$	259.9	$	1,195.3	$	1,853.8	$	11,819.9


(In millions)	2019 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	4,199.1		207.6		533.3		422.1		5,362.1
Complex Gx and Biosimilars	1,127.4		0.4		23.8		59.7		1,211.3
Generics	2,913.5		6.6		635.4		1,241.4		4,796.9
Total Viatris	$	8,240.0	$	214.6	$	1,192.5	$	1,723.2	$	11,370.3

The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:


(In millions)	Year Ended December 31, 2021

Select Key Global Products
Lipitor ®	$	1,663.2
Norvasc ®	824.7
Lyrica ®	728.5
Viagra ®	533.8
EpiPen® Auto-Injectors	391.7
Celebrex ®	344.4
Effexor ®	316.8
Creon ®	309.8
Zoloft ®	284.3
Xalabrands	226.0

Select Key Segment Products
Influvac ®	$	299.3
Amitiza ®	201.5
Xanax ®	185.9
Dymista ®	168.0
Yupelri ®	161.9

____________

(a)The Company does not disclose net sales for any products considered competitively sensitive.

(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.

(c)Prior periods are not presented due to significance of products acquired as part of the Combination.

The following is a rollforward of the categories of variable consideration during 2021:


(In millions)	Balance at December 31, 2020		Current Provision Related to Sales Made in the Current Period		Measurement Period Adjustments and Reclasses		Checks/ Credits Issued to Third Parties		Effects of Foreign Exchange		Balance at December 31, 2021
Chargebacks	$	585.2	$	5,530.1	$	63.4	$	(5,585.4)	$	(1.6)	$	591.7
Rebates, promotional programs and other sales allowances	1,576.3		6,135.6		(57.6)		(6,267.1)		(14.2)		1,373.0
Returns	539.9		384.6		269.0		(499.0)		(7.7)		686.8
Governmental rebate programs	313.3		689.5		110.6		(705.2)		(9.0)		399.2
Total	$	3,014.7	$	12,739.8	$	385.4	$	(13,056.7)	$	(32.5)	$	3,050.7

Schedule of Accounts Receivable, Net

Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:


(In millions)	December 31, 2021		December 31, 2020
Accounts receivable, net	$	1,688.6	$	1,802.9
Other current liabilities	1,362.1		1,211.8
Total	$	3,050.7	$	3,014.7

Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2021

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts

VIATRIS INC. AND SUBSIDIARIES

SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS

(In millions)


Description	Beginning Balance		Additions Charged to Costs and Expenses	Additions Charged to Other Accounts (1)	Deductions	Ending Balance
Allowance for doubtful accounts:
Year ended December 31, 2021	$	159.9	16.0	—	(21.4)	$	154.5
Year ended December 31, 2020	$	72.8	16.9	77.3	(7.1)	$	159.9
Year ended December 31, 2019	$	98.2	14.2	—	(39.6)	$	72.8
Valuation allowance for deferred tax assets:
Year ended December 31, 2021	$	443.6	82.2	260.8	(6.2)	$	780.4
Year ended December 31, 2020	$	603.5	39.0	—	(198.9)	$	443.6
Year ended December 31, 2019	$	806.0	36.8	—	(239.3)	$	603.5

Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 50.9	$ 0.9
Equity securities	51.0	45.8
Fair Value	38.2	39.1
Total assets at recurring fair value measurement	284.7	204.4
Total liabilities at recurring fair value measurement	260.7	327.2
Foreign Exchange Contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	144.6	118.6
Foreign Exchange Contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative liabilities	61.0	103.6
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	199.7	223.6
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	50.9	0.9
Equity securities — exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	50.3	45.1
Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	38.2	39.1
U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	14.6	14.4
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	16.6	17.8
Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	2.0	1.9
Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	4.6	4.6
Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0.4	0.4
Total equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		45.8
Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.7
Marketable Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		0.7
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	50.9	0.9
Equity securities	51.0
Total assets at recurring fair value measurement	101.9	46.7
Level 1 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	50.9	0.9
Level 1 \| Equity securities — exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	50.3	45.1
Level 1 \| Total equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		45.8
Level 1 \| Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.7
Level 1 \| Marketable Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		0.7
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at recurring fair value measurement	182.8	157.7
Total liabilities at recurring fair value measurement	61.0	103.6
Level 2 \| Foreign Exchange Contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	144.6	118.6
Level 2 \| Foreign Exchange Contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative liabilities	61.0	103.6
Level 2 \| Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	38.2	39.1
Level 2 \| U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	14.6	14.4
Level 2 \| Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	16.6	17.8
Level 2 \| Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	2.0	1.9
Level 2 \| Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	4.6	4.6
Level 2 \| Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0.4	0.4
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at recurring fair value measurement	199.7	223.6
Level 3 \| Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 199.7	$ 223.6

Acquisitions and Other Transactions (Purchase Price Allocations) (Details) - USD ($) $ in Millions			12 Months Ended
	Dec. 31, 2020	Nov. 13, 2020	Dec. 31, 2021	Dec. 31, 2020	Nov. 16, 2020	Dec. 31, 2019	May 28, 2019
Business Acquisition, Date of Acquisition [Abstract]
Goodwill	$ 12,347.0		$ 12,113.7	$ 12,347.0		$ 9,590.6
Cash Acquired from Acquisition	415.8
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]
Goodwill				295.6
Other assets			(7.4)
Deferred tax liabilities			1.0
Upjohn Inc. \| Pfizer, Inc.
Business Acquisition, Date of Acquisition [Abstract]
Long-term debt, including current portion					$ 13,080.0
Upjohn Inc.
Business Acquisition, Date of Acquisition [Abstract]
Current assets (excluding inventories and net of cash acquired)	2,841.9		2,803.2	2,841.9
Inventories	2,588.9		2,554.7	2,588.9
Property, plant and equipment	1,394.1		1,389.1	1,394.1
Identified intangible assets	18,040.0	$ 18,040.0	18,040.0	18,040.0
Goodwill	2,107.5	2,400.0	2,403.1	2,107.5
Deferred income tax benefit	1,481.9		1,678.2	1,481.9
Other assets	792.1		784.7	792.1
Total assets acquired	29,246.4		29,653.0	29,246.4
Current liabilities	2,760.2		3,179.9	2,760.2
Long-term debt, including current portion	13,076.2		13,076.2	13,076.2
Deferred tax liabilities	1,656.9		1,657.9	1,656.9
Other noncurrent liabilities	1,441.5		1,427.4	1,441.5
Net assets acquired	$ 10,311.6		10,311.6	$ 10,311.6			$ 10,730.0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]
Current assets (excluding inventories and net of cash acquired)			(38.7)
Inventories		1,430.0	(34.2)
Property, plant and equipment		$ 385.0	(5.0)
Goodwill			295.6
Deferred income tax benefit			196.3
Total assets acquired			406.6
Current liabilities			419.7
Other noncurrent liabilities			(14.1)
Net assets acquired (net of $415.8 of cash acquired)			$ 0.0

Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2021

Retirement Benefits [Abstract]

Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost

Included in accumulated other comprehensive loss as of December 31, 2021 and 2020 are:


	Pension Benefits				Other Postretirement Benefits
	December 31,				December 31,
(In millions)	2021		2020		2021		2020
Unrecognized actuarial (gain) loss	$	(59.9)	$	33.9	$	21.7	$	5.7
Unrecognized prior service cost (credit)	6.6		(1.4)		(3.7)		0.6
Total	$	(53.3)	$	32.5	$	18.0	$	6.3

Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits

The increase in accumulated other comprehensive loss in 2021 relating to pension benefits and other postretirement benefits consists of:


(In millions)	Pension Benefits		Other Postretirement Benefits
Unrecognized actuarial (gain) loss	$	(102.2)	$	16.2
Amortization of actuarial gain/(loss)	7.6		(0.2)
Unrecognized prior service credit (cost)	8.0		(4.3)
Amortization of prior service costs	(0.5)		—
Impact of foreign currency translation	1.3		—
Net change	$	(85.8)	$	11.7

Net Periodic Benefit Cost

Components of net periodic benefit cost for the years ended December 31, 2021, 2020 and 2019 were as follows:


	Pension Benefits						Other Postretirement Benefits
	December 31,						December 31,
(In millions)	2021		2020		2019		2021		2020		2019
Service cost	$	38.6	$	23.5	$	20.7	$	3.4	$	1.2	$	0.6
Interest cost	31.6		13.5		13.6		2.6		1.4		1.5
Expected return on plan assets	(66.1)		(19.9)		(12.1)		—		—		—
Plan curtailment, settlement and termination	(16.5)		1.1		(0.3)		—		—		3.2
Amortization of prior service costs	0.9		—		0.9		—		—		—
Recognized net actuarial losses (gains)	1.3		0.4		(0.8)		0.2		0.3		0.2
Net periodic benefit cost	$	(10.2)	$	18.6	$	22.0	$	6.2	$	2.9	$	5.5

During the year ended December 31, 2021, the Company recognized a settlement gain as a result of cash payments from lump sum elections related to the U.S. and Puerto Rico pension plans.

Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan

The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2021 and 2020.


	Pension Benefits				Other Postretirement Benefits
(In millions)	2021		2020		2021		2020
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year	$	2,145.8	$	674.7	$	188.8	$	33.8
Service cost	38.6		23.5		3.4		1.1
Interest cost	31.6		13.5		2.6		1.4
Participant contributions	2.0		1.8		2.4		0.1
Acquisitions	4.0		1,389.4		—		153.1

Plan settlements and terminations	(128.6)		(23.1)		(4.3)		(0.2)
Actuarial (gains) losses	(26.1)		37.2		16.2		1.1
Benefits paid	(52.8)		(24.6)		(20.7)		(1.6)
Impact of foreign currency translation	(67.9)		53.4		—		—
Projected benefit obligation, end of year	$	1,946.6	$	2,145.8	$	188.4	$	188.8

Change in Plan Assets
Fair value of plan assets, beginning of year	$	1,354.6	$	315.7	$	—	$	—
Actual return on plan assets	141.7		46.0		—		—
Company contributions	97.0		58.2		18.3		1.7
Participant contributions	2.0		1.8		2.4		0.1
Acquisitions	(2.1)		959.3		—		—

Plan settlements	(128.9)		(23.1)		—		(0.2)
Benefits paid	(52.8)		(24.6)		(20.7)		(1.6)

Impact of foreign currency translation	(45.1)		21.3		—		—
Fair value of plan assets, end of year	1,366.4		1,354.6		—		—
Funded status of plans	$	(580.2)	$	(791.2)	$	(188.4)	$	(188.8)

Net Accrued Benefit Costs Classification on Balance Sheet

Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheets at December 31, 2021 and 2020:


	Pension Benefits				Other Postretirement Benefits
	December 31,				December 31,
(In millions)	2021		2020		2021		2020
Noncurrent assets	$	117.2	$	70.7	$	—	$	—
Current liabilities	(14.6)		(15.1)		(16.1)		(16.3)
Noncurrent liabilities	(682.8)		(846.8)		(172.3)		(172.5)
Net accrued benefit costs	$	(580.2)	$	(791.2)	$	(188.4)	$	(188.8)

Plans with Accumulated Benefit Obligation in Excess of Plan Assets

The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of the fair value of plan assets at December 31, 2021 and 2020 were as follows:


	December 31,
(In millions)	2021		2020
Plans with accumulated benefit obligation in excess of plan assets:
Projected benefit obligation	$	1,591.8	$	1,747.2
Accumulated benefit obligation	1,546.4		1,678.2
Fair value of plan assets	904.1		893.9

Schedule of Allocation of Plan Assets

The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:


	December 31, 2021
(In millions)	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	63.1	$	1.9	$	—	$	65.0
Equity securities	53.9		497.2		—		551.1
Fixed income securities	211.4		405.5		—		616.9
Assets held by insurance companies and other	10.2		41.6		81.6		133.4
Total	$	338.6	$	946.2	$	81.6	$	1,366.4


	December 31, 2020
(In millions)	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	51.2	$	0.6	$	—	$	51.8
Equity securities	145.3		468.1		—		613.4
Fixed income securities	292.6		299.4		—		592.0
Assets held by insurance companies and other	4.0		20.0		73.4		97.4
Total	$	493.1	$	788.1	$	73.4	$	1,354.6

Schedule of Assumptions Used

The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2021 and 2020:


	Pension Benefits				Other Postretirement Benefits
	2021		2020		2021		2020
Discount rate	2.3	%	1.9	%	2.5	%	1.9	%
Expected return on plan assets	5.1	%	4.3	%	—	%	—	%
Rate of compensation increase	3.1	%	2.9	%	—	%	—	%

The following weighted average assumptions were used to determine the net periodic benefit cost for the Company’s defined benefit pension and other postretirement benefit plans for the three years in the period ended December 31, 2021:


	Pension Benefits						Other Postretirement Benefits
	2021		2020		2019		2021		2020		2019
Discount rate	1.9	%	1.6	%	2.3	%	1.9	%	3.3	%	4.3	%
Expected return on plan assets	5.1	%	4.3	%	4.3	%	—	%	—	%	—	%
Rate of compensation increase	2.9	%	2.7	%	2.9	%	—	%	—	%	—	%

Schedule of Expected Benefit Payments

Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows:


(In millions)	Pension Benefits		Other Postretirement Benefits
2022	$	101.8	$	16.1
2023	97.1		16.5
2024	103.0		16.9
2025	100.7		16.8
2026	104.3		16.6
Thereafter	528.5		73.0
Total	$	1,035.4	$	155.9

Restructuring (Narrative) (Details) - USD ($)
$ in Millions

12 Months Ended

60 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2020

Dec. 31, 2018

Restructuring Cost and Reserve [Line Items]

Payments for Restructuring

$ (25.7)

$ (59.4)

Restructuring Reserve, Period Increase (Decrease)

8.1

Restructuring and Related Cost, Incurred Cost

(32.9)

(78.3)

Restructuring Reserve, Translation and Other Adjustment

1.7

(2.2)

Restructuring and Related Cost, Cost Incurred to Date

50.5

^[1]

104.6

Restructuring Reserve

22.8

29.2

$ 22.8

$ 72.6

Effect on Future Cash Flows, Amount

$ 900.0

2016 Restructuring Program

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

733.0

Employee Severance

Restructuring Cost and Reserve [Line Items]

Payments for Restructuring

(18.1)

(48.9)

Restructuring Reserve, Period Increase (Decrease)

0.0

Restructuring and Related Cost, Incurred Cost

0.0

Restructuring Reserve, Translation and Other Adjustment

1.8

(2.1)

Restructuring and Related Cost, Cost Incurred to Date

9.9

^[1]

16.6

Restructuring Reserve

20.0

26.4

20.0

60.8

Other Restructuring

Restructuring Cost and Reserve [Line Items]

Payments for Restructuring

(7.6)

(10.5)

Restructuring Reserve, Period Increase (Decrease)

8.1

Restructuring and Related Cost, Incurred Cost

(32.9)

(78.3)

Restructuring Reserve, Translation and Other Adjustment

(0.1)

Restructuring and Related Cost, Cost Incurred to Date

40.6

^[1]

88.0

Restructuring Reserve

2.8

$ 2.8

$ 11.8

Developed Markets | Operating Segments

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

623.8

292.1

100.4

JANZ | Operating Segments

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

138.1

2.9

$ 4.2

Greater China | Operating Segments

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

$ 5.8

$ 18.4

[1]

For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively.

(2) For the year ended December 31, 2020, total restructuring charges, for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively.

(3) For the year ended December 31, 2019, total restructuring charges for the 2016 Restructuring Program in Developed Markets and JANZ were approximately $100.4 million and $4.2 million, respectively.

Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Mature within one year	$ 1.2
Mature in one to five years	19.7
Mature in five years and later	17.3
Available-for-sale securities, debt securities	$ 38.2	$ 39.1

Share-Based Incentive Plan

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Incentive Plan

Prior to the Distribution, Viatris adopted and Pfizer, in the capacity as Viatris’ sole stockholder at such time, approved the Plan (the Viatris Inc. 2020 Stock Incentive Plan) which became effective as of the Distribution. In connection with the Combination, as of November 16, 2020, the Company assumed the 2003 LTIP (Mylan N.V. Amended and Restated 2003 Long-Term Incentive Plan), which had previously been approved by Mylan shareholders. The Plan and 2003 LTIP include (i) 72,500,000 shares of Common Stock authorized for grant pursuant to the Plan, which may include dividend payments payable in Common Stock on unvested shares granted under awards, (ii) 6,757,640 shares of Common Stock to be issued pursuant to the exercise of outstanding stock options granted to participants under the 2003 LTIP and assumed by Viatris in connection with the Combination and (iii) 13,535,627 shares of Common Stock subject to outstanding equity-based awards, other than stock options, assumed by Viatris in connection with the Combination, or that otherwise remain available for issuance under the 2003 LTIP.

Under the Plan and 2003 LTIP, shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, SARs, restricted stock and units, PSUs, other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the shares underlying the stock options at the date of the grant, generally become exercisable over periods ranging from three to four years, and generally expire in ten years.

The following table summarizes stock awards (stock options and SARs) activity under the Plan and 2003 LTIP:


	Number of Shares Under Stock Awards	Weighted Average Exercise Price per Share
Outstanding at December 31, 2018	6,815,278	$	36.61
Granted	829,322	26.18
Exercised	(580,950)	14.40
Forfeited	(715,941)	39.40

Outstanding at December 31, 2019	6,347,709	$	36.97
Granted	814,351	17.37
Exercised	(27,615)	21.13
Forfeited	(422,714)	25.74
Outstanding at December 31, 2020	6,711,731	$	35.36


Forfeited	(1,135,241)	26.39
Outstanding at December 31, 2021	5,576,490	$	37.19
Vested and expected to vest at December 31, 2021	5,487,788	$	37.45
Exercisable at December 31, 2021	4,969,602	$	39.21

As of December 31, 2021, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had average remaining contractual terms of 4.6 years, 4.6 years and 4.2 years, respectively. Also, at December 31, 2021, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had no aggregate intrinsic value.

A summary of the status of the Company’s nonvested restricted stock awards (restricted stock and restricted stock unit awards, including PSUs), as of December 31, 2020 and the changes during the year ended December 31, 2021 are presented below:


	Number of Restricted Stock Awards	Weighted Average Grant-Date Fair Value Per Share
Nonvested at December 31, 2020	12,073,790	$	18.34
Granted	9,850,443	14.46
Released	(3,168,152)	24.65
Forfeited	(1,897,953)	15.33
Nonvested at December 31, 2021	16,858,128	$	15.12

Of the 9,850,443 restricted stock awards granted during the year ended December 31, 2021, 6,057,602 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining restricted stock awards granted, 587,025 are not subject to market conditions and will cliff vest within a three-year period, and 3,205,816 are subject to market or performance conditions and will cliff vest in three years or less.

As of December 31, 2021, the Company had $143.1 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 1.7 years. The total intrinsic value of stock awards exercised and restricted stock units released during the years ended December 31, 2021 and 2020 was $78.1 million and $20.9 million, respectively.

With respect to options granted under the Plan and 2003 LTIP, the fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield and employee exercise behavior. Expected volatilities utilized in the model are based mainly on the implied volatility of the Company’s stock price and other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The model incorporates exercise and post-vesting forfeiture assumptions based on an analysis of historical data. The expected lives of the grants are derived from historical and other factors.

There were no options granted during the year ended December 31, 2021. The assumptions used for options granted under the Plan and 2003 LTIP during the years ended December 31, 2020 and 2019, respectively, are as follows:


	Year Ended December 31,
	2020	2019
Volatility	46.7%	38.1%
Risk-free interest rate	1.0%	2.5%
Expected term (years)	6.5	6.5
Forfeiture rate	5.5%	5.5%
Weighted average grant date fair value per option	$8.07	$11.03

Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net change	$ 73.9	$ (14.0)	$ (24.8)
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain) loss	(102.2)
Amortization of actuarial gain/(loss)	7.6
Unrecognized prior service credit (cost)	(8.0)
Amortization of prior service costs	(0.5)
Impact of foreign currency translation	1.3
Net change	(85.8)
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain) loss	16.2
Amortization of actuarial gain/(loss)	(0.2)
Unrecognized prior service credit (cost)	4.3
Amortization of prior service costs	0.0
Impact of foreign currency translation	0.0
Net change	$ 11.7

Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) - Restricted Stock Awards	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted stock awards, nonvested beginning balance \| shares	12,073,790
Weighted average grant-date fair value per share, nonvested beginning balance \| $ / shares	$ 18.34
Number of restricted stock awards, granted \| shares	9,850,443
Weighted average grant-date fair value per share, granted \| $ / shares	$ 14.46
Number of restricted stock awards, released \| shares	(3,168,152)
Weighted average grant-date fair value per share, released \| $ / shares	$ 24.65
Number of restricted stock awards, forfeited \| shares	(1,897,953)
Weighted average grant-date fair value per share, forfeited \| $ / shares	$ 15.33
Number of restricted stock awards, nonvested ending balance \| shares	16,858,128
Weighted average grant-date fair value per share, nonvested ending balance \| $ / shares	$ 15.12

Balance Sheet Components (Trade Accounts Payable) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Accounts Payable, Current [Abstract]
Trade accounts payable	$ 1,056.1	$ 1,345.7
Other payables	601.3	558.5
Accounts payable	$ 1,657.4	$ 1,904.2

Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	$ 159.9	$ 72.8	$ 98.2
Additions Charged to Costs and Expenses	16.0	16.9	14.2
Additions Charged to Other Accounts	0.0	77.3	0.0
Deductions	(21.4)	(7.1)	(39.6)
Ending balance	154.5	159.9	72.8
Valuation allowance for deferred tax assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	443.6	603.5	806.0
Additions Charged to Costs and Expenses	82.2	39.0	36.8
Additions Charged to Other Accounts	260.8	0.0	0.0
Deductions	(6.2)	(198.9)	(239.3)
Ending balance	$ 780.4	$ 443.6	$ 603.5

Nature of Operations	12 Months Ended
Nature of Operations	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations Viatris is a global healthcare company formed in November 2020 whose mission is to empower people worldwide to live healthier at every stage of life, regardless of geography or circumstance. Improving the ability of patients to gain access to sustainable and high-quality healthcare is our relentless pursuit. One that rests on visionary thinking, determination and best-in-class capabilities that were strategically built to remove barriers across the health spectrum and advance access globally. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. The Company operates approximately 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs. We conduct our business through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India. In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and all historical financial information of the Company prior to November 16, 2020 represents Mylan’s historical results and the Company’s thereafter.

Litigation (Narrative) (Details) £ in Thousands, case in Thousands, € in Millions, $ in Millions								1 Months Ended		3 Months Ended	12 Months Ended
	Jun. 17, 2019 agreement patent	Jun. 17, 2019 patent	Sep. 10, 2018 patent	Oct. 24, 2017 patent	Jun. 30, 2017 patent	Feb. 12, 2016 GBP (£)	Jul. 09, 2014 EUR (€)	Feb. 28, 2022 USD ($)	Jun. 19, 2013 EUR (€)	Dec. 31, 2014 USD ($)	Dec. 31, 2021 USD ($) agreement state case increase	Dec. 31, 2021 GBP (£) state case	Apr. 02, 2020 patent
Loss Contingencies [Line Items]
Number of cases \| case											1	1
Product Liability
Loss Contingencies [Line Items]
Loss contingency accrual											$ 74.8
Intellectual Property
Loss Contingencies [Line Items]
Loss contingency accrual											$ 226.9
Number of times damages may be increased in cases of willful infringement \| increase											3
Other Foreign Operations
Loss Contingencies [Line Items]
Loss contingency accrual											$ 8.4
MDL
Loss Contingencies [Line Items]
Number of states \| state											47	47
Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil
Loss Contingencies [Line Items]
Number of states \| state											37	37
Anticompetitive Conduct with Generic Drugs
Loss Contingencies [Line Items]
Number of states \| state											48	48
Amended Anticompetitive Conduct with Generic Drugs
Loss Contingencies [Line Items]
Number of states \| state											43	43
EU Commission Proceedings Perindorpril \| Antitrust Proceedings \| Mylan Laboratories Limited
Loss Contingencies [Line Items]
Damages awarded \| €							€ 17.2
Loss contingency accrual										$ 21.7
U.K. Competition and Markets Authority Proceedings Paroxetine
Loss Contingencies [Line Items]
Damages awarded \| £						£ 5,800
Loss Contingency, Damages Awarded On Appeal, Value \| £						3,900
U.K. Competition and Markets Authority Proceedings Paroxetine \| Mylan
Loss Contingencies [Line Items]
Loss contingency accrual \| £												£ 8,800
Damages awarded \| £						2,700
Loss Contingency, Damages Awarded On Appeal, Value \| £						£ 2,050
EU Commission Proceedings Citalopram
Loss Contingencies [Line Items]
Loss contingency accrual											$ 11.4
Damages awarded \| €									€ 7.8
Dimethyl Fumarate
Loss Contingencies [Line Items]
Loss Contingency, Patents Allegedly Infringed, Number \| patent					6
Insulin Glargine
Loss Contingencies [Line Items]
Loss Contingency, Patents Allegedly Infringed, Number \| patent			5	18
Loss Contingency, Patents Found Not Infringed, Number	12	3
Loss Contingency, Remaining Claims, Number \| patent	4	4		2									2
Loss Contingency, Other Asserted Patents, Number \| patent	16	16
EpiPen Auto-Injector Litigation
Loss Contingencies [Line Items]
Loss contingency accrual											$ 264.0
Loss Contingency, Number of States \| agreement											17
EpiPen Auto-Injector Litigation \| Subsequent Event
Loss Contingencies [Line Items]
Amount awarded to other party								$ 264.0
EpiPen Auto-Injector Litigation \| Other current liabilities
Loss Contingencies [Line Items]
Estimated Litigation Liability											$ 274.0

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Earnings Per Common Share Attributable To Mylan

Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:


	Year Ended December 31,
(In millions, except per share amounts)	2021		2020		2019
Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders	$	(1,269.1)	$	(669.9)	$	16.8
Shares (denominator):
Weighted average shares outstanding	1,208.8		601.2		515.7
Basic (loss) earnings per share attributable to Viatris Inc. shareholders	$	(1.05)	$	(1.11)	$	0.03

Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders	$	(1,269.1)	$	(669.9)	$	16.8
Shares (denominator):
Weighted average shares outstanding	1,208.8		601.2		515.7
Share-based awards	—		—		0.8
Total dilutive shares outstanding	1,208.8		601.2		516.5
Diluted (loss) earnings per share attributable to Viatris Inc. shareholders	$	(1.05)	$	(1.11)	$	0.03

Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 701.2	$ 844.4	$ 475.6
Restricted cash, included in other current and non-current assets	5.0	5.6	15.5
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 706.2	$ 850.0	$ 491.1	$ 389.3

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in carrying amount of goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:


(In millions)	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Balance at December 31, 2019:
Goodwill	$	8,258.0	$	67.8	$	584.8	$	1,065.0	$	9,975.6
Accumulated impairment losses	(385.0)		—		—		—		(385.0)
	7,873.0		67.8		584.8		1,065.0		9,590.6
Acquisitions	704.3		652.8		217.4		533.0		2,107.5
Foreign currency translation	607.2		17.7		61.8		(37.8)		648.9
	9,184.5		738.3		864.0		1,560.2		12,347.0
Balance at December 31, 2020:
Goodwill	9,569.5		738.3		864.0		1,560.2		12,732.0
Accumulated impairment losses	(385.0)		—		—		—		(385.0)
	9,184.5		738.3		864.0		1,560.2		12,347.0
Measurement period and other adjustments	67.7		220.4		(30.9)		38.4		295.6
Foreign currency translation	(528.8)		10.8		(56.8)		45.9		(528.9)
	8,723.4		969.5		776.3		1,644.5		12,113.7
Balance at December 31, 2021
Goodwill	9,108.4		969.5		776.3		1,644.5		12,498.7
Accumulated impairment losses	(385.0)		—		—		—		(385.0)
	$	8,723.4	$	969.5	$	776.3	$	1,644.5	$	12,113.7

Components of intangible assets

Intangible assets consist of the following components at December 31, 2021 and 2020:


(In millions)	Weighted Average Life (Years)	Cost		Accumulated Amortization		Net Book Value
December 31, 2021
Product rights, licenses and other (1)	15	$	39,006.2	$	12,918.5	$	26,087.7
In-process research and development		46.5		—		46.5
		$	39,052.7	$	12,918.5	$	26,134.2
December 31, 2020
Product rights, licenses and other (1)	15	$	40,404.1	$	10,801.6	$	29,602.5
In-process research and development		80.7		—		80.7
		$	40,484.8	$	10,801.6	$	29,683.2

____________

(1)Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights.

Product rights and licenses by therapeutic category

Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by product category, is as follows:


(In millions)	Developed Markets		Greater China		JANZ		Emerging Markets		December 31, 2021
Brands	$	10,066.6	$	6,102.9	$	1,174.8	$	3,801.7	$	21,146.0
Complex Gx and Biosimilars	226.8		—		1.5		—		228.3
Generics	4,020.2		12.1		319.5		358.4		4,710.2
Total Product Rights and Licenses	$	14,313.6	$	6,115.0	$	1,495.8	$	4,160.1	$	26,084.5


(In millions)	Developed Markets		Greater China		JANZ		Emerging Markets		December 31, 2020
Brands	$	10,988.1	$	4,372.3	$	2,377.0	$	4,478.7	$	22,216.1
Complex Gx and Biosimilars	272.5		—		2.3		—		274.8
Generics	6,253.9		12.7		423.9		417.3		7,107.8
Total Product Rights and Licenses	$	17,514.5	$	4,385.0	$	2,803.2	$	4,896.0	$	29,598.7

Finite-lived Intangible Assets Amortization Expense [Table Text Block]

Amortization expense and intangible asset impairment charges, which are included as a component of amortization expense, which is classified primarily within cost of sales in the consolidated statements of operations, for the years ended December 31, 2021, 2020 and 2019 was as follows:


	Year ended December 31,
(In millions)	2021		2020		2019
Intangible asset amortization expense	$	2,702.2	$	1,605.8	$	1,582.7
IPR&D intangible asset impairment charges	19.4		37.4		138.3
Finite-lived intangible asset impairment charges	83.4		45.0		42.3
Total intangible asset amortization expense (including impairment charges)	$	2,805.0	$	1,688.2	$	1,763.3

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Intangible asset amortization expense for the years ending December 31, 2022 through 2026 is estimated to be as follows:


(In millions)
2022	$	2,577
2023	2,414
2024	2,320
2025	2,222
2026	2,164

Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Unrecognized tax benefit — beginning of year	$ 322.9	$ 391.1	$ 92.1		$ 96.3
Additions for current year tax positions	0.0		13.4	$ 0.0
Additions for prior year tax positions	0.0		35.7	154.9
Reductions for prior year tax positions	(9.1)		(5.2)	(11.7)
Settlements	(47.3)		(8.9)	(112.5)
Reductions due to expirations of statute of limitations	(7.0)		0.0	$ (34.9)
Unrecognized Tax Benefits, Decrease Resulting from Acquisition	(4.8)
(Reduction) addition due to acquisition		264.0	0.0
Unrecognized tax benefit — end of year	$ 322.9	$ 391.1	$ 92.1

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017	Dec. 31, 2016
Income Tax Contingency [Line Items]
Deferred tax liability not recognized, amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries		$ 3,400.0
Statutory tax rate		21.00%	21.00%	19.00%
Valuation allowance, amount		$ 780.4	$ 443.6
Expected foreign tax credits		230.3
Unrecognized tax benefit		322.9	391.1	$ 92.1		$ 96.3
Unrecognized tax benefits that impact effective tax rate		230.2
Accrued interest and penalties		96.8	86.7
Interest expense (income) related to uncertain tax positions		18.5		6.0	$ 35.2
Amount of unrecognized deferred tax liability		$ 55.0
Deduction limit of GILTI tax		50.00%
Unrecognized tax benefit — beginning of year		$ 322.9	391.1	92.1		$ 96.3
Reserve for Uncertain Tax Positions, Including Interest And Penalties		315.6
CARES Act, Income Tax Expense (Benefit)			$ 22.1
U.S. Federal Tax Authority
Income Tax Contingency [Line Items]
Net operating loss carryforwards		7.9
U.S. State Tax Authority
Income Tax Contingency [Line Items]
Net operating loss carryforwards		3,100.0
Foreign
Income Tax Contingency [Line Items]
Net operating loss carryforwards		1,570.0
Foreign deductible attributes		39.6
Credit carryforward		329.2
Foreign \| Australian Taxation Office
Income Tax Contingency [Line Items]
Partial payment of anticipated tax expense		56.0
Indefinite \| Foreign
Income Tax Contingency [Line Items]
Net operating loss carryforwards		748.4
2016 through 2035 \| Foreign
Income Tax Contingency [Line Items]
Net operating loss carryforwards		$ 817.8
Tax Year 2015 \| Domestic Tax Authority \| Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Income Tax Examination, Reserve for Uncertain Tax Position				155.0
Income Tax Examination, Reserve Impact On Income Tax Provision				$ 144.9
Scenario, Forecast
Income Tax Contingency [Line Items]
Deduction limit of GILTI tax	37.50%

Revenue Recognition and Accounts Receivable Variable Consideration (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Gross sales	$ 30,553.4	$ 19,899.1	$ 19,012.2
Chargebacks	(5,530.1)	(3,656.2)	(3,309.6)
Rebates, promotional programs and other sales allowances	(6,135.6)	(3,765.5)	(3,629.3)
Returns	(384.6)	(329.7)	(237.9)
Medicaid and other governmental rebates	(689.5)	(327.8)	(465.1)
Sales Revenue, Gross to net adjustments	12,739.8	8,079.2	7,641.9
Net sales	17,813.6	11,819.9	11,370.3
Net sales
Disaggregation of Revenue [Line Items]
Net sales	17,813.6	11,819.9	$ 11,370.3
Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	$ 17,813.6	$ 11,819.9

Debt Debt (Receivables Facility and Commercial Paper Program) (Details) - USD ($) $ in Thousands		12 Months Ended
	Jun. 06, 2017	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Short-term borrowings		$ 1,493,000	$ 1,100,900
Securitized accounts receivable		388,900	389,400
Commercial Paper Program [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,650,000
Debt Instrument, Term	364 days
Receivables Facility [Member]
Debt Instrument [Line Items]
Short-term borrowings		318,500	248,400
Accounts receivable securitization facility maximum borrowing capacity		400,000
Note Securitization Facility [Member]
Debt Instrument [Line Items]
Short-term borrowings		0	$ 200,000
Accounts receivable securitization facility maximum borrowing capacity		$ 200,000
London Interbank Offered Rate (LIBOR) [Member] \| Receivables Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.925%
London Interbank Offered Rate (LIBOR) [Member] \| Note Securitization Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.85%

Leases

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Lessee, Operating Leases

Leases

The Company has operating leases of real estate, consisting primarily of administrative offices, manufacturing and distribution facilities, and R&D facilities. We also have operating leases of certain equipment, primarily automobiles, and certain limited supply arrangements.

We elected to apply the practical expedient to not separate lease and non-lease components for our leases except for those related to certain limited supply arrangements. We have also elected to apply the short-term lease recognition exemption which means we will not recognize ROU assets or lease liabilities for leases with an initial term of 12 months of less.

As of December 31, 2021, the Company recognized ROU assets of $290.8 million and total lease liabilities of $287.6 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance sheets. Refer to Note 5 Balance Sheet Components for additional information.

ROU assets and liabilities are recognized at the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use an applicable incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Options to extend or terminate the ROU assets are reviewed at lease inception and these options are accounted for when they are reasonably certain of being exercised.

Other information related to leases was as follows:


	As of December 31, 2021
Remaining lease terms	1 year to 23 years
Weighted-average remaining lease term	6 years
Weighted-average discount rate	2.6	%

As of December 31, 2021, maturities of lease liabilities were as follows:


(In millions)
Year ending December 31,
2022	$	82.0
2023	65.0
2024	42.9
2025	28.8
2026	23.9
Thereafter	68.2
Total lease payments	$	310.8
Less imputed interest	23.2
Total lease liability	$	287.6

As of December 31, 2021, we have additional operating leases, primarily for administrative offices, that have not yet commenced totaling approximately $13.6 million. These leases are expected to commence in 2022 and have lease terms of 5 to 9 years. For the years ended December 31, 2021, 2020 and 2019, the Company had operating lease expense of approximately $97.6 million, $80.7 million and $87.6 million, respectively. Operating lease costs are classified primarily as selling, general and administrative expenses and cost of sales in the consolidated statements of operations.

Comprehensive Earnings

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Comprehensive Earnings

Comprehensive (Loss) Earnings

Accumulated other comprehensive loss, as reflected in the consolidated balance sheets, is comprised of the following:


(In millions)	December 31, 2021		December 31, 2020
Accumulated other comprehensive loss:
Net unrealized gain on marketable securities, net of tax	$	—	$	1.2
Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax	32.2		(26.1)
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax	9.2		(18.0)
Net unrecognized loss on derivatives in net investment hedging relationships, net of tax	16.7		(353.6)
Foreign currency translation adjustment	(1,802.4)		(461.5)
	$	(1,744.3)	$	(858.0)

Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following:


	Year Ended December 31, 2021
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax			62.7		456.8		(1.1)		67.0		(1,340.9)		(755.5)
Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(30.9)		(30.9)										(30.9)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.3	4.3										4.3
Amortization of prior service costs included in SG&A									(0.5)				(0.5)
Amortization of actuarial loss included in SG&A									7.4				7.4
Net other comprehensive earnings (loss), before tax			36.1		456.8		(1.1)		73.9		(1,340.9)		(775.2)
Income tax provision			8.9		86.5		0.1		15.6		—		111.1

Balance at December 31, 2021, net of tax			$	9.2	$	16.7	$	—	$	32.2	$	(1,802.4)	$	(1,744.3)


	Year Ended December 31, 2020
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2019, net of tax			$	(31.6)	$	(74.3)	$	0.6	$	(17.4)	$	(1,674.5)	$	(1,797.2)
Other comprehensive (loss) earnings before reclassifications, before tax			18.5		(305.2)		0.6		(12.1)		1,213.0		914.8
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(4.8)		(4.8)										(4.8)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.5	4.5										4.5
Amortization of prior service costs included in SG&A									—				—
Amortization of actuarial loss included in SG&A									(1.9)				(1.9)
Net other comprehensive (loss) earnings, before tax			18.2		(305.2)		0.6		(14.0)		1,213.0		912.6
Income tax provision (benefit)			4.6		(25.9)		—		(5.3)		—		(26.6)

Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)


	Year Ended December 31, 2019
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2018, net of tax			$	(53.1)	$	(130.9)	$	—	$	1.7	$	(1,259.0)	$	(1,441.3)
Other comprehensive earnings (loss) before reclassifications, before tax			29.3		59.6		0.5		(21.0)		(415.5)		(347.1)
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales	0.7		0.7										0.7
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		7.1	7.1										7.1
Amortization of prior service costs included in SG&A									(0.9)				(0.9)
Amortization of actuarial loss included in SG&A									(2.9)				(2.9)
Net other comprehensive earnings (loss), before tax			37.1		59.6		0.5		(24.8)		(415.5)		(343.1)
Income tax provision (benefit)			12.2		3.0		(0.1)		(5.9)		—		9.2
Cumulative effect of the adoption of new accounting standards			(3.4)		—		—		(0.2)		—		(3.6)
Balance at December 31, 2019, net of tax			$	(31.6)	$	(74.3)	$	0.6	$	(17.4)	$	(1,674.5)	$	(1,797.2)

Share-Based Incentive Plan (Valuation Assumptions) (Details) - Long Term Incentive Plan 2003 - Stock options - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	46.70%	38.10%
Risk-free interest rate	1.00%	2.50%
Expected term (years)	6 years 6 months	6 years 6 months
Forfeiture rate	5.50%	5.50%
Weighted average grant date fair value per option	$ 8.07	$ 11.03

Balance Sheet Components (Tables)

12 Months Ended

Dec. 31, 2021

Balance Sheet Components [Abstract]

Schedule of Cash, Cash Equivalents, and Restricted Cash

Cash and restricted cash


(In millions)	December 31, 2021		December 31, 2020		December 31, 2019
Cash and cash equivalents	$	701.2	$	844.4	$	475.6
Restricted cash, included in other current and non-current assets	5.0		5.6		15.5
Cash, cash equivalents and restricted cash	$	706.2	$	850.0	$	491.1

Inventories


(In millions)	December 31, 2021		December 31, 2020
Raw materials	$	922.4	$	958.4
Work in process	993.3		1,438.1
Finished goods	2,062.0		3,075.4
Inventories	$	3,977.7	$	5,471.9

Property, plant and equipment

Property, plant and equipment, net


(In millions)	December 31, 2021		December 31, 2020
Machinery and equipment	$	3,054.0	$	3,235.0
Buildings and improvements	1,808.5		1,954.8
Construction in progress	588.7		376.3
Land and improvements	137.9		155.8
Gross property, plant and equipment	5,589.1		5,721.9
Accumulated depreciation	2,400.5		2,262.0
Property, plant and equipment, net	$	3,188.6	$	3,459.9

Other assets


(In millions)	December 31, 2021		December 31, 2020
Equity method investments, clean energy investments	$	—	$	47.9
Operating lease right-of-use assets	290.8		323.6

Other long-term assets	879.9		676.0
Other assets	$	1,170.7	$	1,047.5

Other current liabilities


(In millions)	December 31, 2021		December 31, 2020
Accrued sales allowances	$	1,362.1	$	1,211.8
Payroll and employee benefit liabilities	741.9		828.2
Legal and professional accruals, including litigation accruals	715.6		362.9
Contingent consideration	66.7		100.5
Accrued restructuring	233.5		149.2
Equity method investments, clean energy investments	10.9		47.5
Accrued interest	86.6		90.9
Fair value of financial instruments	61.0		103.6
Operating lease liability	86.7		92.9
Other	1,254.6		1,973.2
Other current liabilities	$	4,619.6	$	4,960.7

Other noncurrent liabilities


(In millions)	December 31, 2021		December 31, 2020
Employee benefit liabilities	$	876.4	$	1,020.4

Contingent consideration	133.0		123.1
Tax related items, including contingencies	426.1		469.5
Operating lease liability	200.9		229.5
Accrued restructuring	64.3		134.8
Other	232.9		505.8
Other long-term obligations	$	1,933.6	$	2,483.1

Schedule of Other Current Assets

Prepaid expenses and other current assets


(In millions)	December 31, 2021		December 31, 2020
Prepaid expenses	$	256.7	$	267.8

Available-for-sale fixed income securities	38.2		39.1
Fair value of financial instruments	144.6		118.6
Equity securities	51.0		45.8
Other current assets	1,467.1		1,236.1
Prepaid expenses and other current assets	$	1,957.6	$	1,707.4

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable


(In millions)	December 31, 2021		December 31, 2020
Trade accounts payable	$	1,056.1	$	1,345.7
Other payables	601.3		558.5
Accounts payable	$	1,657.4	$	1,904.2

Revenue Recognition and Accounts Receivable

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue Recognition and Accounts Receivable

The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:


(In millions)	2021 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	5,759.2		2,207.8		1,197.1		1,677.2		10,841.3
Complex Gx and Biosimilars	1,241.6		0.2		46.5		53.8		1,342.1
Generics	3,427.9		4.8		783.8		1,413.7		5,630.2
Total Viatris	$	10,428.7	$	2,212.8	$	2,027.4	$	3,144.7	$	17,813.6


(In millions)	2020 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	3,920.7		253.9		617.0		443.3		5,234.9
Complex Gx and Biosimilars	1,202.6		0.7		42.8		49.4		1,295.5
Generics	3,387.6		5.3		535.5		1,361.1		5,289.5
Total Viatris	$	8,510.9	$	259.9	$	1,195.3	$	1,853.8	$	11,819.9


(In millions)	2019 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	4,199.1		207.6		533.3		422.1		5,362.1
Complex Gx and Biosimilars	1,127.4		0.4		23.8		59.7		1,211.3
Generics	2,913.5		6.6		635.4		1,241.4		4,796.9
Total Viatris	$	8,240.0	$	214.6	$	1,192.5	$	1,723.2	$	11,370.3

The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:


(In millions)	Year Ended December 31, 2021

Select Key Global Products
Lipitor ®	$	1,663.2
Norvasc ®	824.7
Lyrica ®	728.5
Viagra ®	533.8
EpiPen® Auto-Injectors	391.7
Celebrex ®	344.4
Effexor ®	316.8
Creon ®	309.8
Zoloft ®	284.3
Xalabrands	226.0

Select Key Segment Products
Influvac ®	$	299.3
Amitiza ®	201.5
Xanax ®	185.9
Dymista ®	168.0
Yupelri ®	161.9

____________

(a)The Company does not disclose net sales for any products considered competitively sensitive.

(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.

(c)Prior periods are not presented due to significance of products acquired as part of the Combination.

Variable Consideration and Accounts Receivable

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2021, 2020 and 2019, respectively:


	Year Ended December 31,
(In millions)	2021		2020		2019
Gross sales	$	30,553.4	$	19,899.1	$	19,012.2
Gross to net adjustments:
Chargebacks	(5,530.1)		(3,656.2)		(3,309.6)
Rebates, promotional programs and other sales allowances	(6,135.6)		(3,765.5)		(3,629.3)
Returns	(384.6)		(329.7)		(237.9)
Governmental rebate programs	(689.5)		(327.8)		(465.1)
Total gross to net adjustments	$	(12,739.8)	$	(8,079.2)	$	(7,641.9)
Net sales	$	17,813.6	$	11,819.9	$	11,370.3

The following is a rollforward of the categories of variable consideration during 2021:


(In millions)	Balance at December 31, 2020		Current Provision Related to Sales Made in the Current Period		Measurement Period Adjustments and Reclasses		Checks/ Credits Issued to Third Parties		Effects of Foreign Exchange		Balance at December 31, 2021
Chargebacks	$	585.2	$	5,530.1	$	63.4	$	(5,585.4)	$	(1.6)	$	591.7
Rebates, promotional programs and other sales allowances	1,576.3		6,135.6		(57.6)		(6,267.1)		(14.2)		1,373.0
Returns	539.9		384.6		269.0		(499.0)		(7.7)		686.8
Governmental rebate programs	313.3		689.5		110.6		(705.2)		(9.0)		399.2
Total	$	3,014.7	$	12,739.8	$	385.4	$	(13,056.7)	$	(32.5)	$	3,050.7

Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net revenues and as a contra-asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:


(In millions)	December 31, 2021		December 31, 2020
Accounts receivable, net	$	1,688.6	$	1,802.9
Other current liabilities	1,362.1		1,211.8
Total	$	3,050.7	$	3,014.7

We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

Balance Sheet Components

12 Months Ended

Dec. 31, 2021

Balance Sheet Components [Abstract]

Balance Sheet Components

Selected balance sheet components consist of the following:

Cash and restricted cash


(In millions)	December 31, 2021		December 31, 2020		December 31, 2019
Cash and cash equivalents	$	701.2	$	844.4	$	475.6
Restricted cash, included in other current and non-current assets	5.0		5.6		15.5
Cash, cash equivalents and restricted cash	$	706.2	$	850.0	$	491.1

Inventories


(In millions)	December 31, 2021		December 31, 2020
Raw materials	$	922.4	$	958.4
Work in process	993.3		1,438.1
Finished goods	2,062.0		3,075.4
Inventories	$	3,977.7	$	5,471.9

Inventory reserves totaled $519.0 million and $353.6 million at December 31, 2021 and 2020, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $474.9 million, $206.1 million and $399.2 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Prepaid expenses and other current assets


(In millions)	December 31, 2021		December 31, 2020
Prepaid expenses	$	256.7	$	267.8

Available-for-sale fixed income securities	38.2		39.1
Fair value of financial instruments	144.6		118.6
Equity securities	51.0		45.8
Other current assets	1,467.1		1,236.1
Prepaid expenses and other current assets	$	1,957.6	$	1,707.4

Prepaid expenses consist primarily of prepaid rent, insurance and other individually insignificant items.

Property, plant and equipment, net


(In millions)	December 31, 2021		December 31, 2020
Machinery and equipment	$	3,054.0	$	3,235.0
Buildings and improvements	1,808.5		1,954.8
Construction in progress	588.7		376.3
Land and improvements	137.9		155.8
Gross property, plant and equipment	5,589.1		5,721.9
Accumulated depreciation	2,400.5		2,262.0
Property, plant and equipment, net	$	3,188.6	$	3,459.9

Capitalized software costs included in our consolidated balance sheets were $62.3 million and $70.9 million, net of accumulated depreciation, at December 31, 2021 and 2020, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $509.5 million, $289.7 million and $256.1 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Other assets


(In millions)	December 31, 2021		December 31, 2020
Equity method investments, clean energy investments	$	—	$	47.9
Operating lease right-of-use assets	290.8		323.6

Other long-term assets	879.9		676.0
Other assets	$	1,170.7	$	1,047.5

Accounts payable


(In millions)	December 31, 2021		December 31, 2020
Trade accounts payable	$	1,056.1	$	1,345.7
Other payables	601.3		558.5
Accounts payable	$	1,657.4	$	1,904.2

Other current liabilities


(In millions)	December 31, 2021		December 31, 2020
Accrued sales allowances	$	1,362.1	$	1,211.8
Payroll and employee benefit liabilities	741.9		828.2
Legal and professional accruals, including litigation accruals	715.6		362.9
Contingent consideration	66.7		100.5
Accrued restructuring	233.5		149.2
Equity method investments, clean energy investments	10.9		47.5
Accrued interest	86.6		90.9
Fair value of financial instruments	61.0		103.6
Operating lease liability	86.7		92.9
Other	1,254.6		1,973.2
Other current liabilities	$	4,619.6	$	4,960.7

Other long-term obligations


(In millions)	December 31, 2021		December 31, 2020
Employee benefit liabilities	$	876.4	$	1,020.4

Contingent consideration	133.0		123.1
Tax related items, including contingencies	426.1		469.5
Operating lease liability	200.9		229.5
Accrued restructuring	64.3		134.8
Other	232.9		505.8
Other long-term obligations	$	1,933.6	$	2,483.1

Goodwill and Other Intangible Assets (Amortization Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Intangible Assets Excluding Goodwill [Line Items]
Intangible asset amortization expense	$ 2,702.2	$ 1,605.8	$ 1,582.7
Total intangible asset amortization expense (including impairment charges)	2,805.0	1,688.2	1,763.3
In-process research and development
Intangible Assets Excluding Goodwill [Line Items]
IPR&D intangible asset impairment charges	$ 19.4	$ 37.4	$ 138.3

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 701,200	$ 844,400
Accounts receivable, net	4,266,400	4,843,800
Inventories	3,977,700	5,471,900
Prepaid expenses and other current assets	1,957,600	1,707,400
Total current assets	10,902,900	12,867,500
Property, plant and equipment, net	3,188,600	3,459,900
Intangible assets, net	26,134,200	29,683,200
Goodwill	12,113,700	12,347,000
Deferred income tax benefit	1,332,700	2,147,900
Other assets	1,170,700	1,047,500
Total assets	54,842,800	61,553,000
Current liabilities:
Accounts payable	1,657,400	1,904,200
Short-term borrowings	1,493,000	1,100,900
Income taxes payable	236,900	288,600
Current portion of long-term debt and other long-term obligations	1,877,500	2,308,500
Other current liabilities	4,619,600	4,960,700
Total current liabilities	9,884,400	10,562,900
Long-term debt	19,717,100	22,429,200
Deferred income tax liability	2,815,000	3,123,700
Other long-term obligations	1,933,600	2,483,100
Total liabilities	34,350,100	38,598,900
Viatris Inc. shareholders’ equity
Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued and outstanding: 1,209,507,463 and 1,206,895,644, respectively	12,100	12,100
Additional paid-in capital	18,536,100	18,438,800
Retained earnings	3,688,800	5,361,200
Accumulated other comprehensive loss	(1,744,300)	(858,000)
Total equity	20,492,700	22,954,100
Total liabilities and equity	$ 54,842,800	$ 61,553,000

Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details) $ in Millions	Dec. 31, 2021 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 2,577
2023	2,414
2024	2,320
2025	2,222
2026	$ 2,164

Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain) loss	$ (59.9)	$ 33.9
Unrecognized prior service cost (credit)	6.6	(1.4)
Total	(53.3)	32.5
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain) loss	21.7	5.7
Unrecognized prior service cost (credit)	(3.7)	0.6
Total	$ 18.0	$ 6.3

Employee Benefit Plans (Estimated Future Benefit Payments) (Details) $ in Millions	Dec. 31, 2021 USD ($)
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2019	$ 101.8
2020	97.1
2021	103.0
2022	100.7
2023	104.3
Thereafter	528.5
Total	1,035.4
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2019	16.1
2020	16.5
2021	16.9
2022	16.8
2023	16.6
Thereafter	73.0
Total	$ 155.9

Balance Sheet Components (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Capitalized Computer Software, Net	$ 62.3	$ 70.9
Net realizable value of inventory recognized as expense	474.9	206.1	$ 399.2
Depreciation	509.5	289.7	256.1
Other Liabilities, Current	4,619.6	4,960.7
Allowance for doubtful accounts
Schedule of Equity Method Investments [Line Items]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount	$ 154.5	$ 159.9	$ 72.8	$ 98.2

Segment Information (Third Party Net Sales by Major Customers) (Details) - Third party net sales - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
McKesson Corporation
Revenue, Major Customer [Line Items]
Concentration risk, percentage	9.00%	13.00%	15.00%
AmeriSourceBergen Corporation
Revenue, Major Customer [Line Items]
Concentration risk, percentage	9.00%	10.00%	9.00%
Cardinal Health Inc
Revenue, Major Customer [Line Items]
Concentration risk, percentage	5.00%	8.00%	8.00%

Balance Sheet Components (Accounts receivable, net) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Receivables, Net, Current [Abstract]
Trade receivables, net	$ 3,774.4	$ 3,891.3
Other receivables	492.0	952.5
Accounts receivable, net	4,266.4	4,843.8
Accounts, Notes, Loans and Financing Receivable [Line Items]
Proceeds from Sale and Collection of Receivables	$ 29.6	$ 153.0

Balance Sheet Components (Other Current Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of other current liabilities [Line Items]
Other receivables	$ 492.0	$ 952.5
Employee-related Liabilities, Current	741.9	828.2
Estimated Litigation Liability, Current	715.6	362.9
Contingent consideration liability	199.7	223.6	$ 250.7
Restructuring Reserve, Current	233.5	149.2
Accrued interest	86.6	90.9
Liability derivatives, fair value	61.0	103.6
Operating Lease, Liability, Current	86.7	92.9
Other Accrued Liabilities, Current	1,254.6	1,973.2
Other current liabilities	4,619.6	4,960.7
Variable Consideration [Member]
Schedule of other current liabilities [Line Items]
Other receivables	1,362.1	1,211.8
Clean energy investments
Schedule of other current liabilities [Line Items]
Other liabilities	10.9	47.5
Other current liabilities
Schedule of other current liabilities [Line Items]
Contingent consideration liability	$ 66.7	$ 100.5	$ 120.4

Leases (Lease Maturities) (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Leases [Abstract]
2022	$ 82,000
2023	65,000
2024	42,900
2025	28,800
2026	23,900
Thereafter	68,200
Total lease payments	310,800
Less imputed interest	23,200
Total lease liability	$ 287,600

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2021 $ / shares shares
Ordinary shares, par value, in USD per share \| $ / shares	$ 0.01
Ordinary shares, number of shares authorized	3,000,000,000
Common Stock
Shares issued	1,209,507,463
Treasury Stock
Shares issued	0

Restructuring (2020 Restructuring Plan) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Restructuring Cost and Reserve [Line Items]

Restructuring Reserve

$ 22.8

$ 29.2

$ 72.6

Payments for Restructuring

(25.7)

(59.4)

Restructuring and Related Cost, Incurred Cost

(32.9)

(78.3)

Restructuring Reserve, Translation and Other Adjustment

1.7

(2.2)

Restructuring and Related Cost, Cost Incurred to Date

50.5

^[1]

104.6

Restructuring Reserve, Reimbursable Restructuring Charges

$ 26.4

Corporate (Other)

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

30.4

Emerging Markets | Operating Segments

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

94.1

8.4

Greater China | Operating Segments

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

5.8

18.4

JANZ | Operating Segments

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

138.1

2.9

4.2

Developed Markets | Operating Segments

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

623.8

292.1

100.4

Employee Severance

Restructuring Cost and Reserve [Line Items]

Restructuring Reserve

20.0

26.4

60.8

Payments for Restructuring

(18.1)

(48.9)

Restructuring and Related Cost, Incurred Cost

0.0

Restructuring Reserve, Translation and Other Adjustment

1.8

(2.1)

Restructuring and Related Cost, Cost Incurred to Date

9.9

^[1]

16.6

Restructuring Reserve, Reimbursable Restructuring Charges

26.4

Other Restructuring

Restructuring Cost and Reserve [Line Items]

Restructuring Reserve

2.8

$ 11.8

Payments for Restructuring

(7.6)

(10.5)

Restructuring and Related Cost, Incurred Cost

(32.9)

(78.3)

Restructuring Reserve, Translation and Other Adjustment

(0.1)

Restructuring and Related Cost, Cost Incurred to Date

40.6

^[1]

$ 88.0

Restructuring Reserve, Reimbursable Restructuring Charges

0.0

2020 Restructuring Plan

Restructuring Cost and Reserve [Line Items]

Restructuring Reserve

$ 296.7

296.7

267.4

Payments for Restructuring

(537.2)

(25.5)

Restructuring and Related Cost, Incurred Cost

(345.0)

(70.8)

Restructuring Reserve, Translation and Other Adjustment

(7.1)

0.4

Restructuring and Related Cost, Cost Incurred to Date

892.2

271.3

Restructuring Reserve, Acquired During Period

92.0

2020 Restructuring Plan | Maximum

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Cost Incurred to Date

1,400.0

Restructuring Reserve, Settled without Cash

450.0

Restructuring and Related Cost, Expected Cost Remaining

950.0

2020 Restructuring Plan | Employee Severance

Restructuring Cost and Reserve [Line Items]

Restructuring Reserve

292.6

262.6

Payments for Restructuring

(385.5)

(25.1)

Restructuring and Related Cost, Incurred Cost

0.0

Restructuring Reserve, Translation and Other Adjustment

(7.0)

0.4

Restructuring and Related Cost, Cost Incurred to Date

396.1

195.6

Restructuring Reserve, Acquired During Period

91.7

2020 Restructuring Plan | Other Restructuring

Restructuring Cost and Reserve [Line Items]

Restructuring Reserve

$ 4.1

4.1

4.8

Payments for Restructuring

(151.7)

(0.4)

Restructuring and Related Cost, Incurred Cost

(345.0)

(70.8)

Restructuring Reserve, Translation and Other Adjustment

(0.1)

0.0

Restructuring and Related Cost, Cost Incurred to Date

$ 496.1

75.7

Restructuring Reserve, Acquired During Period

$ 0.3

[1]

Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-lived intangible asset, estimated useful life, in years	15 years	15 years
Finite-lived intangible assets, original cost	$ 39,006.2	$ 40,404.1
Finite-lived intangible assets, accumulated amortization	12,918.5	10,801.6
Finite-lived intangible assets, net book value	26,087.7	29,602.5
In-process research and development	46.5	80.7
Intangible assets, gross, excluding goodwill	39,052.7	40,484.8
Intangible assets, net book value, excluding goodwill	$ 26,134.2	$ 29,683.2

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Net sales	$ 17,813.6	$ 11,819.9	$ 11,370.3
Total revenues	17,886.3	11,946.0	11,500.5
Cost of sales	12,310.8	8,149.3	7,602.9
Gross profit	5,575.5	3,796.7	3,897.6
Operating expenses:
Research and development	751.1	555.1	639.9
Selling, general and administrative	4,529.2	3,344.6	2,563.6
Litigation settlements and other contingencies, net	329.2	107.8	(21.4)
Total operating expenses	5,609.5	4,007.5	3,182.1
(Loss) earnings from operations	(34.0)	(210.8)	715.5
Interest expense	636.2	497.8	517.3
Other (income) expense, net	(5.8)	12.6	43.8
(Loss) earnings before income taxes	(664.4)	(721.2)	154.4
Income tax provision (benefit)	604.7	(51.3)	137.6
Net (loss) earnings	$ (1,269.1)	$ (669.9)	$ 16.8
(Loss) earnings per share attributable to Viatris Inc. shareholders
Basic (in USD per share)	$ (1.05)	$ (1.11)	$ 0.03
Diluted (in USD per share)	$ (1.05)	$ (1.11)	$ 0.03
Weighted average shares outstanding:
Basic (in shares)	1,208.8	601.2	515.7
Diluted (in shares)	1,208.8	601.2	516.5
Net sales
Revenues:
Net sales	$ 17,813.6	$ 11,819.9	$ 11,370.3
Other revenues
Revenues:
Other revenues	$ 72.7	$ 126.1	$ 130.2

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

The income tax provision (benefit) consisted of the following components:


	Year Ended December 31,
(In millions)	2021		2020		2019
U.S. Federal:
Current	$	12.6	$	(6.4)	$	118.1
Deferred	(182.7)		(277.0)		(165.5)
	(170.1)		(283.4)		(47.4)
U.S. State:
Current	7.7		(0.1)		21.1
Deferred	(10.8)		7.7		(13.6)
	(3.1)		7.6		7.5
Non-U.S.:
Current	(91.3)		168.7		191.0
Deferred	869.2		55.8		(13.5)
	777.9		224.5		177.5
Income tax provision (benefit)	$	604.7	$	(51.3)	$	137.6
Earnings before income taxes:

United States	(1,982.5)		(945.5)		(1,031.4)
Foreign - Other	1,318.1		224.3		1,185.8
Total (loss) earnings before income taxes	$	(664.4)	$	(721.2)	$	154.4

For all periods presented, the allocation of earnings before income taxes between U.S. and non-U.S. operations includes intercompany interest allocations between certain domestic and foreign subsidiaries. These amounts are eliminated on a consolidated basis.

Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows:


(In millions)	December 31, 2021		December 31, 2020
Deferred tax assets:
Employee benefits	$	271.3	$	273.0
Litigation reserves	94.4		43.5
Accounts receivable allowances	425.9		393.7
Inventory	187.8		1,187.9
Tax credit and loss carry-forwards	1,256.0		1,080.4
Operating lease assets	63.6		66.5
Interest expense	111.6		67.9
Intangible assets	151.1		156.3
Other	327.8		396.0
	2,889.5		3,665.2
Less: Valuation allowance	(780.4)		(443.6)
Total deferred tax assets	2,109.1		3,221.6
Deferred tax liabilities:
Plant and equipment	19.6		50.2
Operating lease liabilities	63.6		66.5
Intangible assets and goodwill	3,468.3		4,058.6
Other	39.9		22.1
Total deferred tax liabilities	3,591.4		4,197.4
Deferred tax liabilities, net	$	(1,482.3)	$	(975.8)

For those foreign subsidiaries whose investments are permanent in duration, income and foreign withholding taxes have not been provided on the unremitted earnings of those subsidiaries. This amount may become taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. The amount of such unremitted earnings is approximately $3.4 billion at December 31, 2021. Determination of the amount of any unrecognized deferred income tax liability on these unremitted earnings is not practicable as such determination involves material uncertainties about the potential extent and timing of any distributions, the availability and complexity of calculating foreign tax credits, and the potential indirect tax consequences of such distributions, including withholding taxes.


	Year Ended December 31,
	2021		2020		2019
Statutory tax rate	21.0	%	21.0	%	19.0	%

United States Operations
Clean energy and research credits	9.8	%	12.8	%	(43.4)	%
U.S. rate differentials	—	%	—	%	(3.1)	%
Impact of changes in legislation	—	%	(9.2)	%	—	%
State income taxes and credits	(0.6)	%	(1.6)	%	(4.1)	%
Valuation allowance	(0.1)	%	8.6	%	(118.5)	%
Tax settlements and resolution of certain tax positions	0.1	%	0.1	%	199.6	%
Incremental US Tax on Foreign Earnings	(36.9)	%	(3.6)	%	(8.6)	%
Waived deductions under IRC § 59A	—	%	(3.3)	%	64.5	%
Impact of the Combination and Divestitures	(2.8)	%	5.8	%	7.7	%
Other U.S. items	(6.1)	%	1.5	%	6.9	%
Other Foreign Operations
Luxembourg	(6.7)	%	(5.0)	%	(14.8)	%
Gibraltar	9.4	%	8.0	%	(38.8)	%
Ireland	5.8	%	8.2	%	(13.7)	%
France	(1.1)	%	(2.8)	%	15.2	%
Puerto Rico	4.4	%	(2.5)	%	—	%
Switzerland	1.0	%	2.0	%	—	%
Singapore	28.8	%	1.0	%	—	%
Other	(10.2)	%	(0.4)	%	12.8	%
Deferred tax impact of tax law changes	7.0	%	(0.1)	%	36.7	%
Valuation allowance	(8.3)	%	16.1	%	(9.9)	%
Impact of the Combination and divestitures	(106.9)	%	(42.2)	%	—	%
Withholding taxes	(1.3)	%	(1.6)	%	7.1	%
Tax settlements and resolution of certain tax positions	0.8	%	(3.9)	%	(27.6)	%
Other foreign items	1.9	%	(1.8)	%	2.1	%
Effective tax rate	(91.0)	%	7.1	%	89.1	%

In all years, our effective tax rate is impacted by the jurisdictional location of earnings and the corresponding tax rates in those jurisdictions. Subsequent to the Combination, the Company realizes benefits from lower tax rates in Singapore and Puerto Rico due to manufacturing and other incentives..

Tax Act

On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act makes broad and complex changes to the Code including, but not limited to, reducing the U.S. federal corporate income tax rate and requiring a one-time transition tax on certain unrepatriated earnings of non-U.S. corporate subsidiaries of large U.S. shareholders that may electively be paid over eight years.

The Tax Act also puts in place new tax laws that impact our taxable income beginning in 2018, which include, but are not limited to (1) creating a BEAT, which is a new minimum tax, (2) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries, (3) a new provision designed to tax currently GILTI earned by non-U.S. corporate subsidiaries of large U.S. shareholders and a deduction generally equal to 50 percent of GILTI (37.5 percent for tax years beginning after December 31, 2025) to offset the income tax liability, (4) a provision limiting the amount of deductible interest expense in the U.S., (5) limitations on the deductibility of certain executive compensation, and (6) limitations on the utilization of foreign tax credits to reduce the U.S. income tax liability.

As of December 31, 2021, no U.S. deferred income taxes or foreign withholding taxes were recorded on earnings in the Company’s non-U.S. subsidiaries where there would be no U.S. or foreign tax upon repatriation or where the Company’s practice and intention was to reinvest the earnings outside of the U.S. The transition tax noted above resulted in the previously untaxed foreign earnings of U.S. subsidiaries being included in federal and state taxable income. We analyze on an ongoing basis our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries repatriate cash, which include potential local country withholding taxes and U.S. state taxation. The Company has elected to not record deferred taxes associated with the GILTI provision of the Tax Act.

Valuation Allowance

A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2021, a valuation allowance has been applied to certain deferred tax assets in the amount of $780.4 million.

When assessing the realizability of deferred tax assets, management considers all available evidence, including historical information, long-term forecasts of future taxable income and possible tax planning strategies. Amounts recorded for valuation allowances can result from a complex series of estimates, assumptions and judgments about future events. Due to the inherent uncertainty involved in making these estimates, assumptions and judgments, actual results could differ materially. Any future increases to the Company’s valuation allowances could materially impact the Company’s consolidated financial condition and results of operations.

Net Operating Losses

As of December 31, 2021, the Company had the following carryforwards and attributes:

•U.S. federal net operating loss carryforwards of $7.9 million.

•U.S. state income tax loss carryforwards of approximately $3.10 billion, which are largely offset by a valuation allowance.

•Non-U.S. net operating loss carryforwards of approximately $1.57 billion, of which $748.4 million can be carried forward indefinitely, with the remaining $817.8 million expiring in years 2022 through 2041.

•Foreign deductible attributes of $39.6 million that can be carried forward indefinitely, which are offset by a full valuation allowance.

•U.S. and foreign credit carryovers of $329.2 million, expiring in various amounts through 2041.

•Anticipatory foreign tax credits of $230.3 million which will generate from the reversal of future taxable income in certain non-U.S. jurisdictions which are taxed both in their local jurisdictions and in the U.S.

On November 16, 2020, the Company had a change in ownership pursuant to Section 382 of the Code. Under this provision of the Code, the utilization of any NOL or tax credit carryforwards incurred prior to the date of ownership change may be limited. Analyses of the limits for each ownership change indicates the annual limitation would not impair the Company's ability to utilize our U.S. federal credit carryovers. While state loss carryforwards may be limited by Section 382 of the Code, the carryforwards are largely offset by a valuation allowance.

CARES Act

On March 27, 2020, the CARES Act was enacted and signed into law. The CARES Act includes several provisions, including increasing the amount of deductible interest, allowing companies to carryback certain NOLs, and increasing the amount of NOLs that corporations can use to offset income.During the year ended December 31, 2020, the CARES Act reduced the Company’s 2020 income tax expense by $22.1 million resulting from additional deductible interest.

Tax Examinations

The Company is subject to income taxes and tax audits in many jurisdictions. A certain degree of estimation is thus required in recording the assets and liabilities related to income taxes. Tax audits and examinations can involve complex issues, interpretations, and judgments and the resolution of matters that may span multiple years, particularly if subject to litigation or negotiation.

Although the Company believes that adequate provisions have been made for these uncertain tax positions, the Company’s assessment of uncertain tax positions, including those arising from legal entity restructuring transactions in connection with the Combination, is based on estimates and assumptions that the Company believes are reasonable but the estimates for unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variations from such estimates could materially affect the Company’s financial condition, results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire.

The Company is subject to ongoing IRS examinations. The years 2015 through 2018 are open years under examination. The years 2012, 2013 and 2014 have one matter open, and a Tax Court petition was filed regarding the matter and a trial was held in December 2018 and is discussed further below.

During the year ended December 31, 2019, Mylan reached an agreement in principle with the IRS to resolve all issues relating to our positions on the February 27, 2015 acquisition by Mylan N.V. of Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business. Under the agreement in principle, which was finalized as part of a closing agreement with the IRS on October 11, 2019, Mylan’s status as a non-U.S. corporation for U.S. Federal income tax purposes was confirmed, and we have adjusted the interest rates used for intercompany loans as necessary. During the year ended December 31, 2019, the Company recorded a reserve of approximately $155.0 million as part of its liability for uncertain tax positions, with a net impact to the income tax provision of approximately $144.9 million related to this matter.

Several international audits are currently in progress. In some cases, the tax auditors have proposed adjustments or issued assessments to our tax positions, including with respect to intercompany transactions, and we are in ongoing discussions with some of the auditors regarding the validity of their positions.

In instances where assessments have been issued, we disagree with these assessments and believe they are without merit and incorrect as a matter of law. As a result, we anticipate that certain of these matters may become the subject of litigation before tax courts where we intend to vigorously defend our position.

In Australia, the tax authorities have issued notices of assessments to the Company for the years ended December 2009 to December 2019, subject to additional interest and penalties, concerning our tax position with respect to certain intercompany transactions. The tax authorities denied our objections to the assessments and we have commenced litigation in the Australian Federal Court challenging that decision. During 2021, the Company made a partial payment of $56.0 million in order to stay potential interest and penalties resulting from this litigation.

In France, the tax authorities have issued notices of assessments to the Company for the years ended December 2013 to December 2016 concerning our tax position with respect to (i) certain intercompany transactions and (ii) whether income earned by a Company entity not domiciled in France should be subject to French tax. We have resolved our position concerning certain intercompany transactions with the tax authorities. Concerning the remaining issue, we have commenced litigation before the French tax courts where the tax authorities will seek unpaid taxes, penalties, and interest.

In India, the tax authorities have issued notices of assessments to the Company seeking unpaid taxes and interest for the financial years covering 2013 to 2018 concerning our tax position with respect to certain corporate tax deductions and certain intercompany transactions. Some of these assessments remain in the audit phase where we are challenging them before the tax authorities while we are challenging some of the other assessments in the Indian tax courts.

The Company has recorded a net reserve for uncertain tax positions of $315.6 million, including interest and penalties, in connection with its international audits at December 31, 2021. The reserve balance at December 31, 2021 reflects the impact of current year settlement payments. In connection with our international tax audits, it is possible that we will incur material losses above the amounts reserved.

The Company’s major U.S. state taxing jurisdictions remain open from fiscal year 2013 through 2020, with several state audits currently in progress. The Company’s major international taxing jurisdictions remain open from 2012 through 2020.

Tax Court Proceedings

The Company's U.S. federal income tax returns for 2012 through 2014 had been subject to proceedings in U.S. Tax Court involving a dispute with the IRS regarding whether certain costs related to ANDAs were eligible to be expensed and deducted immediately or required to be amortized over longer periods. A trial was held in U.S. Tax Court in December 2018 and on April 27, 2021, the Court affirmed Mylan’s position and held that patent litigation expenses related to ANDAs are immediately deductible. The IRS has appealed this decision.

Accounting for Uncertainty in Income Taxes

The impact of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of an uncertain tax position will be recognized if the position has less than a 50% likelihood of being sustained.

As of December 31, 2021 and 2020, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $322.9 million and $391.1 million, respectively, of which $230.2 million as of December 31, 2021 would affect the Company’s effective tax rate if recognized, with the remainder being offset by potential correlative adjustments. Related accrued interest and penalties included in the consolidated balance sheets were $96.8 million and $86.7 million as of December 31, 2021 and 2020, respectively. For the years ended December 31, 2021, 2020 and 2019, the Company recognized $18.5 million of tax expense, $6.0 million, and $35.2 million of tax benefits, respectively, related to interest and penalties on uncertain tax positions. Interest and penalties related to income taxes are included in the tax provision.

A reconciliation of the unrecognized tax benefits is as follows:


	Year Ended December 31,
(In millions)	2021		2020		2019
Unrecognized tax benefit — beginning of year	$	391.1	$	92.1	$	96.3
Additions for current year tax positions	—		13.4		—
Additions for prior year tax positions	—		35.7		154.9
Reductions for prior year tax positions	(9.1)		(5.2)		(11.7)
Settlements	(47.3)		(8.9)		(112.5)
Reductions due to expirations of statute of limitations	(7.0)		—		(34.9)
(Reduction) addition due to acquisition	(4.8)		264.0		—
Unrecognized tax benefit — end of year	$	322.9	$	391.1	$	92.1

The Company believes that it is reasonably possible that the amount of unrecognized tax benefits will decrease in the next twelve months by approximately $55.0 million, involving international and state audits and settlements and expiring statutes of limitations. The Company does not anticipate significant increases to the reserve within the next twelve months.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net earnings	$ (1,269.1)	$ (669.9)	$ 16.8
Weighted average common shares outstanding	1,208.8	601.2	515.7
Basic (loss) earnings per share attributable to Viatris Inc. shareholders	$ (1.05)	$ (1.11)	$ 0.03
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants	0.0	0.0	0.8
Total dilutive shares outstanding	1,208.8	601.2	516.5
Diluted (loss) earnings per share attributable to Viatris Inc. shareholders	$ (1.05)	$ (1.11)	$ 0.03
Retained Earnings
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net earnings	$ (1,269.1)	$ (669.9)	$ 16.8

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

+ Details

Employee Benefit Plans

12 Months Ended

Dec. 31, 2021

Retirement Benefits [Abstract]

Employee Benefits

Employee Benefit Plans

Defined Benefit Plans

The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. Employees in the U.S., Puerto Rico and certain international locations are also provided retirement benefits through defined contribution plans.

The Company also sponsors other postretirement benefit plans including plans that provide for postretirement supplemental medical coverage. Benefits from these plans are provided to employees and their spouses and dependents who meet various minimum age and service requirements. In addition, the Company sponsors other plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees.

In connection with the Combination, the Company assumed certain post retirement defined benefit pension plans sponsored by Upjohn. The most significant plans include those in Puerto Rico, Ireland and Japan. Upjohn is also the sponsor of one postretirement medical plan in Puerto Rico. As part of the acquisition accounting, the Company has recorded the fair value of these plans. Upon completion of the Combination, the excess of projected benefit obligation over the plan assets was recognized as a liability and any existing unrecognized actuarial gains or losses and unrecognized service costs or benefits were eliminated in purchase accounting.

Accounting for Defined Benefit Pension and Other Postretirement Plans

The Company recognizes on its balance sheet an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension and other postretirement plan. Actuarial gains or losses and prior service costs or credits that arise during the period are not recognized as components of net periodic benefit cost, but are recognized, net of tax, as a component of other comprehensive (loss) earnings.

Included in accumulated other comprehensive loss as of December 31, 2021 and 2020 are:


	Pension Benefits				Other Postretirement Benefits
	December 31,				December 31,
(In millions)	2021		2020		2021		2020
Unrecognized actuarial (gain) loss	$	(59.9)	$	33.9	$	21.7	$	5.7
Unrecognized prior service cost (credit)	6.6		(1.4)		(3.7)		0.6
Total	$	(53.3)	$	32.5	$	18.0	$	6.3

The unrecognized net actuarial losses exceeded 10% of the higher of the market value of plan assets or the projected benefit obligation at the beginning of the year for certain of the plans, therefore, amortization of such excess has been included in net periodic benefit costs for pension and other postretirement benefits in each of the last three years. The amortization period is the average remaining service period that active employees are expected to receive benefits, unless a plan is mostly inactive in which case the amortization period is the average remaining life expectancy of the plan participants. Unrecognized prior service cost is amortized over the future service periods of those employees who are active at the dates of the plan amendments and who are expected to receive benefits. If all or almost all of a plan's participants are inactive, unrecognized prior service cost is amortized over the remaining life expectancy of those participants. The increase in accumulated other comprehensive loss in 2021 relating to pension benefits and other postretirement benefits consists of:


(In millions)	Pension Benefits		Other Postretirement Benefits
Unrecognized actuarial (gain) loss	$	(102.2)	$	16.2
Amortization of actuarial gain/(loss)	7.6		(0.2)
Unrecognized prior service credit (cost)	8.0		(4.3)
Amortization of prior service costs	(0.5)		—
Impact of foreign currency translation	1.3		—
Net change	$	(85.8)	$	11.7

Components of net periodic benefit cost, change in projected benefit obligation, change in plan assets, funded status, fair value of plan assets, assumptions used to determine net periodic benefit cost, funding policy and estimated future benefit payments are summarized below for the Company’s pension plans and other postretirement plans.

Net Periodic Benefit Cost

Components of net periodic benefit cost for the years ended December 31, 2021, 2020 and 2019 were as follows:


	Pension Benefits						Other Postretirement Benefits
	December 31,						December 31,
(In millions)	2021		2020		2019		2021		2020		2019
Service cost	$	38.6	$	23.5	$	20.7	$	3.4	$	1.2	$	0.6
Interest cost	31.6		13.5		13.6		2.6		1.4		1.5
Expected return on plan assets	(66.1)		(19.9)		(12.1)		—		—		—
Plan curtailment, settlement and termination	(16.5)		1.1		(0.3)		—		—		3.2
Amortization of prior service costs	0.9		—		0.9		—		—		—
Recognized net actuarial losses (gains)	1.3		0.4		(0.8)		0.2		0.3		0.2
Net periodic benefit cost	$	(10.2)	$	18.6	$	22.0	$	6.2	$	2.9	$	5.5

During the year ended December 31, 2021, the Company recognized a settlement gain as a result of cash payments from lump sum elections related to the U.S. and Puerto Rico pension plans.

Change in Projected Benefit Obligation, Change in Plan Assets and Funded Status

The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2021 and 2020.


	Pension Benefits				Other Postretirement Benefits
(In millions)	2021		2020		2021		2020
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year	$	2,145.8	$	674.7	$	188.8	$	33.8
Service cost	38.6		23.5		3.4		1.1
Interest cost	31.6		13.5		2.6		1.4
Participant contributions	2.0		1.8		2.4		0.1
Acquisitions	4.0		1,389.4		—		153.1

Plan settlements and terminations	(128.6)		(23.1)		(4.3)		(0.2)
Actuarial (gains) losses	(26.1)		37.2		16.2		1.1
Benefits paid	(52.8)		(24.6)		(20.7)		(1.6)
Impact of foreign currency translation	(67.9)		53.4		—		—
Projected benefit obligation, end of year	$	1,946.6	$	2,145.8	$	188.4	$	188.8

Change in Plan Assets
Fair value of plan assets, beginning of year	$	1,354.6	$	315.7	$	—	$	—
Actual return on plan assets	141.7		46.0		—		—
Company contributions	97.0		58.2		18.3		1.7
Participant contributions	2.0		1.8		2.4		0.1
Acquisitions	(2.1)		959.3		—		—

Plan settlements	(128.9)		(23.1)		—		(0.2)
Benefits paid	(52.8)		(24.6)		(20.7)		(1.6)

Impact of foreign currency translation	(45.1)		21.3		—		—
Fair value of plan assets, end of year	1,366.4		1,354.6		—		—
Funded status of plans	$	(580.2)	$	(791.2)	$	(188.4)	$	(188.8)

Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheets at December 31, 2021 and 2020:


	Pension Benefits				Other Postretirement Benefits
	December 31,				December 31,
(In millions)	2021		2020		2021		2020
Noncurrent assets	$	117.2	$	70.7	$	—	$	—
Current liabilities	(14.6)		(15.1)		(16.1)		(16.3)
Noncurrent liabilities	(682.8)		(846.8)		(172.3)		(172.5)
Net accrued benefit costs	$	(580.2)	$	(791.2)	$	(188.4)	$	(188.8)

The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, but does not include the effects of estimated future pay increases. The accumulated benefit obligation for the Company’s pension plans was $1.86 billion and $2.04 billion at December 31, 2021 and 2020, respectively.


	December 31,
(In millions)	2021		2020
Plans with accumulated benefit obligation in excess of plan assets:
Projected benefit obligation	$	1,591.8	$	1,747.2
Accumulated benefit obligation	1,546.4		1,678.2
Fair value of plan assets	904.1		893.9

Fair Value of Plan Assets

The Company measures the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy described in Note 9 Financial Instruments and Risk Management. The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:


	December 31, 2021
(In millions)	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	63.1	$	1.9	$	—	$	65.0
Equity securities	53.9		497.2		—		551.1
Fixed income securities	211.4		405.5		—		616.9
Assets held by insurance companies and other	10.2		41.6		81.6		133.4
Total	$	338.6	$	946.2	$	81.6	$	1,366.4


	December 31, 2020
(In millions)	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	51.2	$	0.6	$	—	$	51.8
Equity securities	145.3		468.1		—		613.4
Fixed income securities	292.6		299.4		—		592.0
Assets held by insurance companies and other	4.0		20.0		73.4		97.4
Total	$	493.1	$	788.1	$	73.4	$	1,354.6

Risk tolerance on invested pension plan assets is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Investment risk is measured and monitored on an ongoing basis through annual liability measures, periodic asset/liability studies and investment portfolio reviews. The Company’s investment strategy is to maintain, where possible, a diversified investment portfolio across several asset classes that, when combined with the Company’s contributions to the plans, will ensure that required benefit obligations are met.

Assumptions

The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2021 and 2020:


	Pension Benefits				Other Postretirement Benefits
	2021		2020		2021		2020
Discount rate	2.3	%	1.9	%	2.5	%	1.9	%
Expected return on plan assets	5.1	%	4.3	%	—	%	—	%
Rate of compensation increase	3.1	%	2.9	%	—	%	—	%


	Pension Benefits						Other Postretirement Benefits
	2021		2020		2019		2021		2020		2019
Discount rate	1.9	%	1.6	%	2.3	%	1.9	%	3.3	%	4.3	%
Expected return on plan assets	5.1	%	4.3	%	4.3	%	—	%	—	%	—	%
Rate of compensation increase	2.9	%	2.7	%	2.9	%	—	%	—	%	—	%

The assumptions for each plan are reviewed on an annual basis. The discount rate reflects the current rate at which the pension and other benefit liabilities could be effectively settled at the measurement date. In setting the discount rates, we utilize comparable corporate bond indices as an indication of interest rate movements and levels. Corporate bond indices were selected based on individual plan census data and duration. The expected return on plan assets was determined using historical market returns and long-term historical relationships between equities and fixed income securities. The Company compares the expected return on plan assets assumption to actual historic returns to ensure reasonableness. Current market factors such as inflation and interest rates are also evaluated.

The weighted-average healthcare cost trend rate used for 2021 was 5.7% declining to a projected 4.5% in the year 2037. For 2022, the assumed weighted-average healthcare cost trend rate used will be 6.3% declining to a projected 4.0% in the year 2045. In selecting rates for current and long-term healthcare cost assumptions, the Company takes into consideration a number of factors including the Company’s actual healthcare cost increases, the design of the Company’s benefit programs, the demographics of the Company’s active and retiree populations and external expectations of future medical cost inflation rates.

Estimated Future Benefit Payments

The Company’s funding policy for its funded pension plans is based upon local statutory requirements. The Company’s funding policy is subject to certain statutory regulations with respect to annual minimum and maximum company contributions. Plan benefits for the non-qualified plans are paid as they come due.

Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows:


(In millions)	Pension Benefits		Other Postretirement Benefits
2022	$	101.8	$	16.1
2023	97.1		16.5
2024	103.0		16.9
2025	100.7		16.8
2026	104.3		16.6
Thereafter	528.5		73.0
Total	$	1,035.4	$	155.9

Defined Contribution Plans

The Company sponsors defined contribution plans covering its employees in the U.S. and Puerto Rico, as well as certain employees in a number of countries outside the U.S. The Company’s domestic defined contribution plans consist primarily of a Profit Sharing 401(k) Plan and a 401(k) retirement plan for union-represented employees. Profit sharing contributions are made at the discretion of the Board of Directors. The Company’s non-domestic plans vary in form depending on local legal requirements. The Company’s contributions are based upon employee contributions, service hours, or pre-determined amounts depending upon the plan. Obligations for contributions to defined contribution plans are recognized as expense in the consolidated statements of operations when they are earned.

The Company maintains a 401(k) Restoration Plan, which permits employees who earn compensation in excess of the limits imposed by Section 401(a)(17) of the Code to (i) defer a portion of base salary and bonus compensation, (ii) be credited with a Company matching contribution in respect of deferrals under the Restoration Plan, and (iii) be credited with Company non-elective contributions (to the extent so made by the Company), in each case, to the extent that participants otherwise would be able to defer or be credited with such amounts, as applicable, under the Profit Sharing 401(k) Plan if not for the limits on contributions and deferrals imposed by the Code.

The Company maintains an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50% of base salary and up to 100% of bonus compensation, in each case, in addition to any amounts that may be deferred by such participants under the Profit Sharing 401(k) Plan and the Restoration Plan. In addition, under the Income Deferral Plan, eligible participants may be granted employee deferral awards, which awards will be subject to the terms and conditions (including vesting) as determined by the plan administrator at the time such awards are granted.

Total employer contributions to defined contribution plans were approximately $107.4 million, $115.5 million and $95.6 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Other Benefit Arrangements

The Company participated in a multi-employer pension plan under previous collective bargaining agreements. The PACE Industry Union-Management Pension Fund (the “PACE Plan”) provides defined benefits to certain retirees and certain production and maintenance employees at the Company’s manufacturing plant in Morgantown, West Virginia who were covered by the previous collective bargaining agreements. Pursuant to a collective bargaining agreement entered into on April 16, 2012, the Company withdrew from the PACE Plan effective May 10, 2012. In 2013, the PACE Plan trustee notified the Company that its withdrawal liability was approximately $27.3 million, which was accrued by the Company in 2013. The withdrawal liability is being paid over a period of approximately nine years; payments began in March 2014. The withdrawal liability was approximately $5.5 million and $8.9 million at December 31, 2021 and 2020, respectively. The Employer Identification Number for the PACE Plan is 11-6166763.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Employee Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2016
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized net actuarial losses exceed higher of market value of plan assets or the projected benefit obligation at the beginning of the year	10.00%
Accumulated benefit obligation	$ 1,860.0	$ 2,040.0
Defined benefit plan, ultimate health care cost trend rate	5.70%
Defined benefit plan, ultimate health care cost trend rate, projected	4.50%
Total employer contributions	$ 107.4	115.5	$ 95.6
Multiemployer plans, withdrawal obligation	$ 5.5	$ 8.9		$ 27.3
Fiscal Year 2017
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, ultimate health care cost trend rate	6.30%
Defined benefit plan, ultimate health care cost trend rate, projected	4.00%
Deferred Base Salary
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, maximum annual contribution per employee, percent	50.00%
Deferred Bonus
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, maximum annual contribution per employee, percent	100.00%

Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Net sales	$ 17,813.6	$ 11,819.9	$ 11,370.3
Segment profitability	(34.0)	(210.8)	715.5
Intangible asset amortization expense	(2,702.2)	(1,605.8)	(1,582.7)
Globally managed research and development costs	(751.1)	(555.1)	(639.9)
Litigation settlements & other contingencies	(329.2)	(107.8)	21.4
Operating Segments
Segment Reporting Information [Line Items]
Net sales	17,813.6	11,819.9
Segment profitability	8,705.0	5,271.6	5,112.3
Segment Reconciling
Segment Reporting Information [Line Items]
Intangible asset amortization expense	(2,702.2)	(1,605.8)	(1,582.7)
Intangible asset impairment charges	(102.8)	(82.4)	(180.6)
Globally managed research and development costs	(751.1)	(555.1)	(639.9)
Litigation settlements & other contingencies	(329.2)	(107.8)	21.4
Transaction related and other special items	(2,832.2)	(1,739.7)	(682.2)
Corporate (Other)
Segment Reporting Information [Line Items]
Corporate costs	(2,021.5)	(1,391.6)	(1,332.8)
Developed Markets \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	10,428.7	8,510.9	8,240.0
Segment profitability	5,143.1	4,243.9	4,137.3
Greater China \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,212.8	259.9	214.6
Segment profitability	1,397.1	52.7	89.9
JANZ \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,027.4	1,195.3	1,192.5
Segment profitability	762.4	364.6	323.2
Emerging Markets \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	3,144.7	1,853.8	1,723.2
Segment profitability	$ 1,402.4	$ 610.4	$ 561.9

Employee Benefit Plans (Fair Values of Plan Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 1,366.4	$ 1,354.6
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	65.0	51.8
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	551.1	613.4
Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	616.9	592.0
Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	133.4	97.4
Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	338.6	493.1
Level 1 \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	63.1	51.2
Level 1 \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	53.9	145.3
Level 1 \| Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	211.4	292.6
Level 1 \| Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	10.2	4.0
Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	946.2	788.1
Level 2 \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1.9	0.6
Level 2 \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	497.2	468.1
Level 2 \| Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	405.5	299.4
Level 2 \| Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	41.6	20.0
Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	81.6	73.4
Level 3 \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.0	0.0
Level 3 \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.0	0.0
Level 3 \| Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.0	0.0
Level 3 \| Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 81.6	$ 73.4

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

Debt (Tables)

12 Months Ended

Dec. 31, 2021

Debt Instrument [Line Items]

Schedule of Short-term Debt

Short-Term Borrowings

The Company had $1.49 billion and $1.10 billion of borrowings as of December 31, 2021 and 2020, respectively.


(In millions)	December 31, 2021		December 31, 2020
Commercial paper notes	$	1,173.4	$	651.3
Receivables Facility	318.5		248.4
Note Securitization Facility	—		200.0
Other	1.1		1.2
Short-term borrowings	$	1,493.0	$	1,100.9

The following provides an overview of the Company’s short-term credit facilities.

Minimum Repayments on Outstanding Borrowings

Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at December 31, 2021 were as follows for each of the periods ending December 31:


(In millions)	Total
2022	$	1,853
2023	1,250
2024	1,990
2025	1,318
2026	2,598
Thereafter	11,940
Total	$	20,949

Upjohn Inc.

Debt Instrument [Line Items]

Summary of Long-Term Debt

The following table provides information about the Upjohn Senior Notes issued in June 2020:


(In millions)	Notional Value


2022 Senior Notes	$	1,000.0
2025 Senior Notes	750.0
2027 Senior Notes	750.0
2030 Senior Notes	1,450.0
2040 Senior Notes	1,500.0
2050 Senior Notes	2,000.0
2022 Euro Senior Note	916.2
2024 Euro Senior Note	916.2
2027 Euro Senior Note	1,038.4
2032 Euro Senior Note	1,527.0
Total	$	11,847.8

Restructuring (Tables)

12 Months Ended

Dec. 31, 2021

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs [Table Text Block]

The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program:


(In millions)	Employee Related Costs		Other Exit Costs		Total
Charges (2)	$	195.6	$	75.7	$	271.3
Acquired in the Combination	91.7		0.3		92.0
Cash payment	(25.1)		(0.4)		(25.5)
Utilization	—		(70.8)		(70.8)
Foreign currency translation	0.4		—		0.4
Balance at December 31, 2020	$	262.6	$	4.8	$	267.4
Charges (1)	396.1		496.1		892.2
Reimbursable restructuring charges	26.4		—		26.4
Cash payment	(385.5)		(151.7)		(537.2)
Utilization	—		(345.0)		(345.0)
Foreign currency translation	(7.0)		(0.1)		(7.1)
Balance at December 31, 2021	$	292.6	$	4.1	$	296.7


(In millions)	Employee Related Costs		Other Exit Costs		Total
Balance at December 31, 2018:	$	60.8	$	11.8	$	72.6
Charges (3)	16.6		88.0		$	104.6
Cash payment	(48.9)		(10.5)		$	(59.4)
Reclassifications	—		(8.1)		$	(8.1)
Utilization	—		(78.3)		$	(78.3)
Foreign currency translation	(2.1)		(0.1)		$	(2.2)
Balance at December 31, 2019:	$	26.4	$	2.8	$	29.2
Charges (2)	9.9		40.6		50.5
Cash payment	(18.1)		(7.6)		(25.7)
Utilization	—		(32.9)		(32.9)
Foreign currency translation	$	1.8	$	(0.1)	$	1.7
Balance at December 31, 2020:	$	20.0	$	2.8	$	22.8

(1) For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively.

Employee Benefit Plans (Net Periodic Benefit Costs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Service cost			$ 0.6
Interest cost			1.5
Expected return on plan assets			0.0
Plan curtailment, settlement and termination			3.2
Amortization of prior service costs included in SG&A			0.0
Recognized net actuarial losses			0.2
Net periodic benefit cost			5.5
Other Pension, Postretirement and Supplemental Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 3.4	$ 1.2
Interest cost	2.6	1.4
Expected return on plan assets	0.0	0.0
Plan curtailment, settlement and termination	0.0	0.0
Amortization of prior service costs included in SG&A	0.0	0.0
Recognized net actuarial losses	0.2	0.3
Net periodic benefit cost	6.2	2.9
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	38.6	23.5	20.7
Interest cost	31.6	13.5	13.6
Expected return on plan assets	(66.1)	(19.9)	(12.1)
Plan curtailment, settlement and termination	(16.5)	1.1	(0.3)
Amortization of prior service costs included in SG&A	0.9	0.0	0.9
Recognized net actuarial losses	1.3	0.4	(0.8)
Net periodic benefit cost	(10.2)	18.6	$ 22.0
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	3.4	1.1
Interest cost	$ 2.6	$ 1.4

Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Apr. 01, 2021
Goodwill [Line Items]
Goodwill, gross, beginning balance	$ 12,732.0	$ 9,975.6
Accumulated impairment losses, beginning balance	(385.0)	(385.0)
Goodwill	12,113.7	12,347.0	$ 9,590.6
Acquisitions			2,107.5
Foreign currency translation		(528.9)	648.9
Goodwill, gross, ending balance	12,498.7	12,732.0	9,975.6
Accumulated impairment losses, ending balance	(385.0)	(385.0)	(385.0)
Goodwill, net, ending balance	12,113.7	12,347.0	9,590.6
Goodwill		295.6
Developed Markets
Goodwill [Line Items]
Goodwill, gross, beginning balance	9,569.5	8,258.0
Accumulated impairment losses, beginning balance	(385.0)	(385.0)
Goodwill	8,723.4	9,184.5	7,873.0
Acquisitions			704.3
Foreign currency translation		(528.8)	607.2
Goodwill, gross, ending balance	9,108.4	9,569.5	8,258.0
Accumulated impairment losses, ending balance	(385.0)	(385.0)	(385.0)
Goodwill, net, ending balance	8,723.4	9,184.5	7,873.0
Goodwill		67.7
Greater China
Goodwill [Line Items]
Goodwill, gross, beginning balance	738.3	67.8
Accumulated impairment losses, beginning balance	0.0	0.0
Goodwill	969.5	738.3	67.8	$ 700.0
Acquisitions			652.8
Foreign currency translation		10.8	17.7
Goodwill, gross, ending balance	969.5	738.3	67.8
Accumulated impairment losses, ending balance	0.0	0.0	0.0
Goodwill, net, ending balance	969.5	738.3	67.8
Goodwill		220.4
JANZ
Goodwill [Line Items]
Goodwill, gross, beginning balance	864.0	584.8
Accumulated impairment losses, beginning balance	0.0	0.0
Goodwill	776.3	864.0	584.8	820.0
Acquisitions			217.4
Foreign currency translation		(56.8)	61.8
Goodwill, gross, ending balance	776.3	864.0	584.8
Accumulated impairment losses, ending balance	0.0	0.0	0.0
Goodwill, net, ending balance	776.3	864.0	584.8
Goodwill		(30.9)
Emerging Markets
Goodwill [Line Items]
Goodwill, gross, beginning balance	1,560.2	1,065.0
Accumulated impairment losses, beginning balance	0.0	0.0
Goodwill	1,644.5	1,560.2	1,065.0	$ 1,580.0
Acquisitions			533.0
Foreign currency translation		45.9	(37.8)
Goodwill, gross, ending balance	1,644.5	1,560.2	1,065.0
Accumulated impairment losses, ending balance	0.0	0.0	0.0
Goodwill, net, ending balance	$ 1,644.5	1,560.2	$ 1,065.0
Goodwill		$ 38.4

Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 144.6	$ 118.6
Liability derivatives, fair value	61.0	103.6
Designated as hedging instrument
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	62.0	28.3
Designated as hedging instrument \| Prepaid expenses and other current assets \| Foreign Exchange Forward
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	62.0	28.3
Designated as hedging instrument \| Other current liabilities \| Foreign Exchange Forward
Derivatives, Fair Value [Line Items]
Liability derivatives, fair value	$ 4.3	$ 0.8

Share-Based Incentive Plan (Stock Awards) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares under stock awards, outstanding at beginning of period	6,711,731	6,347,709	6,815,278
Weightedaverage exercise price per share, outstanding at beginning of period	$ 35.36	$ 36.97	$ 36.61
Number of shares under stock awards, granted		814,351	829,322
Weighted average exercise price per share, granted		$ 17.37	$ 26.18
Number of shares under stock awards, exercised		(27,615)	(580,950)
Weighted average exercise price per share, exercised		$ 21.13	$ 14.40
Number of shares under stock awards, forfeited	(1,135,241)	(422,714)	(715,941)
Weighted average exercise price per share, forfeited	$ 26.39	$ 25.74	$ 39.40
Number of shares under stock awards, outstanding at end of period	5,576,490	6,711,731	6,347,709
Weighted average exercise price per share, outstanding at end of period	$ 37.19	$ 35.36	$ 36.97
Number of shares under stock awards, vested and expected to vest at period end	5,487,788
Weighted average exercise price per share, vested and expected to vest at period end	$ 37.45
Number of shares under stock awards, exercisable at period end	4,969,602
Weighted average exercise price per share, exercisable at period end	$ 39.21

Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details) € in Millions, shares in Millions, $ in Millions					1 Months Ended		2 Months Ended	12 Months Ended
	Nov. 13, 2020 USD ($) shares	Jul. 29, 2019 USD ($)	Feb. 27, 2019 USD ($)	Sep. 20, 2018 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2020 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2021 USD ($) market	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jun. 25, 2021 EUR (€)
Business Acquisition [Line Items]
Research and development								$ 751.1	$ 555.1	$ 639.9
Contingent consideration liability					$ 223.6		$ 223.6	199.7	223.6	250.7
Goodwill					12,347.0		12,347.0	12,113.7	12,347.0	$ 9,590.6
Machinery and equipment
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years	5 years
Finite-Lived Intangible Assets
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years	15 years
Maximum \| Building
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years	20 years
Minimum \| Building
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years	10 years
Upjohn Inc.
Business Acquisition [Line Items]
Cash paid to acquire asset	$ 12,000.0
Business Acquisition, Percentage of Voting Interests Acquired		43.00%
Property, plant and equipment					1,394.1		1,394.1	1,389.1	1,394.1
Business Combination, Acquisition Related Costs								234.6	602.9
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 10,730.0
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares \| shares	689.9
Net earnings							360.9	1,483.7	1,873.5
Total revenues							866.5	18,284.8	21,582.7
Goodwill	$ 2,400.0				2,107.5		2,107.5	2,403.1	2,107.5
Inventories	1,430.0							(34.2)
Property, plant and equipment	385.0							(5.0)
Identified intangible assets	18,040.0				18,040.0		$ 18,040.0	18,040.0	18,040.0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt	$ 759.4
Amortization of Inventory Step Up								$ 1,190.0	$ 238.2
Number Of Markets \| market								165
Other companies \| Product rights and licenses
Business Acquisition [Line Items]
Acquisition purchase price								$ 10.0
Aspen Global Incorporated
Business Acquisition [Line Items]
Acquisition purchase price \| €						€ 641.9
Cash paid to acquire asset \| €						€ 263.2
Aspen Global Incorporated \| Contractual Rights
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years						8 years
FKB
Business Acquisition [Line Items]
Upfront payments			$ 33.0	$ 25.0
Research and development			$ 23.3
Net sales \| Upjohn Inc.
Business Acquisition [Line Items]
Number Of Products		20
Pfizer, Inc.
Business Acquisition [Line Items]
Inventory, Firm Purchase Commitment, Loss					$ 86.5
Pfizer, Inc. \| Upjohn Inc.
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		57.00%
Upjohn Inc. \| Pfizer, Inc.
Business Acquisition [Line Items]
Payments for Business Separation		$ 12,000.0
Scenario, Plan \| Aspen Global Incorporated
Business Acquisition [Line Items]
Contingent consideration liability \| €											€ 378.7

Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 17,813.6	$ 11,819.9	$ 11,370.3
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	4,176.4	3,746.1	3,965.9
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 1,981.5	$ 216.1	$ 171.1

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Income Taxes (Schedule of Components of Income Tax Provision) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Income tax provision (benefit)	$ 604.7	$ (51.3)	$ 137.6
Earnings (loss) before income taxes and noncontrolling interest:
Operating and non-operating expense	(664.4)	(721.2)	154.4
Foreign Tax Authority
Income Tax Contingency [Line Items]
U.S. Federal Current	12.6	(6.4)	118.1
U.S. Federal Deferred	(182.7)	(277.0)	(165.5)
Income tax provision (benefit), U.S. Federal	(170.1)	(283.4)	(47.4)
Earnings (loss) before income taxes and noncontrolling interest:
Earnings before income taxes and noncontrolling interest, United States	(1,982.5)	(945.5)	(1,031.4)
U.S. State Tax Authority
Income Tax Contingency [Line Items]
U.S. State Current	7.7	(0.1)	21.1
U.S. State Deferred	(10.8)	7.7	(13.6)
Income tax provision (benefit), U.S. State	(3.1)	7.6	7.5
Non-U.S. state tax authority
Income Tax Contingency [Line Items]
Non-U.S. Current	(91.3)	168.7	191.0
Non-U.S. Deferred	869.2	55.8	(13.5)
Income tax provision (benefit), Non-U.S.	777.9	224.5	177.5
Other Foreign Operations
Earnings (loss) before income taxes and noncontrolling interest:
Earnings before income taxes and noncontrolling interest, foreign	$ 1,318.1	$ 224.3	$ 1,185.8

Revenue Recognition and Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Revenue Recognition And Accounts Receivable [Line Items]
Securitized accounts receivable	$ 388.9	$ 389.4
Receivables Facility [Member]
Revenue Recognition And Accounts Receivable [Line Items]
Accounts receivable securitization facility maximum borrowing capacity	$ 400.0

Segment Information

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Segment Information

ment Information

Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics and biosimilars, and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise.

The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability.

Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following:

◦Intangible asset amortization expense and impairments of intangible assets;

◦R&D expense;

◦Net charges or net gains for litigation settlements and other contingencies;

◦Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.

◦Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs.

The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker.

The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies.

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.


	Net Sales						Segment Profitability
	Years Ended December 31,						Years Ended December 31,
(in millions)	2021		2020		2019		2021		2020		2019
Reportable Segments:
Developed Markets	$	10,428.7	$	8,510.9	$	8,240.0	$	5,143.1	$	4,243.9	$	4,137.3
Greater China	2,212.8		259.9		214.6		1,397.1		52.7		89.9
JANZ	2,027.4		1,195.3		1,192.5		762.4		364.6		323.2
Emerging Markets	3,144.7		1,853.8		1,723.2		1,402.4		610.4		561.9
Total reportable segments	$	17,813.6	$	11,819.9	$	11,370.3	$	8,705.0	$	5,271.6	$	5,112.3

Reconciling items:
Intangible asset amortization expense							(2,702.2)		(1,605.8)		(1,582.7)
Intangible asset impairment charges							(102.8)		(82.4)		(180.6)
Globally managed research and development costs							(751.1)		(555.1)		(639.9)
Litigation settlements & other contingencies							(329.2)		(107.8)		21.4
Transaction related and other special items							(2,832.2)		(1,739.7)		(682.2)
Corporate and other unallocated							(2,021.5)		(1,391.6)		(1,332.8)
(Loss) earnings from operations							$	(34.0)	$	(210.8)	$	715.5

The following table represents the percentage of consolidated net sales to Viatris’ major customers during the years ended December 31, 2021, 2020, and 2019:


	Percentage of Consolidated Net Sales
	2021		2020		2019
McKesson Corporation	9	%	13	%	15	%
AmerisourceBergen Corporation	9	%	10	%	9	%
Cardinal Health, Inc.	5	%	8	%	8	%

Sales by Country Information

Net sales by country are presented on the basis of geographic location of our subsidiaries:


	Year Ended December 31,
(In millions)	2021		2020		2019
United States	$	4,176.4	$	3,746.1	$	3,965.9
China	1,981.5		216.1		171.1

____________

No other country’s net sales represents more than 10% of consolidated net sales.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Balance Sheet Components (Prepaids and other current assets) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses	$ 256.7	$ 267.8
Restricted cash	5.0	5.6	$ 15.5
Available-for-sale fixed income securities	38.2	39.1
Fair value of financial instruments	144.6	118.6
Equity securities	51.0	45.8
Other current assets	1,467.1	1,236.1
Prepaid expenses and other current assets	$ 1,957.6	$ 1,707.4

Restructuring

12 Months Ended

Dec. 31, 2021

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

Restructuring

2020 Restructuring Program

During the fourth quarter of 2020, Viatris announced a significant global restructuring program in order to achieve synergies and ensure that the organization is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders. Viatris’ restructuring initiative incorporates and expands on the restructuring program announced by Mylan N.V. earlier in 2020 as part of its business transformation efforts. As part of the restructuring, the Company is optimizing its commercial capabilities and enabling functions, and closing, downsizing or divesting certain manufacturing facilities globally that are deemed to be no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex products.

For the committed restructuring actions, the Company expects to incur total pre-tax charges of up to approximately $1.4 billion. Such charges are expected to include up to approximately $450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including inventory write-offs. The remaining estimated cash costs of up to approximately $950 million are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations and other plant disposal costs. In addition, management believes the potential annual savings related to these committed restructuring activities to be up to approximately $900 million once fully implemented, with most of these savings expected to improve operating cash flow.

The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program:


(In millions)	Employee Related Costs		Other Exit Costs		Total
Charges (2)	$	195.6	$	75.7	$	271.3
Acquired in the Combination	91.7		0.3		92.0
Cash payment	(25.1)		(0.4)		(25.5)
Utilization	—		(70.8)		(70.8)
Foreign currency translation	0.4		—		0.4
Balance at December 31, 2020	$	262.6	$	4.8	$	267.4
Charges (1)	396.1		496.1		892.2
Reimbursable restructuring charges	26.4		—		26.4
Cash payment	(385.5)		(151.7)		(537.2)
Utilization	—		(345.0)		(345.0)
Foreign currency translation	(7.0)		(0.1)		(7.1)
Balance at December 31, 2021	$	292.6	$	4.1	$	296.7

As part of the Combination, the Company acquired reserve balances related to restructuring activities initiated by the Upjohn Business prior to the Combination, primarily related to accrued severance.

2016 Restructuring Program

Mylan previously announced a restructuring program representing a series of actions in certain locations to further streamline its operations globally. We incurred total restructuring related costs of approximately $733.0 million through December 31, 2020. The 2016 Restructuring Program was substantially completed at December 31, 2020.

In April 2018, the FDA completed an inspection at Mylan’s plant in Morgantown, West Virginia and made observations through a Form 483. In the fourth quarter of 2018, Mylan received a warning letter related to the previously disclosed observations at the plant. The issues raised in the warning letter were addressed within the context of the Mylan’s comprehensive restructuring and remediation activities. On May 11, 2020, Mylan received the close-out of the warning letter. On December 11, 2020, the Company announced that it expects the Morgantown plant to be closed or divested as part of the 2020 Restructuring Program. The Morgantown plant was closed during the third quarter of 2021.

The following table summarizes the restructuring charges and the reserve activity for the 2016 restructuring program from December 31, 2018 to December 31, 2020:


(In millions)	Employee Related Costs		Other Exit Costs		Total
Balance at December 31, 2018:	$	60.8	$	11.8	$	72.6
Charges (3)	16.6		88.0		$	104.6
Cash payment	(48.9)		(10.5)		$	(59.4)
Reclassifications	—		(8.1)		$	(8.1)
Utilization	—		(78.3)		$	(78.3)
Foreign currency translation	(2.1)		(0.1)		$	(2.2)
Balance at December 31, 2019:	$	26.4	$	2.8	$	29.2
Charges (2)	9.9		40.6		50.5
Cash payment	(18.1)		(7.6)		(25.7)
Utilization	—		(32.9)		(32.9)
Foreign currency translation	$	1.8	$	(0.1)	$	1.7
Balance at December 31, 2020:	$	20.0	$	2.8	$	22.8

At December 31, 2021 and 2020, accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities and other long-term obligations in the consolidated balance sheets.

Acquisitions and Other Transactions (Unaudited Pro Forma Financial Results) (Details) - Upjohn Inc. - USD ($) $ / shares in Units, shares in Millions, $ in Millions	2 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Total revenues	$ 866.5	$ 18,284.8	$ 21,582.7
Net earnings	$ 360.9	$ 1,483.7	$ 1,873.5
Basic (in usd per share)		$ 1.23	$ 1.55
Diluted (in usd per share)		$ 1.23	$ 1.55
Basic (in shares)		1,206.8	1,205.6
Diluted (in shares)		1,207.7	1,206.4

Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Statutory tax rate	21.00%	21.00%	19.00%
Valuation allowance	(106.90%)	(42.20%)	0.00%
Incremental US Tax on Foreign Earnings	(36.90%)	(3.60%)	(8.60%)
Waived deductions under IRC § 59A	0.00%	(3.30%)	64.50%
Impact of the Combination and Divestitures	(2.80%)	5.80%	7.70%
Effective tax rate	(91.00%)	7.10%	89.10%
United States
Income Tax Contingency [Line Items]
Clean energy and research credits	9.80%	12.80%	(43.40%)
U.S. rate differentials	0.00%	0.00%	(3.10%)
Impact of changes in legislation	0.00%	(9.20%)	0.00%
State income taxes and credits	(0.60%)	(1.60%)	(4.10%)
Valuation allowance	(0.10%)	8.60%	(118.50%)
Tax settlements and resolution of certain tax positions	0.10%	0.10%	199.60%
Other	(6.10%)	1.50%	6.90%
LUXEMBOURG
Income Tax Contingency [Line Items]
Other Foreign Operations	(6.70%)	(5.00%)	(14.80%)
GIBRALTAR
Income Tax Contingency [Line Items]
Other Foreign Operations	9.40%	8.00%	(38.80%)
IRELAND
Income Tax Contingency [Line Items]
Other Foreign Operations	5.80%	8.20%	(13.70%)
France
Income Tax Contingency [Line Items]
Other Foreign Operations	(1.10%)	(2.80%)	15.20%
Other foreign
Income Tax Contingency [Line Items]
Other Foreign Operations	(10.20%)	(0.40%)	12.80%
Other Foreign Operations
Income Tax Contingency [Line Items]
Valuation allowance	(8.30%)	16.10%	(9.90%)
Other	1.90%	(1.80%)	2.10%
Uncertain tax positions	7.00%	(0.10%)	36.70%
Withholding taxes	(1.30%)	(1.60%)	7.10%
Tax settlements and resolution of certain tax positions	0.80%	(3.90%)	(27.60%)
PUERTO RICO
Income Tax Contingency [Line Items]
Other Foreign Operations	4.40%	(2.50%)	0.00%
SWITZERLAND
Income Tax Contingency [Line Items]
Other Foreign Operations	1.00%	2.00%	0.00%
SINGAPORE
Income Tax Contingency [Line Items]
Other Foreign Operations	28.80%	1.00%	0.00%

Equity Method Investments

12 Months Ended

Dec. 31, 2021

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments

The Company had three equity method investments in limited liability companies that owned refined coal production plants whose activities qualified for income tax credits under Section 45 of the Code. The Company did not consolidate these entities as we had determined that we were not the primary beneficiary of these entities and did not have the power to individually direct the activities of these entities. Accordingly, these investments were accounted for under the equity method of accounting. For each of the clean energy investments, the Company had entered into notes payable with the respective project sponsor, which in part were paid to the sponsor as certain production levels were met. The law that provides for IRC Section 45 tax credits expired during the year ended December 31, 2021 for all three clean energy investments and all of the clean energy investments have wound down operations.

During the years ended December 31, 2021, 2020, and 2019, the Company reduced its long-term obligations for its three investments as a result of lower than anticipated production levels and lower expected future variable debt payments to the respective project sponsor. The Company recognized a net gain of approximately $5.7 million, $21.4 million and $7.0 million, respectively, which was recognized as a component of the net loss of the equity method investments in the consolidated statements of operations.

The carrying values and respective balance sheet locations of the Company’s clean energy investments were as follows at December 31, 2021 and 2020, respectively:


(In millions)	December 31, 2021		December 31, 2020
Other assets	$	—	$	47.9
Other current liabilities	10.9		47.5

Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis as of December 31, 2021 and 2020 and for the years ended December 31, 2021, 2020 and 2019 are as follows:


(In millions)	December 31, 2021		December 31, 2020
Current assets	$	4.2	$	38.9
Noncurrent assets	0.5		1.0
Total assets	4.7		39.9
Current liabilities	2.8		33.0
Noncurrent liabilities	—		1.8
Total liabilities	2.8		34.8
Net assets	$	1.9	$	5.1


	Year Ended December 31,
(In millions)	2021		2020		2019
Total revenues	$	326.7	$	374.5	$	385.0
Gross loss	(4.6)		(4.6)		(4.4)
Operating and non-operating expense	16.8		19.0		20.0
Net loss	$	(21.4)	$	(23.6)	$	(24.4)

The Company’s net losses from its equity method investments include amortization expense related to the excess of the cost basis of the Company’s investment over the underlying assets of each individual investee. For the years ended December 31, 2021, 2020 and 2019, the Company recognized net losses from equity method investments of $61.9 million, $48.4 million, and $62.1 million, respectively, which were recognized as a component of other expense, net in the consolidated statements of operations. The Company recognizes the income tax credits and benefits from the clean energy investments as part of its provision for income taxes.

Share-Based Incentive Plan (Narrative) (Details) - USD ($) $ in Millions		12 Months Ended
	Nov. 16, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares exercised			27,615	580,950
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		5,576,490	6,711,731	6,347,709	6,815,278
Restricted stock \| Vest ratably in five years or less [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		3 years
Number of restricted stock awards, granted		6,057,602
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock awards, granted		9,850,443
Long Term Incentive Plan 2003
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares exercised	6,757,640
Common stock shares reserved for issuance to employees	13,535,627
Total unrecognized compensation expense, net of estimated forfeitures		$ 143.1
Weighted-average period over which total unrecognized compensation expense expected to be recognized (years)		1 year 8 months 12 days
Intrinsic value of stock-based awards exercised and restricted stock units converted		$ 78.1	$ 20.9
Long Term Incentive Plan 2003 \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award expiration period, in years		10 years
Average remaining contractual term for options outstanding, in years		4 years 7 months 6 days
Average remaining contractual term for options vested and expected to vest, in years		4 years 7 months 6 days
Average remaining contractual term for options exercisable, in years		4 years 2 months 12 days
Long Term Incentive Plan 2003 \| Minimum \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		3 years
Long Term Incentive Plan 2003 \| Maximum \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		4 years
2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount of common stock shares authorized	72,500,000
2014 Program \| Stock appreciation rights and performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		5 years
Not subject to market conditions \| Performance Shares \| Vest after three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock awards, granted		587,025
Subject to Market Conditions \| Performance Shares \| Vest after three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		3 years
Number of restricted stock awards, granted		3,205,816

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Billions					12 Months Ended
	Jan. 06, 2022	Dec. 16, 2021	Sep. 16, 2021	Jun. 16, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Mar. 16, 2022	Feb. 28, 2022
Accounting Policies [Line Items]
Finite-lived intangible asset, estimated useful life, in years					15 years	15 years
Anti-dilutive securities excluded from computation of earnings per share					12.7	10.3	9.1
Dividends paid per share		$ 0.11	$ 0.11	$ 0.11
Subsequent Event
Accounting Policies [Line Items]
Common Stock, Dividends, Per Share, Declared	$ 0.12
Dividends Payable, Amount Per Share								$ 0.12
Stock Repurchase Program, Authorized Amount									$ 1
Minimum
Accounting Policies [Line Items]
Finite-lived intangible asset, estimated useful life, in years					3 years
Maximum
Accounting Policies [Line Items]
Finite-lived intangible asset, estimated useful life, in years					20 years
Machinery and equipment \| Minimum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)					3 years
Machinery and equipment \| Maximum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)					18 years
Buildings and improvements \| Minimum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)					15 years
Buildings and improvements \| Maximum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)					39 years
Capitalized software \| Minimum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)					3 years
Capitalized software \| Maximum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)					7 years

Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details) - Pension Benefits - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	$ 1,591.8	$ 1,747.2
Accumulated benefit obligation	1,546.4	1,678.2
Fair value of plan assets	$ 904.1	$ 893.9

Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Noncurrent assets	$ 117.2	$ 70.7
Current liabilities	(14.6)	(15.1)
Noncurrent liabilities	(682.8)	(846.8)
Net accrued benefit costs	(580.2)	(791.2)
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Noncurrent assets	0.0	0.0
Current liabilities	(16.1)	(16.3)
Noncurrent liabilities	(172.3)	(172.5)
Net accrued benefit costs	$ (188.4)	$ (188.8)

- Definition

Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.

+ References + Details

Equity Method Investments (Tables)

12 Months Ended

Dec. 31, 2021

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments

The carrying values and respective balance sheet locations of the Company’s clean energy investments were as follows at December 31, 2021 and 2020, respectively:


(In millions)	December 31, 2021		December 31, 2020
Other assets	$	—	$	47.9
Other current liabilities	10.9		47.5


(In millions)	December 31, 2021		December 31, 2020
Current assets	$	4.2	$	38.9
Noncurrent assets	0.5		1.0
Total assets	4.7		39.9
Current liabilities	2.8		33.0
Noncurrent liabilities	—		1.8
Total liabilities	2.8		34.8
Net assets	$	1.9	$	5.1


	Year Ended December 31,
(In millions)	2021		2020		2019
Total revenues	$	326.7	$	374.5	$	385.0
Gross loss	(4.6)		(4.6)		(4.4)
Operating and non-operating expense	16.8		19.0		20.0
Net loss	$	(21.4)	$	(23.6)	$	(24.4)

Balance Sheet Components (Other noncurrent liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Other Noncurrent Liabilities [Line Items]
Liability, Defined Benefit Pension Plan, Noncurrent	$ 876.4	$ 1,020.4
Contingent consideration liability	199.7	223.6	$ 250.7
Liability for Uncertainty in Income Taxes, Noncurrent	426.1	469.5
Operating Lease, Liability, Noncurrent	200.9	229.5
Restructuring Reserve, Noncurrent	64.3	134.8
Liabilities, Other than Long-term Debt, Noncurrent	232.9	505.8
Other Liabilities, Noncurrent	1,933.6	2,483.1
Other Noncurrent Liabilities
Schedule of Other Noncurrent Liabilities [Line Items]
Contingent consideration liability	$ 133.0	$ 123.1	$ 130.3

Share-Based Incentive Plan (Tables)

12 Months Ended

Dec. 31, 2021

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Awards Activity

The following table summarizes stock awards (stock options and SARs) activity under the Plan and 2003 LTIP:


	Number of Shares Under Stock Awards	Weighted Average Exercise Price per Share
Outstanding at December 31, 2018	6,815,278	$	36.61
Granted	829,322	26.18
Exercised	(580,950)	14.40
Forfeited	(715,941)	39.40

Outstanding at December 31, 2019	6,347,709	$	36.97
Granted	814,351	17.37
Exercised	(27,615)	21.13
Forfeited	(422,714)	25.74
Outstanding at December 31, 2020	6,711,731	$	35.36


Forfeited	(1,135,241)	26.39
Outstanding at December 31, 2021	5,576,490	$	37.19
Vested and expected to vest at December 31, 2021	5,487,788	$	37.45
Exercisable at December 31, 2021	4,969,602	$	39.21

Nonvested Restricted Stock and Restricted Stock Unit, Including Performance Units, Activity


	Number of Restricted Stock Awards	Weighted Average Grant-Date Fair Value Per Share
Nonvested at December 31, 2020	12,073,790	$	18.34
Granted	9,850,443	14.46
Released	(3,168,152)	24.65
Forfeited	(1,897,953)	15.33
Nonvested at December 31, 2021	16,858,128	$	15.12

Long Term Incentive Plan 2003

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-Based Compensation Plans, Valuation Assumptions


	Year Ended December 31,
	2020	2019
Volatility	46.7%	38.1%
Risk-free interest rate	1.0%	2.5%
Expected term (years)	6.5	6.5
Forfeiture rate	5.5%	5.5%
Weighted average grant date fair value per option	$8.07	$11.03

Leases (Lease Information) (Details)	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Weighted-average remaining lease term	6 years
Weighted-average discount rate	2.60%
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	23 years

Acquisitions and Other Transactions

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Acquisitions and Other Transactions

Upjohn Business Combination Agreement

On July 29, 2019, Mylan, Pfizer, Upjohn, a wholly-owned subsidiary of Pfizer, and certain other affiliated entities entered into a Business Combination Agreement pursuant to which Mylan would combine with the Upjohn Business in a Reverse Morris Trust transaction. The Upjohn Business was a global, primarily off-patent branded and generic established medicines business, which includes 20 primarily off-patent solid oral dose legacy brands, such as Lyrica®, Lipitor®, Celebrex® and Viagra®. The Combination was completed on November 16, 2020.

Prior to the Combination and pursuant to a Separation and Distribution Agreement, Pfizer had, among other things, transferred to Viatris substantially all of the assets and liabilities comprising the Upjohn Business (the Separation) and, thereafter, Pfizer had distributed to Pfizer stockholders all of the issued and outstanding shares of Viatris (the Distribution). When the Distribution and Combination were complete, Pfizer stockholders as of the record date of the Distribution owned 57% of the outstanding shares of Viatris common stock and Mylan shareholders as of immediately before the Combination owned 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted basis. Viatris also made a cash payment to Pfizer equal to $12 billion, which was funded with the proceeds of debt incurred by Upjohn prior to the Combination.

The transaction involved multiple legal entity restructuring transactions and a reverse merger acquisition with Viatris representing the legal acquirer and Mylan representing the accounting acquirer of the Upjohn Business. In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and Viatris applied purchase accounting to the acquired assets and assumed liabilities of the Upjohn Business as of November 16, 2020. The debt incurred by Upjohn prior to the Combination was a liability assumed in purchase accounting. The fair value of the debt as of November 16, 2020 was $13.08 billion.

The purchase price consists of the issuance of approximately 689.9 million Viatris shares of common stock at a fair value of approximately $10.73 billion based on the closing price of Mylan’s ordinary shares on November 13, 2020, as reported by the NASDAQ. In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction have been recorded at their respective estimated fair values at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company incurred acquisition related costs of approximately $234.6 million and $602.9 million, respectively. Acquisition related costs were recorded primarily in SG&A in the consolidated statements of operations for such periods.


(In millions)	Preliminary Purchase Price Allocation as of December 31, 2020 (a)		Measurement Period and Other Adjustments (b)		Purchase Price Allocation as of December 31, 2021 (as adjusted)
Current assets (excluding inventories and net of cash acquired)	$	2,841.9	$	(38.7)	$	2,803.2
Inventories	2,588.9		(34.2)		2,554.7
Property, plant and equipment	1,394.1		(5.0)		1,389.1
Identified intangible assets	18,040.0		—		18,040.0
Goodwill	2,107.5		295.6		2,403.1
Deferred income tax benefit	1,481.9		196.3		1,678.2
Other assets	792.1		(7.4)		784.7
Total assets acquired	$	29,246.4	$	406.6	$	29,653.0
Current liabilities	2,760.2		419.7		3,179.9
Long-term debt, including current portion	13,076.2		—		13,076.2
Deferred tax liabilities	1,656.9		1.0		1,657.9
Other noncurrent liabilities	1,441.5		(14.1)		1,427.4
Net assets acquired (net of $415.8 of cash acquired)	$	10,311.6	$	—	$	10,311.6

____________

(a)As previously reported in Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

The Combination enhanced each businesses’ ability to serve patients’ needs and expand their capabilities across more than 165 markets. Mylan brought a diverse portfolio across many geographies and key therapeutic areas, such as central nervous system and anesthesia, infectious disease and cardiovascular, as well as a robust pipeline, high-quality manufacturing and supply chain excellence. The Upjohn Business brought trusted, iconic brands, such as Lipitor® (atorvastatin calcium), Celebrex® (celecoxib) and Viagra® (sildenafil), and proven commercialization capabilities, including leadership positions in China and other emerging markets.

The Company recorded a step-up in the fair value of inventory of approximately $1.43 billion at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company recorded amortization of the inventory step-up of approximately $1.19 billion and $238.2 million, respectively, which is included in cost of sales in the consolidated statements of operations. The inventory step-up was fully amortized during 2021. In addition, a step-up in the fair value of property, plant and equipment of approximately $385.0 million was recognized. The related depreciation is being expensed over a service life of five years for machinery and equipment and between 10 and 20 years for buildings.

The identified intangible assets of $18.04 billion are comprised of product rights and are being amortized over a weighted average useful life of 15 years. Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. The goodwill of $2.40 billion arising from the Combination consisted largely of the value of the employee workforce and products to be sold in new markets leveraging the combined entity. In addition, an allocation of the goodwill was assigned to the respective segments. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes.

The Company recorded a fair value adjustment of approximately $759.4 million related to the long-term debt assumed as part of the acquisition. The fair value of long-term debt as of the Combination date was determined by broker or dealer quotations, which is classified as Level 2 in the fair value hierarchy. The total fair value adjustment is being amortized as a reduction to interest expense over the maturity dates of the related debt instruments.

The operating results of the Upjohn Business have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of the Upjohn Business for the period from the acquisition date to December 31, 2020, were $866.5 million and net loss, net of tax, was approximately $360.9 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs.

Unaudited Pro Forma Financial Results

The following table presents supplemental unaudited pro forma information for the Combination, as if it had occurred on January 1, 2019. The unaudited pro forma results reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased depreciation and amortization expense based on the fair value of assets acquired, the impact of transaction costs and the related income tax effects. The unaudited pro forma results do not include any anticipated synergies which may be achievable, or have been achieved, subsequent to the closing of the Combination. Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.


	Year Ended December 31,
(Unaudited, in millions, except per share amounts)	2020		2019
Total revenues	$	18,284.8	$	21,582.7
Net earnings	$	1,483.7	$	1,873.5
Earnings per share:
Basic	$	1.23	$	1.55
Diluted	$	1.23	$	1.55
Weighted average shares outstanding:
Basic	1,206.8		1,205.6
Diluted	1,207.7		1,206.4

Other Transactions

In December 2020, Viatris and Pfizer terminated their strategic collaboration for generic drugs in Japan pursuant to an amendment and termination agreement. Under the prior collaboration agreement, both parties contributed products, which Pfizer distributed to third-parties in the Japan market. Under the terms of the amendment and termination agreement, Viatris purchased all collaboration related inventory held by Pfizer. As a result of the termination, and the repurchase of collaboration inventory, the Company reduced revenue by $86.5 million during the year ended December 31, 2020.

In September 2020, the Company entered into an agreement to acquire the related intellectual property and commercialization rights of Aspen’s thrombosis product portfolio in Europe for €641.9 million. The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra®, Fraxiparine®, Mono-Embolex® and Orgaran®. Upon closing of the transaction in November 2020, the Company made a payment of €263.2 million to Aspen and the remaining payment of €378.7 million was made on June 25, 2021. The Company accounted for this transaction as an asset acquisition and recognized an intangible asset of €641.9 million for the product rights, which is being amortized over a useful life of 8 years.

Goodwill and Other Intangible Assets (Narrative) (Details)		12 Months Ended
	Apr. 01, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net		$ 26,087,700,000	$ 29,602,500,000
Contingent consideration liability		199,700,000	223,600,000	$ 250,700,000
Contingent consideration payments		(83,200,000)	(111,800,000)
In-process research and development		46,500,000	80,700,000
Goodwill, Impaired, Accumulated Impairment Loss		385,000,000.0	385,000,000.0	385,000,000.0
Goodwill		12,113,700,000	12,347,000,000	9,590,600,000
In-process research and development
Intangible Assets Excluding Goodwill [Line Items]
IPR&D intangible asset impairment charges		19,400,000	37,400,000	138,300,000
Product rights and licenses
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net		26,084,500,000	29,598,700,000
Impairment of products rights and licenses intangible assets		83,400,000	45,000,000.0	42,300,000
Europe Segment
Intangible Assets Excluding Goodwill [Line Items]
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount	$ 910,000,000
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	5.80%
Goodwill	$ 5,150,000,000
Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input, Term	10 years
North America Segment
Intangible Assets Excluding Goodwill [Line Items]
Goodwill	$ 3,660,000,000
JANZ
Intangible Assets Excluding Goodwill [Line Items]
Goodwill, Impaired, Accumulated Impairment Loss		0	0	0
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount	$ 230,000,000
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	7.00%
Goodwill	$ 820,000,000	776,300,000	864,000,000.0	$ 584,800,000
JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input, Term	10 years
JANZ \| Product rights and licenses
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net		$ 1,495,800,000	$ 2,803,200,000
Measurement Input, Discount Rate [Member] \| In-process research and development \| Minimum
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values		0.070	0.090	0.090
Measurement Input, Discount Rate [Member] \| In-process research and development \| Maximum
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values		0.090	0.110	0.110
Measurement Input, Discount Rate [Member] \| Product rights and licenses \| Minimum
Intangible Assets Excluding Goodwill [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 0.090
Measurement Input, Discount Rate [Member] \| Product rights and licenses \| Maximum
Intangible Assets Excluding Goodwill [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		0.110
Measurement Input, Discount Rate [Member] \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.085
Measurement Input, Long-term Revenue Growth Rate [Member] \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.030
Measurement Input, Long-term Revenue Growth Rate [Member] \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.015
Measurement Input, Estimated Tax Rate [Member] \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.190
Measurement Input, Estimated Tax Rate [Member] \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.305
Measurement Input, EBITDA Multiple [Member] \| Europe Segment \| Minimum \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	7.5
Measurement Input, EBITDA Multiple [Member] \| Europe Segment \| Maximum \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	8.5
Measurement Input, EBITDA Multiple [Member] \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	6.0
Measurement Input, Control Premium [Member] \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.150
Measurement Input, Control Premium [Member] \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.150
Measurement Input, Terminal Year Revenue Growth Rate \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.009
Measurement Input, Terminal Year Revenue Growth Rate \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.007
Measurement Input, Reduction in Terminal Year Revenue Growth Rate \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	(0.029)
Measurement Input, Reduction in Terminal Year Revenue Growth Rate \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	(0.042)
Measurement Input, Increase in Discount Rate \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.015
Measurement Input, Increase in Discount Rate \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.020
Respiratory delivery platform [Member]
Intangible Assets Excluding Goodwill [Line Items]
Contingent consideration liability		177,800,000
Other current liabilities
Intangible Assets Excluding Goodwill [Line Items]
Contingent consideration liability		66,700,000	$ 100,500,000	$ 120,400,000
Contingent consideration payments		$ (83,200,000)	$ (111,800,000)

Financial Instruments and Risk Management (Tables)

12 Months Ended

Dec. 31, 2021

Derivative [Line Items]

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to December 31, 2021 is as follows:


(In millions)	Current Portion (1)		Long-Term Portion (2)		Total Contingent Consideration
Balance at December 31, 2019	$	120.4	$	130.3	$	250.7

Payments	(111.8)		—		(111.8)
Reclassifications	58.1		(58.1)		—
Accretion	—		11.6		11.6
Fair value loss (3)	33.8		39.3		73.1

Balance at December 31, 2020	$	100.5	$	123.1	$	223.6
Payments	(83.2)		—		(83.2)
Reclassifications	49.4		(49.4)		—
Accretion	—		9.0		9.0
Fair value loss (3)	—		50.3		50.3
Balance at December 31, 2021	$	66.7	$	133.0	$	199.7

____________

(1)Included in other current liabilities in the consolidated balance sheets.

(2)Included in other long-term obligations in the consolidated balance sheets.

(3)Included in litigation settlements and other contingencies, net in the consolidated statements of operations.

Financial Assets and Liabilities Carried at Fair Value

Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:


	December 31, 2021
(In millions)	Level 1		Level 2		Level 3		Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds	$	50.9	$	—	$	—	$	50.9
Total cash equivalents	50.9		—		—		50.9
Equity securities:
Exchange traded funds	50.3		—		—		50.3
Marketable securities	0.7		—		—		0.7
Total equity securities	51.0		—		—		51.0
Available-for-sale fixed income investments:
Corporate bonds	—		16.6		—		16.6
U.S. Treasuries	—		14.6		—		14.6
Agency mortgage-backed securities	—		2.0		—		2.0
Asset backed securities	—		4.6		—		4.6
Other	—		0.4		—		0.4
Total available-for-sale fixed income investments	—		38.2		—		38.2
Foreign exchange derivative assets	—		144.6		—		144.6

Total assets at recurring fair value measurement	$	101.9	$	182.8	$	—	$	284.7
Financial Liabilities
Foreign exchange derivative liabilities	$	—	$	61.0	$	—	$	61.0
Contingent consideration	—		—		199.7		199.7
Total liabilities at recurring fair value measurement	$	—	$	61.0	$	199.7	$	260.7


	December 31, 2020
(In millions)	Level 1		Level 2		Level 3		Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds	$	0.9	$	—	$	—	$	0.9
Total cash equivalents	0.9		—		—		0.9
Equity securities:
Exchange traded funds	45.1		—		—		45.1
Marketable securities	0.7		—		—		0.7
Total equity securities	45.8		—		—		45.8
Available-for-sale fixed income investments:
Corporate bonds	—		17.8		—		17.8
U.S. Treasuries	—		14.4		—		14.4
Agency mortgage-backed securities	—		1.9		—		1.9
Asset backed securities	—		4.6		—		4.6
Other	—		0.4		—		0.4
Total available-for-sale fixed income investments	—		39.1		—		39.1
Foreign exchange derivative assets	—		118.6		—		118.6

Total assets at recurring fair value measurement	$	46.7	$	157.7	$	—	$	204.4
Financial Liabilities
Foreign exchange derivative liabilities	$	—	$	103.6	$	—	$	103.6
Contingent consideration	—		—		223.6		223.6
Total liabilities at recurring fair value measurement	$	—	$	103.6	$	223.6	$	327.2

Schedule of Available-for-Sale Securities Reconciliation

The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows:


(In millions)	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
December 31, 2021
Debt securities	$	38.1	$	0.1	$	—	$	38.2
	$	38.1	$	0.1	$	—	$	38.2
December 31, 2020
Debt securities	$	37.5	$	1.6	$	—	$	39.1
	$	37.5	$	1.6	$	—	$	39.1

Maturities Of Available-for-Sale Debt Securities At Fair Value

Maturities of available-for-sale debt securities at fair value as of December 31, 2021, were as follows:


(In millions)
Mature within one year	$	1.2
Mature in one to five years	19.7
Mature in five years and later	17.3
	$	38.2

Cash flow hedging relationships

Derivative [Line Items]

Effect of Derivative Instruments on the Consolidated Statements of Operations

The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:


		Amount of Gains/(Losses) Recognized in Earnings						Amount of Gain Excluded from the Assessment of Hedge Effectiveness
		Year Ended December 31,						Year Ended December 31,
(In millions)	Location of Gain/(Loss)	2021		2020		2019		2021		2020		2019
Derivative Financial Instruments in Fair Value Hedge Relationships (1) :
Interest rate swaps	Interest expense (3)	$	—	$	22.1	$	18.7	$	—	$	—	$	—
2023 Senior Notes (3.125% coupon)	Interest expense (3)	—		(22.1)		(18.7)		—		—		—
Derivative Financial Instruments in Cash Flow Hedging Relationships :
Foreign currency forward contracts	Other expense, net (5)	—		—		—		—		7.1		—
Derivative Financial Instruments Not Designated as Hedging Instruments:
Foreign currency option and forward contracts	Other expense, net (3)	39.3		(10.1)		(17.3)		—		—		—
Total		$	39.3	$	(10.1)	$	(17.3)	$	—	$	7.1	$	—

		Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on Derivatives						Amount of Gains/(Losses) Reclassified from AOCE into Earnings
		Year Ended December 31,						Year Ended December 31,
(In millions)	Location of Gain/(Loss)	2021		2020		2019		2021		2020		2019
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :
Foreign currency forward contracts	Net sales (4)	$	45.8	$	20.6	$	16.6	$	30.9	$	4.8	$	(0.7)
Interest rate swaps	Interest expense (4)	(3.4)		—		3.0		(4.3)		(4.5)		(7.1)
Derivative Financial Instruments in Net Investment Hedging Relationships:
Foreign currency borrowings and forward contracts		436.6		(346.4)		56.7		—		—		—
Total		$	479.0	$	(325.8)	$	76.3	$	26.6	$	0.3	$	(7.8)

____________

(1)In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The amount included in the above tables represents the fair value adjustment recognized at the date the interest rate swaps were settled.

(2)At December 31, 2021, the Company expects that approximately $21.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months.

(3)Represents the location of the gain/(loss) recognized in earnings on derivatives.

(4)Represents the location of the gain/(loss) reclassified from AOCE into earnings.

(5)Represents the location of the gain excluded from the assessment of hedge effectiveness.

Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 17,813.6	$ 11,819.9	$ 11,370.3
Brands
Disaggregation of Revenue [Line Items]
Net sales	10,841.3	5,234.9	5,362.1
Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	1,342.1	1,295.5	1,211.3
Generics
Disaggregation of Revenue [Line Items]
Net sales	5,630.2	5,289.5	4,796.9
Net sales
Disaggregation of Revenue [Line Items]
Net sales	17,813.6	11,819.9	11,370.3
Developed Markets \| Brands
Disaggregation of Revenue [Line Items]
Net sales	5,759.2	3,920.7	4,199.1
Developed Markets \| Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	1,241.6	1,202.6	1,127.4
Developed Markets \| Generics
Disaggregation of Revenue [Line Items]
Net sales	3,427.9	3,387.6	2,913.5
Greater China \| Brands
Disaggregation of Revenue [Line Items]
Net sales	2,207.8	253.9	207.6
Greater China \| Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.2	0.7	0.4
Greater China \| Generics
Disaggregation of Revenue [Line Items]
Net sales	4.8	5.3	6.6
JANZ \| Brands
Disaggregation of Revenue [Line Items]
Net sales	1,197.1	617.0	533.3
JANZ \| Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	46.5	42.8	23.8
JANZ \| Generics
Disaggregation of Revenue [Line Items]
Net sales	783.8	535.5	635.4
Emerging Markets \| Brands
Disaggregation of Revenue [Line Items]
Net sales	1,677.2	443.3	422.1
Emerging Markets \| Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	53.8	49.4	59.7
Emerging Markets \| Generics
Disaggregation of Revenue [Line Items]
Net sales	1,413.7	1,361.1	1,241.4
Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	17,813.6	11,819.9
Operating Segments \| Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	10,428.7	8,510.9	8,240.0
Operating Segments \| Greater China
Disaggregation of Revenue [Line Items]
Net sales	2,212.8	259.9	214.6
Operating Segments \| JANZ
Disaggregation of Revenue [Line Items]
Net sales	2,027.4	1,195.3	1,192.5
Operating Segments \| Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 3,144.7	$ 1,853.8	$ 1,723.2

Comprehensive Earnings (Components of Other Comprehensive Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity	$ 20,492.7	$ 22,954.1	$ 11,883.8	$ 12,167.1
Net unrealized gains on marketable securities, net of tax, beginning of period	1.2
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period	(26.1)
Foreign currency translation adjustment, beginning of period	(461.5)
Accumulated other comprehensive loss, net of tax, beginning of period	(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax	(1.1)
Net sales	17,813.6	11,819.9	11,370.3
Interest expense	(636.2)	(497.8)	(517.3)
Amortization of prior service costs included in SG&A			0.0
Other comprehensive (loss) earnings, before tax	(775.2)	912.6	(343.1)
Income tax related to items of other comprehensive (loss) earnings, derivatives	(604.7)	51.3	(137.6)
Net unrealized gains on marketable securities, net of tax, end of period	0.0	1.2
Net unrealized gains on marketable securities, net of tax, end of period	32.2	(26.1)
Foreign currency translation adjustment, end of period	(1,802.4)	(461.5)
Accumulated other comprehensive loss, net of tax, end of period	(1,744.3)	(858.0)
Net unrealized (loss) gain on marketable securities	(1.1)	0.6	0.5
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	(73.9)	14.0	24.8
Income tax provision (benefit)	111.1	(26.6)	9.2
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity				0.0
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period		(0.2)
Accumulated other comprehensive loss, net of tax, beginning of period		(3.6)
Net unrealized gains on marketable securities, net of tax, end of period			(0.2)
Accumulated other comprehensive loss, net of tax, end of period			(3.6)
Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax related to items of other comprehensive (loss) earnings, derivatives	(0.1)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period		(31.6)	(53.1)
Other comprehensive earnings (loss) before reclassifications, before tax			29.3
Income tax related to items of other comprehensive (loss) earnings, derivatives		(4.6)
Net unrecognized gains (losses) on derivatives, net of tax, end of period			(31.6)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales			0.7
Interest expense			7.1
Income tax related to items of other comprehensive (loss) earnings, derivatives			12.2
Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Foreign Exchange Contract \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(30.9)	(4.8)	0.7
Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	(4.3)	(4.5)	7.1
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gains on marketable securities, net of tax, beginning of period		0.6	0.0
Other comprehensive earnings (loss) before reclassifications, before tax		0.6	0.5
Net unrealized gains on marketable securities, net of tax, end of period			0.6
Net unrealized (loss) gain on marketable securities			0.5
Gains and Losses on Marketable Securities \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax related to items of other comprehensive (loss) earnings, derivatives		0.0	(0.1)
Defined Pension Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period		(17.4)	1.7
Other comprehensive earnings (loss) before reclassifications, before tax	67.0	(12.1)	(21.0)
Net unrealized gains on marketable securities, net of tax, end of period			(17.4)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax			(24.8)
Defined Pension Plan Items \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs included in SG&A	(0.5)	0.0	(0.9)
Amortization of actuarial loss included in SG&A	7.4	(1.9)	(2.9)
Income tax related to items of other comprehensive (loss) earnings, derivatives	(15.6)	(5.3)	(5.9)
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustment, beginning of period		(1,674.5)	(1,259.0)
Other comprehensive earnings (loss) before reclassifications, before tax	(1,340.9)	1,213.0	(415.5)
Income tax related to items of other comprehensive (loss) earnings, derivatives		0.0
Foreign currency translation adjustment, end of period			(1,674.5)
Foreign currency translation adjustment	(1,340.9)	1,213.0	(415.5)
Foreign Currency Translation Adjustment \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax related to items of other comprehensive (loss) earnings, derivatives	0.0		0.0
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity	(1,744.3)		(1,797.2)	(1,441.3)
Accumulated other comprehensive loss, net of tax, beginning of period		(1,797.2)	(1,441.3)
Other comprehensive earnings (loss) before reclassifications, before tax	(755.5)	914.8	(347.1)
Other comprehensive (loss) earnings, before tax		912.6	(343.1)
Accumulated other comprehensive loss, net of tax, end of period			(1,797.2)
Accumulated Other Comprehensive Loss \| Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity				(3.6)
Accumulated Other Comprehensive Loss \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs included in SG&A	(0.5)	0.0	(0.9)
Amortization of actuarial loss included in SG&A	7.4	(1.9)	(2.9)
Income tax provision (benefit)	111.1	(26.6)	9.2
Accumulated Other Comprehensive Loss \| Foreign Exchange Contract \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(30.9)	(4.8)	0.7
Accumulated Other Comprehensive Loss \| Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	(4.3)	(4.5)	7.1
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive earnings (loss) before reclassifications, before tax	62.7	18.5
Other comprehensive (loss) earnings, before tax	36.1
Income tax related to items of other comprehensive (loss) earnings, derivatives	(8.9)
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax			37.1
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income, Other, Net of Tax			(3.4)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Foreign Exchange Contract
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(30.9)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Foreign Exchange Contract \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales		(4.8)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	(4.3)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense		(4.5)
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	16.7	(353.6)	(74.3)	$ (130.9)
Other comprehensive earnings (loss) before reclassifications, before tax	456.8	(305.2)	59.6
Income tax related to items of other comprehensive (loss) earnings, derivatives	$ (86.5)	$ 25.9	$ (3.0)

Debt (Short-term borrowings) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Short-term borrowings	$ 1,493,000	$ 1,100,900
Commercial Paper
Short-term Debt [Line Items]
Short-term borrowings	1,173,400	651,300
Receivables Facility [Member]
Short-term Debt [Line Items]
Short-term borrowings	318,500	248,400
Note Securitization Facility [Member]
Short-term Debt [Line Items]
Short-term borrowings	0	200,000
Other Current Portion of Long-term Debt
Short-term Debt [Line Items]
Short-term borrowings	$ 1,100	$ 1,200

Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	$ 4,843.8
End of period	4,266.4
Variable Consideration [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	3,014.7
Current Provision Related to Sales Made in the Current Period	12,739.8
Measurement Period Adjustments and Reclasses	385.4
Checks/ Credits Issued to Third Parties	(13,056.7)
Effects of Foreign Exchange	(32.5)
End of period	3,050.7
Variable Consideration [Member] \| Chargebacks [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	585.2
Current Provision Related to Sales Made in the Current Period	5,530.1
Measurement Period Adjustments and Reclasses	63.4
Checks/ Credits Issued to Third Parties	(5,585.4)
Effects of Foreign Exchange	(1.6)
End of period	591.7
Variable Consideration [Member] \| Rebates, Promotional Programs and Other Sales Allowances [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	1,576.3
Current Provision Related to Sales Made in the Current Period	6,135.6
Measurement Period Adjustments and Reclasses	(57.6)
Checks/ Credits Issued to Third Parties	(6,267.1)
Effects of Foreign Exchange	(14.2)
End of period	1,373.0
Variable Consideration [Member] \| Variable Consideration Returns [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	539.9
Current Provision Related to Sales Made in the Current Period	384.6
Measurement Period Adjustments and Reclasses	269.0
Checks/ Credits Issued to Third Parties	(499.0)
Effects of Foreign Exchange	(7.7)
End of period	686.8
Variable Consideration [Member] \| Governmental Rebate Programs [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	313.3
Current Provision Related to Sales Made in the Current Period	689.5
Measurement Period Adjustments and Reclasses	110.6
Checks/ Credits Issued to Third Parties	(705.2)
Effects of Foreign Exchange	(9.0)
End of period	$ 399.2

Debt (Issuance of 2018 Senior Notes) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long-term debt	$ 19,717.1	$ 22,429.2
Senior Notes \| 2028 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	4.55%
Senior Notes \| 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	5.20%

Balance Sheet Components (Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5,589.1	$ 5,721.9
Accumulated depreciation	2,400.5	2,262.0
Property, plant and equipment, net	3,188.6	3,459.9
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	137.9	155.8
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,808.5	1,954.8
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,054.0	3,235.0
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 588.7	$ 376.3

Debt (Senior Notes) (Details) $ in Millions, ¥ in Billions	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Jul. 31, 2021 JPY (¥) Rate	Jun. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)
Debt Instrument [Line Items]
Long-term debt	$ 19,717.1				$ 22,429.2
Long-term Debt, Gross	$ 20,949.0
Upjohn Inc.
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 11,847.8
2020 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	0.816%
YEN Term Loan
Debt Instrument [Line Items]
Long-term debt	$ 347.6
Senior Notes \| Upjohn Inc.
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 7,450.0
Senior Notes \| 2.250% Euro Senior Notes due 2024
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	2.25%
Long-term debt	$ 1,135.8				1,219.9
Senior Notes \| 2.250% Euro Senior Notes due 2024 \| Upjohn Inc.
Debt Instrument [Line Items]
Debt Instrument, Face Amount				916.2
Senior Notes \| 2028 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	3.125%
Long-term debt	$ 847.4				909.7
Senior Notes \| 2028 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	4.55%
Long-term debt	$ 748.7				748.6
Senior Notes \| 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	5.20%
Long-term debt	$ 747.8				747.7
Senior Notes \| 2025 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	2.125%
Long-term debt	$ 567.8				$ 609.9
Senior Notes \| USD Term Loan Facility
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 600.0
Revolving Credit Facility \| Twenty Twenty One Revolving Facility
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 4,000.0
Revolving Credit Facility \| 2020 Revolving Facility
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 4,000.0
Medium-term Notes \| YEN Term Loan
Debt Instrument [Line Items]
Debt Instrument, Face Amount \| ¥			¥ 40
Medium-term Notes \| Twenty Twenty One Loan Facilities
Debt Instrument [Line Items]
Maximum Leverage Ratio, Period Two \| Rate			400.00%
Maximum Leverage Ratio, Period One \| Rate			425.00%
Maximum Leverage Ratio, Period Three \| Rate			375.00%

Commitments (Details) - Pfizer, Inc. - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Other Commitments [Line Items]
Reimbursement amount, tranche one	$ 380.0
Amounts incurred	30.4	$ 53.1
Amounts accrued	$ 26.9
Transition Service Agreements
Other Commitments [Line Items]
Limited transition services period	24 months

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax	$ 26.6	$ 0.3	$ (7.8)
Cash Flow Hedging [Mem \| Foreign Exchange Contract \| Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	30.9	4.8	(0.7)
Cash Flow Hedging [Mem \| Interest rate swaps \| Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	$ (4.3)	$ (4.5)	$ (7.1)

Leases (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
Leases (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2017	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Right-of-use asset	$ 290,800			$ 323,600
Total lease liability	287,600
Amount of operating leases not yet commenced	$ 13,600
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other Assets, Noncurrent			Other Assets, Noncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other Liabilities, Current			Other Liabilities, Current
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other Liabilities, Noncurrent			Other Liabilities, Noncurrent
Payments for Rent	$ 97,600	$ 80,700	$ 87,600
Minimum
Lessee, Lease, Description [Line Items]
Term of operating leases not yet commenced	5 years
Maximum
Lessee, Lease, Description [Line Items]
Term of operating leases not yet commenced	9 years

Balance Sheet Components (Other Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Schedule of Other Assets [Line Items]
Operating Lease, Right-of-Use Asset	$ 290.8	$ 323.6
Other long-term assets	879.9	676.0
Other assets	1,170.7	1,047.5
Clean energy investments \| Other assets
Schedule of Other Assets [Line Items]
Investments in subsidiaries	$ 0.0	$ 47.9

Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Projected benefit obligation, beginning of year
Service cost			$ 0.6
Interest cost			1.5
Change in Plan Assets
Fair value of plan assets, beginning of year	$ 1,354.6
Fair value of plan assets, end of year	1,366.4	$ 1,354.6
Pension Benefits
Projected benefit obligation, beginning of year
Projected benefit obligation, beginning of year	2,145.8	674.7
Service cost	38.6	23.5	20.7
Interest cost	31.6	13.5	13.6
Participant contributions	2.0	1.8
Acquisitions	4.0	1,389.4
Plan settlements and terminations	(128.6)	(23.1)
Actuarial (gains) losses	(26.1)	37.2
Benefits paid	(52.8)	(24.6)
Impact of foreign currency translation	(67.9)	53.4
Projected benefit obligation, end of year	1,946.6	2,145.8	674.7
Change in Plan Assets
Fair value of plan assets, beginning of year	1,354.6	315.7
Actual return on plan assets	141.7	46.0
Company contributions	97.0	58.2
Participant contributions	2.0	1.8
Defined Benefit Plan, Plan Assets, Business Combination		959.3
Transferred assets	(2.1)
Plan settlements	(128.9)	(23.1)
Impact of foreign currency translation	(45.1)	21.3
Fair value of plan assets, end of year	1,366.4	1,354.6	315.7
Funded status of plans	(580.2)	(791.2)
Other Postretirement Benefits
Projected benefit obligation, beginning of year
Projected benefit obligation, beginning of year	188.8	33.8
Service cost	3.4	1.1
Interest cost	2.6	1.4
Participant contributions	2.4	0.1
Acquisitions	0.0	153.1
Plan settlements and terminations	(4.3)	(0.2)
Actuarial (gains) losses	16.2	1.1
Benefits paid	(20.7)	(1.6)
Impact of foreign currency translation	0.0	0.0
Projected benefit obligation, end of year	188.4	188.8	33.8
Change in Plan Assets
Fair value of plan assets, beginning of year	0.0	0.0
Actual return on plan assets	0.0	0.0
Company contributions	18.3	1.7
Participant contributions	2.4	0.1
Defined Benefit Plan, Plan Assets, Business Combination	0.0	0.0
Plan settlements	0.0	(0.2)
Impact of foreign currency translation	0.0	0.0
Fair value of plan assets, end of year	0.0	0.0	$ 0.0
Funded status of plans	$ (188.4)	$ (188.8)

Debt (Minimum Repayments on Outstanding Borrowings) (Details) $ in Millions	Dec. 31, 2021 USD ($)
Debt Disclosure [Abstract]
2021	$ 1,853
2022	1,250
2023	1,990
2024	1,318
2025	2,598
Thereafter	11,940
Total	$ 20,949

Consolidated Statements of Equity (Parenthetical)	12 Months Ended
Consolidated Statements of Equity (Parenthetical)	Dec. 31, 2021 $ / shares
Common Stock
Dividends paid per share	$ 0.33

Equity Method Investments (Net Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Assets, Current	$ 10,902.9	$ 12,867.5
Total assets	54,842.8	61,553.0
Current liabilities	9,884.4	10,562.9
Total liabilities	34,350.1	38,598.9
Consolidated Entity
Schedule of Equity Method Investments [Line Items]
Assets, Current	4.2	38.9
Noncurrent assets	0.5	1.0
Total assets	4.7	39.9
Current liabilities	2.8	33.0
Noncurrent liabilities	0.0	1.8
Total liabilities	2.8	34.8
Net assets	$ 1.9	$ 5.1

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

+ Details

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(25))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(26))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(24))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

+ Details

Debt (Summary of Long-term Debt) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt, Current		$ 1,860.3	$ 2,256.3
Unamortized Debt Issuance Expense		(42.3)	(47.8)
Long-term debt		19,717.1	22,429.2
Proceeds from Sale of Securities, Operating Activities	$ 45.0
Other Current Portion of Long-term Debt
Debt Instrument [Line Items]
Debt, Current		0.9	8.0
2020 Euro Senior Notes
Debt Instrument [Line Items]
Debt, Current		$ 856.6	0.0
Debt instrument, interest rate, stated percentage		0.816%
2020 Senior Notes (3.750% coupon)
Debt Instrument [Line Items]
Debt, Current		$ 1,002.9	0.0
Debt instrument, interest rate, stated percentage		1.125%
Other Long Term Debt
Debt Instrument [Line Items]
Long-term debt		$ 1.9	17.4
2020 Floating Rate Euro Notes
Debt Instrument [Line Items]
Debt, Current		$ 0.0	2,249.7
Senior Notes 2021
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.15%
2022 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		0.816%
Long-term debt		$ 0.0	928.8
Senior Notes 2022
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		1.125%
Long-term debt		$ 0.0	1,008.8
2.125% Euro Senior Notes due 2025
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		1.023%
2027 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		1.362%
2027 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		2.30%
Term Loan
Debt Instrument [Line Items]
Long-term debt		$ 0.0
Senior Notes \| Senior Notes 2023 3.125%
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.125%
Long-term debt		$ 766.1	781.6
Senior Notes \| 2023 Senior Notes (4.200%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		4.20%
Long-term debt		$ 499.6	499.3
Senior Notes \| 2.250% Euro Senior Notes due 2024
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		2.25%
Long-term debt		$ 1,135.8	1,219.9
Senior Notes \| 2025 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		2.125%
Long-term debt		$ 567.8	609.9
Senior Notes \| 2026 Senior Notes (3.950%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.95%
Long-term debt		$ 2,241.4	2,239.7
Senior Notes \| 2028 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.125%
Long-term debt		$ 847.4	909.7
Senior Notes \| 2028 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		4.55%
Long-term debt		$ 748.7	748.6
Senior Notes \| 2043 Senior Notes (5.400%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		5.40%
Long-term debt		$ 497.3	497.3
Senior Notes \| 2046 Senior Notes (5.250%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		5.25%
Long-term debt		$ 999.9	999.9
Senior Notes \| 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		5.20%
Long-term debt		$ 747.8	747.7
Senior Notes \| 2.125% Euro Senior Notes due 2025
Debt Instrument [Line Items]
Long-term debt		871.6	944.6
Senior Notes \| 2027 Euro Senior Notes
Debt Instrument [Line Items]
Long-term debt		1,013.0	1,097.4
Senior Notes \| 2027 Senior Notes
Debt Instrument [Line Items]
Long-term debt		$ 780.8	786.1
Senior Notes \| 2030 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		2.70%
Long-term debt		$ 1,520.5	1,528.0
Senior Notes \| 2032 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		1.908%
Long-term debt		$ 1,546.6	1,672.6
Senior Notes \| 2040 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.85%
Long-term debt		$ 1,657.1	1,663.3
Senior Notes \| 2050 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		4.00%
Long-term debt		$ 2,205.1	2,209.3
Senior Notes \| Term Loan
Debt Instrument [Line Items]
Long-term debt			600.0
Senior Notes \| 2025 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		1.65%
Long-term debt		$ 763.4	767.1
Current portion of long-term debt
Debt Instrument [Line Items]
Unamortized Debt Issuance Expense		$ (0.1)	$ (1.4)

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Financial Instruments in Net Investment Hedging Relationships:	$ 479.0	$ (325.8)	$ 76.3
Cash flow hedging relationships \| Foreign Exchange Contract \| Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	30.9	4.8	(0.7)
Cash flow hedging relationships \| Foreign Exchange Contract \| Other income
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Excluded from the Assessment of Hedge Effectiveness	0.0	7.1	0.0
Cash flow hedging relationships \| Interest rate swaps \| Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	$ (4.3)	$ (4.5)	$ (7.1)

Financial Instruments and Risk Management

12 Months Ended

Dec. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments And Risk Management

Financial Instruments and Risk ManagementThe Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk.

Foreign Currency Risk Management

In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the consolidated statements of operations.

The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries and a portion of forecasted intercompany inventory sales denominated in Euro, Japanese Yen and Chinese Renminbi for up to eighteen months. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any changes in the fair value of designated cash flow hedges are deferred in AOCE and are reclassified into earnings when the hedged item impacts earnings.

Net Investment Hedges

The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments.

The Company has designated certain Euro and Yen borrowings as a hedge of its investment in certain Euro-functional and Yen-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro and Yen borrowings not designated as net investment hedges through certain Euro and Yen denominated financial assets and forward currency swaps.

The following table summarizes the principal amounts of the Company’s outstanding Euro and Yen borrowings and the notional amounts of the Euro and Yen borrowings designated as net investment hedges:


			Notional Amount Designated as a Net Investment Hedge
(in millions)	Principal Amount		December 31, 2021		December 31, 2020
Euro
2.250% Euro Senior Notes due 2024	€	1,000.0	€	1,000.0	€	1,000.0
3.125% Euro Senior Notes due 2028	750.0		750.0		750.0
2.125% Euro Senior Notes due 2025	500.0		500.0		500.0
0.816% Euro Senior Notes due 2022	750.0		750.0		750.0
1.023% Euro Senior Notes due 2024	750.0		750.0		750.0
1.362% Euro Senior Notes due 2027	850.0		850.0		850.0
1.908% Euro Senior Notes due 2032	1,250.0		1,250.0		1,250.0
Foreign currency forward contracts	105.6		—		105.6
Euro Total	€	5,955.6	€	5,850.0	€	5,955.6

Yen
YEN Term Loan	¥	40,000.0	¥	40,000.0	¥	—
Yen Total	¥	40,000.0	¥	40,000.0	¥	—

At December 31,2021, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedge was $347.6 million.

Interest Rate Risk Management

The Company enters into interest rate swaps from time to time in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings.

Cash Flow Hedging Relationships

The Company’s interest rate swaps designated as cash flow hedges fix the interest rate on a portion of the Company’s variable-rate debt or hedge part of the Company’s interest rate exposure associated with the variability in the future cash flows attributable to changes in interest rates. Any changes in fair value are included in earnings or deferred through AOCE, depending on the nature and effectiveness of the offset. Any ineffectiveness in a cash flow hedging relationship is recognized immediately in earnings in the consolidated statements of operations.

Fair Value Hedging Relationships

The Company's interest rate swaps designated as fair value hedges convert the fixed rate on a portion of the Company's fixed-rate senior notes to a variable rate. Any changes in the fair value of these derivative instruments, as well as the offsetting change in fair value of the portion of the fixed-rate debt being hedged, is included in interest expense. The Company’s fair value hedge was terminated during 2020.

Credit Risk Management

The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the consolidated balance sheets. Accordingly, there are no offsetting amounts that net assets against liabilities.

The following table summarizes the classification and fair values of derivative instruments in our consolidated balance sheets:


	Asset Derivatives					Liability Derivatives
(In millions)	Balance Sheet Location	December 31, 2021 Fair Value		December 31, 2020 Fair Value		Balance Sheet Location	December 31, 2021 Fair Value		December 31, 2020 Fair Value

Derivatives designated as hedges:

Foreign currency forward contracts	Prepaid expenses & other current assets	$	62.0	$	28.3	Other current liabilities	$	4.3	$	0.8
Total derivatives designated as hedges		62.0		28.3			4.3		0.8
Derivatives not designated as hedges:
Foreign currency forward contracts	Prepaid expenses & other current assets	82.6		90.3		Other current liabilities	56.7		102.8
Total derivatives not designated as hedges		82.6		90.3			56.7		102.8
Total derivatives		$	144.6	$	118.6		$	61.0	$	103.6

The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:


		Amount of Gains/(Losses) Recognized in Earnings						Amount of Gain Excluded from the Assessment of Hedge Effectiveness
		Year Ended December 31,						Year Ended December 31,
(In millions)	Location of Gain/(Loss)	2021		2020		2019		2021		2020		2019
Derivative Financial Instruments in Fair Value Hedge Relationships (1) :
Interest rate swaps	Interest expense (3)	$	—	$	22.1	$	18.7	$	—	$	—	$	—
2023 Senior Notes (3.125% coupon)	Interest expense (3)	—		(22.1)		(18.7)		—		—		—
Derivative Financial Instruments in Cash Flow Hedging Relationships :
Foreign currency forward contracts	Other expense, net (5)	—		—		—		—		7.1		—
Derivative Financial Instruments Not Designated as Hedging Instruments:
Foreign currency option and forward contracts	Other expense, net (3)	39.3		(10.1)		(17.3)		—		—		—
Total		$	39.3	$	(10.1)	$	(17.3)	$	—	$	7.1	$	—

		Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on Derivatives						Amount of Gains/(Losses) Reclassified from AOCE into Earnings
		Year Ended December 31,						Year Ended December 31,
(In millions)	Location of Gain/(Loss)	2021		2020		2019		2021		2020		2019
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :
Foreign currency forward contracts	Net sales (4)	$	45.8	$	20.6	$	16.6	$	30.9	$	4.8	$	(0.7)
Interest rate swaps	Interest expense (4)	(3.4)		—		3.0		(4.3)		(4.5)		(7.1)
Derivative Financial Instruments in Net Investment Hedging Relationships:
Foreign currency borrowings and forward contracts		436.6		(346.4)		56.7		—		—		—
Total		$	479.0	$	(325.8)	$	76.3	$	26.6	$	0.3	$	(7.8)

____________

(2)At December 31, 2021, the Company expects that approximately $21.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months.

(3)Represents the location of the gain/(loss) recognized in earnings on derivatives.

(4)Represents the location of the gain/(loss) reclassified from AOCE into earnings.

(5)Represents the location of the gain excluded from the assessment of hedge effectiveness.

Fair Value Measurement

Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.

Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:


	December 31, 2021
(In millions)	Level 1		Level 2		Level 3		Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds	$	50.9	$	—	$	—	$	50.9
Total cash equivalents	50.9		—		—		50.9
Equity securities:
Exchange traded funds	50.3		—		—		50.3
Marketable securities	0.7		—		—		0.7
Total equity securities	51.0		—		—		51.0
Available-for-sale fixed income investments:
Corporate bonds	—		16.6		—		16.6
U.S. Treasuries	—		14.6		—		14.6
Agency mortgage-backed securities	—		2.0		—		2.0
Asset backed securities	—		4.6		—		4.6
Other	—		0.4		—		0.4
Total available-for-sale fixed income investments	—		38.2		—		38.2
Foreign exchange derivative assets	—		144.6		—		144.6

Total assets at recurring fair value measurement	$	101.9	$	182.8	$	—	$	284.7
Financial Liabilities
Foreign exchange derivative liabilities	$	—	$	61.0	$	—	$	61.0
Contingent consideration	—		—		199.7		199.7
Total liabilities at recurring fair value measurement	$	—	$	61.0	$	199.7	$	260.7


	December 31, 2020
(In millions)	Level 1		Level 2		Level 3		Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds	$	0.9	$	—	$	—	$	0.9
Total cash equivalents	0.9		—		—		0.9
Equity securities:
Exchange traded funds	45.1		—		—		45.1
Marketable securities	0.7		—		—		0.7
Total equity securities	45.8		—		—		45.8
Available-for-sale fixed income investments:
Corporate bonds	—		17.8		—		17.8
U.S. Treasuries	—		14.4		—		14.4
Agency mortgage-backed securities	—		1.9		—		1.9
Asset backed securities	—		4.6		—		4.6
Other	—		0.4		—		0.4
Total available-for-sale fixed income investments	—		39.1		—		39.1
Foreign exchange derivative assets	—		118.6		—		118.6

Total assets at recurring fair value measurement	$	46.7	$	157.7	$	—	$	204.4
Financial Liabilities
Foreign exchange derivative liabilities	$	—	$	103.6	$	—	$	103.6
Contingent consideration	—		—		223.6		223.6
Total liabilities at recurring fair value measurement	$	—	$	103.6	$	223.6	$	327.2

For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including the LIBOR yield curve, foreign exchange forward prices, and bank price quotes. For the years ended December 31, 2021 and 2020, there were no transfers between Level 1 and 2 of the fair value hierarchy. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities:

•Cash equivalents — valued at observable net asset value prices.

•Equity securities, exchange traded funds — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations.

•Equity securities, marketable securities — valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations.

•Available-for-sale fixed income investments — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity.

•Interest rate swap derivative assets and liabilities — valued using the LIBOR/EURIBOR yield curves at the reporting date. Counterparties to these contracts are highly rated financial institutions.

•Foreign exchange derivative assets and liabilities — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions.

Contingent Consideration

In December 2011, the Company completed the acquisition of the exclusive worldwide rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline’s Advair® Diskus incorporating Pfizer’s respiratory delivery platform. The Company accounted for this transaction as a purchase of a business and utilized the acquisition method of accounting. On January 30, 2019, the Company received FDA approval of Wixela® Inhub® (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of GlaxoSmithKline’s Advair Diskus®. The commercial launch of the Wixela® Inhub® occurred in February 2019.

As of December 31, 2021, the Company has a contingent consideration liability of $177.8 million related to the respiratory delivery platform. The fair value measurement of contingent consideration is determined using Level 3 inputs. The Company’s contingent consideration represents a component of the total purchase consideration for Pfizer’s respiratory delivery platform and certain other acquisitions. The measurement is calculated using unobservable inputs based on the Company’s own assumptions primarily related to the probability and timing of future development and commercial milestones and future profit-sharing payments which are discounted using a market rate of return. At December 31, 2021 and 2020, discount rates ranging from 8.0% to 10.5% were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liability.

A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to December 31, 2021 is as follows:


(In millions)	Current Portion (1)		Long-Term Portion (2)		Total Contingent Consideration
Balance at December 31, 2019	$	120.4	$	130.3	$	250.7

Payments	(111.8)		—		(111.8)
Reclassifications	58.1		(58.1)		—
Accretion	—		11.6		11.6
Fair value loss (3)	33.8		39.3		73.1

Balance at December 31, 2020	$	100.5	$	123.1	$	223.6
Payments	(83.2)		—		(83.2)
Reclassifications	49.4		(49.4)		—
Accretion	—		9.0		9.0
Fair value loss (3)	—		50.3		50.3
Balance at December 31, 2021	$	66.7	$	133.0	$	199.7

____________

(1)Included in other current liabilities in the consolidated balance sheets.

(2)Included in other long-term obligations in the consolidated balance sheets.

(3)Included in litigation settlements and other contingencies, net in the consolidated statements of operations.

The Company expects to incur approximately $6 million to $8 million of non-cash accretion expense related to the increase in the net present value of the contingent consideration liabilities in 2022.

Although the Company has not elected the fair value option for financial assets and liabilities, any future transacted financial asset or liability will be evaluated for the fair value election.

Available-for-Sale Securities

The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows:


(In millions)	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
December 31, 2021
Debt securities	$	38.1	$	0.1	$	—	$	38.2
	$	38.1	$	0.1	$	—	$	38.2
December 31, 2020
Debt securities	$	37.5	$	1.6	$	—	$	39.1
	$	37.5	$	1.6	$	—	$	39.1

Maturities of available-for-sale debt securities at fair value as of December 31, 2021, were as follows:


(In millions)
Mature within one year	$	1.2
Mature in one to five years	19.7
Mature in five years and later	17.3
	$	38.2

Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	$ 26,087.7	$ 29,602.5
Product rights and licenses
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	26,084.5	29,598.7
Product rights and licenses \| Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	14,313.6	17,514.5
Product rights and licenses \| Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	6,115.0	4,385.0
Product rights and licenses \| JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1,495.8	2,803.2
Product rights and licenses \| Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	4,160.1	4,896.0
Product rights and licenses \| Brands
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	21,146.0	22,216.1
Product rights and licenses \| Brands \| Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	10,066.6	10,988.1
Product rights and licenses \| Brands \| Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	6,102.9	4,372.3
Product rights and licenses \| Brands \| JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1,174.8	2,377.0
Product rights and licenses \| Brands \| Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,801.7	4,478.7
Product rights and licenses \| Complex Gx and Biosimilars
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	228.3	274.8
Product rights and licenses \| Complex Gx and Biosimilars \| Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	226.8	272.5
Product rights and licenses \| Complex Gx and Biosimilars \| Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.0	0.0
Product rights and licenses \| Complex Gx and Biosimilars \| JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1.5	2.3
Product rights and licenses \| Complex Gx and Biosimilars \| Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.0	0.0
Product rights and licenses \| Generics
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	4,710.2	7,107.8
Product rights and licenses \| Generics \| Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	4,020.2	6,253.9
Product rights and licenses \| Generics \| Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	12.1	12.7
Product rights and licenses \| Generics \| JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	319.5	423.9
Product rights and licenses \| Generics \| Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	$ 358.4	$ 417.3